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CHAPTER 1 GENERAL INTRODUCTION AND OUTLINE OF THIS THESIS
1.1 Anogenital skin
The anogenital area forms a unique environment comprising the external genitalia, 
perineum and anus and is covered with different types of epithelium. The external 
genitalia consist of the vulva of females and the penis and scrotum of males. 
 The vulva is the generic term for all structures of the female external genital tract 
and includes the mons pubis, paired labia majora and minora, clitoris, the vestibule 
of the vagina and the urethral orifice. The hymen partially conceals the vaginal 
opening and forms the separation between vulva and vagina. The vulvar epithelium 
changes from stratified, keratinised squamous cell epithelium on the outer parts to 
mucosa on the innermost regions. The ‘line of Hart’, at the inside of the labia minora 
reflects the sharp demarcation between keratinised and non-keratinised squamous 
cell epithelium.1,2 
 The male external genitalia include the penile shaft, glans, prepuce and scrotum. 
The prepuce forms the anatomical covering of the glans penis and is the junction 
between the mucosal surface of the glans and coronal sulcus and the keratinised 
squamous cell epithelium of the remaining external genital skin.3 The perineum 
connects the external genitalia to the perianal region; both are covered with keratinised 
skin. The external perianal skin is continuous with the skin of the anal opening and the 
keratinised layer of the internal wall of the anal canal. 
 The skin functions as an important barrier to protect individuals from damaging 
external influences. This is particularly beneficial in the anogenital area because of 
exposure to a wide range of micro-organisms, mechanical and chemical irritants. 
Due to the combination of moisture, warmth and friction, anogenital skin folds are 
susceptible to maceration and fissuring. 
 The normal characteristics of common dermatoses may be lost or modified in 
the genital region and these dermatoses may be confused with sexually transmitted 
diseases. Anogenital dermatoses are associated with considerable morbidity, 
discomfort and embarrassment and may considerably impair quality of life and 
psychosexual wellbeing of patients. Because of the high sensitivity of the vulnerable 
thin genital skin and the increased penetration of topical treatments applied to this 
site of the body, treatment of genital lesions is a challenge. 
1.2 Genital psoriasis
1.2.1 Epidemiology
Psoriasis is a multi-factorial, chronic, immune-mediated hyperproliferative inflammatory 
skin disease with a high prevalence in the general population of about 2%.4-6 It is one 
of the most commonly seen dermatoses at genital skin, although often limited 
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currently assumed that both localised and disseminated psoriatic diaper eruptions 
may represent psoriasis or a precursor to psoriasis in some children.36,52-56 
1.2.3 Diagnosis
The diagnosis of genital psoriasis can usually be made on the basis of its clinical 
appearance. Genital psoriatic lesions often are part of a more generalised form of 
psoriasis and confirmatory lesions elsewhere or other clinical signs of psoriasis (such 
as nail deformities or joint complaints) may be present.19,21-24,26,27,29,30,32,34,35,39,40,43-45 
Skin biopsies are therefore rarely needed, but should not be omitted in inconclusive 
cases. Possible differential diagnoses for genital psoriasis are shown in Table 1.
 The main histopathological features of psoriasis are: 1) epidermal hyperplasia 
with regular elongated rete ridges 2) marked hyperkeratosis, mainly composed of 
parakeratosis 3) prominent dilated and elongated superficial capillaries in the dermis 
and 4) dermal inflammatory lymphocytic infiltrate. There is no apparent histological 
attention is paid to the genital presentation of this skin disease. Remarkably few data 
exist on the involvement of the genitalia in patients with psoriasis and moreover, the 
anogenital region is frequently overlooked in daily clinical care for these patients. 
 In many cases, genital psoriasis is part of more generalised plaque psoriasis, 
although the external genitalia may be the only area affected. However, the isolated 
presentation of psoriasis solely on genital skin seems to be rare and occurs in only 
2-5% of the psoriatic patients. Psoriasis on genital skin also occurs in cases of 
intertriginous (synonym: flexural) psoriasis.2,6-8 In both literature and daily clinical 
practice, genital psoriasis is often classified as intertriginous psoriasis. 
 Several questionnaire-based surveys show that involvement of the genitalia 
occurs in 29-40% of patients with psoriasis. Male patients seem to suffer more 
frequently from genital psoriasis compared to female patients.9-13 Overall, about 
2-4% of patients referred to specialised clinics with genital dermatoses are diagnosed 
with psoriasis.14-18 
 Prevalence rates of genital psoriasis in children are scarce. However, two studies 
indicate that vulvar psoriasis is one of the most common diagnoses in prepubertal 
girls with vulvar complaints (affecting 10-17% of the patients).17,19
1.2.2 Clinical presentation 
Psoriatic lesions on genital skin often present as well-demarcated, brightly erythe ma- 
tous, thin plaques.20-38 When scaling is present, it is often minimal and can easily be 
scraped off, leaving pinpoint bleedings.25,26,37,39 
 Vulvar psoriasis is often symmetrical and can vary from silvery scaling patches 
adjacent to the outer parts of the labia majora to moist greyish plaques or glossy red 
plaques without scaling in the skin folds.32,34,39-43
 In male patients, the glans penis is the area that is most commonly affected with 
psoriasis. Occasionally, the entire penis, scrotum, and inguinal folds are involved.24,25,29,44,45 
In uncircumcised males most commonly well-defined non-scaling plaques are present 
under the prepuce and on the proximal glans. In circumcised patients, usually 
erythematous lesions that may be scaly are present on the glans and corona.24,29,44 
 Genital lesions may be accompanied by rhagades or fissures, which can cause 
definite soreness.27,46 Patients with genital psoriasis may also experience pruritus 
and/or a burning sensation in the affected area.22,25,29,35,39,47 Although most genital 
psoriatic lesions represent plaque-type psoriasis, the genital area may incidentally 
also be affected by generalised or localised pustular psoriasis.48-50 Due to the 
Koebner phenomenon, genital psoriasis may be worsened by irritation from urine 
and faeces, tight-fitting clothes and sexual intercourse.25,37,41,51 
 There is no difference in the clinical presentation of genital psoriasis between 
children and adults, although it has been debated whether a psoriatic diaper eruption 
should be regarded as psoriasis, seborrhoic dermatitis or a Candida infection. It is 
Table 1  Possible differential diagnoses for genital psoriasis as mentioned in 
referred articles
Differential diagnose References 
Dermatitis 
(variants: seborrhoic dermatitis, contact dermatitis, atopic 
dermatitis, spongiotic dermatitis)
15,21,22,33,34,39,43,49,53,62
Tinea or candidiasis 15,21,33,39,41,51,62
Squamous cell carcinoma (in situ) 
(variants: morbus Bowen, Bowenoid papulosis, erythroplasia 
de Queyrat)
20,25,29,33,44,45,49
Plasma-cell balanitis or vulvitis 20,33,41,44,45,49
Lichen planus 21,39,44,45,49
Secondary or tertiary (pustular) syphilis 21,39,45,49,50
Reiter’s syndrome (balanitis circinata) 44,49-51
Lichen simplex chronicus (excoriated) 15,22,39
Extramammary Paget’s disease 20,39
Intertrigo 21,33
Fixed drug eruption 44,49
Lichen nitidus 49
Lichen sclerosus 22
Scabies or pediculosis pubis 39
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Vitamin D analogues
Vitamin D analogues are valuable in the treatment of genital psoriasis, because of 
their corticosteroid sparing ability and long-term safety profile.24,25,29,45 They can be 
prescribed as monotherapy or in combination with corticosteroids.24 Irritation and 
burning at the applied area are known side effects of vitamin D analogues, particularly 
at the genital skin. These side effects may be minimised by a combination with cortico-
steroids.24,45 Sometimes however, vitamin D analogues remain too irritating to apply 
to the genital area.32,60 
Calcineurin inhibitors
Topical calcineurin inhibitors (pimecrolimus ointment or tacrolimus cream) are often 
used in the treatment of facial and intertriginous psoriasis. The current literature 
provides only very weak evidence for the use of these immune-modulating 
preparations for the treatment of genital psoriasis.32 Topical calcineurin inhibitors 
may cause local irritation and stinging after application. Monitoring of possible 
complications of calcineurin inhibitors is advised, as they can cause irritant or allergic 
contact dermatitis, candidiasis, or (re)activation of viral skin infections. The risk of 
carcinogenicity from topical immunomodulators is unknown up until now. A careful 
risk-benefit assessment is therefore advised before topical calcineurin inhibitors are 
prescribed.64 
Other modalities/general advices 
Emollients moisturise, soften and protect the skin. They may reduce redness, itch 
and pain caused by psoriatic lesions and belong to the basic genital psoriasis 
therapy. Besides, minimising the contact with local irritating factors is useful in the 
treatment of genital psoriasis.28,41,45,62
Suspected concurrent bacterial or fungal infections of the genital area should be 
treated with topical antibiotics or antimycotics, respectively, to eliminate the possible 
Koebner effect.22,25,29,31,34,35,41,45,60 
 Dithranol (anthralin), topical retinoids/retinoid analogues and photo(chemo)
therapy (psoralen plus ultraviolet A (PUVA), ultraviolet B (UVB) and laser) should be 
avoided in the genital area, because of their high irritating potential.21,32,41 Besides, 
both PUVA and UVB phototherapy, carry an increased risk of developing genital 
squamous cell carcinoma (SCC), particularly in men.65,66
 Systemic therapy is no common practice for isolated genital psoriasis. 
Nevertheless, such treatment modalities may also be beneficial for genital lesions if 
prescribed because of severe and extensive psoriasis.31,32 
 Therapy-resistant penile and vulvar plaques should always be clinically and 
histologically re-evaluated to rule out any (pre-)malignancy.25,29,39 The choice of 
treatment should always be individualised for each patient. Besides the given 
difference between genital and non-genital psoriasis. 14,15,21,22,26,27,33,44,57. However, 
the typical histopathological features of psoriasis might be less evident in genital 
lesions, because of the thin keratinised layer and less evident epithelial hyperplasia.57,58 
1.2.4 Therapy
Numerous different treatment options are available for psoriasis. A division into three 
main modalities, including topical treatment, photo(chemo)therapy and systemic 
treatment can be made. The current literature (predominantly reflecting expert 
opinions and a few case reports) provides extremely limited evidence for the efficacy 
and safety of treatment options for genital psoriasis.
Corticosteroids
Topical corticosteroids are the mainstay in genital psoriasis therapy. The many 
available formulations are classified into four potency groups, based on their clinical 
effectiveness: I weak, II moderate, III potent, IV ultra-potent. 
 The current literature reflects a reluctance in the prescription of (ultra-)potent 
 corticosteroids for genital psoriasis and generally recommends the use of weak (and 
sometimes, if necessary, moderate) corticosteroids, which may be combined with 
vitamin D analogues or coal tar preparations.24,25,31-33,41,44,51,59,60 However, although 
weak corticosteroids are preferable because of their mild side effects, they often 
seem insufficiently potent to induce a response. Therefore, short term, intermittent use of 
moderately potent corticosteroids to induce a response, followed by a subsequent 
gradual shift towards a weak steroid preparation is sometimes advised.14,34,35,40,42,43,61 
On the contrary, intensive, short-term, intermittent use of potent corticosteroids is 
also occasionally advised.21,22,28,29,45,62,63 The application of corticosteroids in the 
genital region may induce symptomatic candidiasis. 
Coal tar preparations
Coal tar preparations have been used in the treatment of various skin diseases for a 
long time. The preparations mainly used in dermatological practice are crude coal tar 
(pix lithantracis) and its extract liquor carbonis detergens. 
 Coal tar preparations are the second-most advised topical therapy for the treatment 
of genital psoriasis. Mild topical coal tar preparations (i.e. 1-5% liquor carbonis detergens 
in aqueous cream) are advised frequently. They may be used as an individual topical 
therapy or, when (maintenance) treatment with weak corticosteroids is insufficient, be 
combined or alternated with topical corticosteroids.24,34,35,41-44,61 Coal tar may also be 
used for diaper psoriasis, for example mixed with zinc oxide.59,60 These preparations 
are generally well tolerated in the anogenital region, however irritation and folliculitis 
can occur.21,28,31,32,41 Other disadvantages of coal tar preparations are its staining 
and odour. 
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growth factors, which may lead to irreversible DNA alteration and subsequent 
carcinogenesis.72,80-83
 In addition, immunosuppressive agents may indirectly contribute to the 
development of cancer, as an impaired surveillance ability of T-cells may disrupt 
anti-tumour immune surveillance and may potentiate oncogenic stimuli as chemical 
carcinogens, ultraviolet (UV) light and viruses.70,84,85 Viruses that are associated with 
the development of cancer in RTRs are the Epstein-Barr virus which can induce PTLD 
and the hepatitis B/C viruses which are linked to the development of hepatocellular 
carcinoma.86-91 Besides, various subtypes of HPV are associated with SCC of the 
cervix, vulva, perineum and anus.84,92 It is also suggested that HPV infection may act 
as cofactor with UV-radiation in the carcinogenesis of extragenital NMSC. However, 
whether HPV plays a causal role in the oncogenesis of NMSC remains a matter of 
debate.93-98 
1.3.2  Human papillomavirus
The human papillomavirus is a double stranded circular DNA virus that belongs to 
the Papillomaviridae family. To date, more than 150 HPV genotypes have been 
completely sequenced.99 The virusses have co-evolved with their hosts over millions 
of years and many HPV genotypes cause only inapparent, asymptomatic infections 
in immunocompetent individuals. Papillomavirus types found in humans are divided 
into five genera based on DNA sequence analysis, with the different types having 
different life-cycle characteristics and disease associations. Based on their tissue 
preferences, HPV can be divided in cutaneous and mucosal genotypes. 
 Cutaneous HPV genotypes (most of which are in the Beta and Gamma genera) 
are found in the skin and cause cutaneous verruccae.94,99 Cutaneous genotypes are 
generally not associated with the development of cancer, although certain types 
have been implicated in the development of NMSC in immunocompromised 
individuals and in epidermodysplasia verruciformis patients.94,99  
 Mucosal HPV genotypes (within the Alpha genera) are found in mucosal epithelium 
of the oropharynx and anogenital tract. According to their carcinogenicity, mucosal 
HPV is further subdivided into low-risk mucosal types (causing condylomata acuminata; 
mainly genotype 6 and 11) and high-risk types (causing anogenital neoplasia and 
cancer; mainly genotype 16 and 18).99-101 
 Acquisition of genital HPV is very common and is mainly transmitted by sexual 
intercourse.102 The overall worldwide HPV prevalence is approximately 10%, with 
higher proportions in the young age groups.103-105 The lifetime risk for infection with 
one or more HPV subtypes is up to 80%.99,103,106,107 However, the majority of these 
infections is transient and will be cleared by the immunesystem without causing any 
lesions. Only when HPV infections persist long enough, neoplasia and subsequent 
cancer will arise.
therapeutic arsenal, education and psychological/sexuological support is of extreme 
value in the care for patients with genital psoriasis. 
1.3  HPV-related genital (pre)malignancies in  
female renal transplant recipients
1.3.1  Renal transplantation, immunosuppressive therapy and post-
transplant malignancies
The first renal transplantation (RT) was performed between identical twins in 1954. 
Five years later, a succesful RT was made between non-identical twins. Following 
this, promising attempts to transplant other organs were made. At present, solid 
organ transplantations are performed routinely in many countries: about 18.000 RTs 
are performed each year in the European Union (500 million inhabitants).67 After solid 
organ transplantation, the administration of lifelong intense immunosuppressive 
therapy is required. 
 Immunosuppressive therapy has developed over the years towards combination 
therapy with several immunosuppressive drugs. The current 1-year patient and renal 
transplant survival exceeds 90%.68 Initially, the clinical management of organ 
transplant recipients was dominated by acute post-operative problems, acute 
rejection, infection and cardiovascular disease. However, the improvement of immu-
nosuppressive protocols and anti-infectious therapy has led to a decrease of these 
problems.69,70
 As a consequence of the improved long term survival of renal transplant 
recipients (RTRs), there is a tremendous increase in the incidence of post-transplant 
malignancies. It is known that the overall incidence rate of cancer in RTRs is at least 
three- to fivefold increased compared to the general population with similar age and 
gender distribution.71-74 However, the elevated risk for specific cancers, such as 
non-melanoma skin cancer (NMSC), cancer of the lip, Kaposi sarcoma, post-trans-
plant lymphoproliferative disease (PTLD) and Human papillomavirus (HPV) related 
anogenital malignancies is known to be even higher.71-77 Besides NMSC, which is 
extremely common in RTRs, the cumulative risk to develop any malignancy has been 
estimated at 20% after 10 years of chronic immunosuppression. Over the next 20 
years, mortality from cancer may exceed that from cardiovascular disease among 
transplant recipients.70
 The aetiology of post-transplant malignancies is multifactorial, with a main role 
for the use of immunosuppressive medication. The duration and dose of immuno-
suppressants is clearly linked to the appearance of post-transplant cancer.70,78,79 
Various immunosuppressants (e.g. azathioprine and cyclosporine) may have direct 
carcinogenic effects by inhibiting DNA repair capacity or by the production of 
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morbidity after treatment is impressive with infertility, ovarian dysfunction, micturition/
defecation problems and sexual discomfort as the most imposing complications.117
1.3.4  Vulvar (pre)malignancies
Vulvar cancer is a rare disease which accounts for approximately 3-5% of all 
gynaecological cancers, with an incidence of about 2 per 100.000 women.118,119 In 
the Netherlands, about 300 new cases of vulvar SCC are diagnosed per year.118,119 
There has long been a three-grade system to define vulvar SCC precursors (vulvar 
intraepithelial neoplasia [VIN] grade 1-3), analogous with CIN lesions. However, as 
clinicopathological data did not support the concept of a continuous spectrum of VIN 
lesions leading to vulvar cancer, the International Society for the Study of Vulvovaginal 
Disease (ISSVD) modified the classification of VIN. VIN 1 was abandoned and VIN 2 
and 3 were consolidated into one category simply termed VIN. Subsequently, as the 
single diagnostic category VIN included two different vulvar premalignancies that 
have a different malignant potential, the classification was modified into VIN 
differentiated type (dVIN) and VIN usual type (uVIN).120
 Vulvar SCC originates from two separate pathways. The first is an HPV-independent 
pathway and occurs in a background of non-neoplastic epithelial disorders (e.g. 
lichen sclerosus). This form is usually seen in older women and encompasses the 
majority of vulvar SCCs in the general population (about 80%).121,122 Differentiated 
VIN is presumed to be the precursor lesion of the HPV-negative vulvar SCC.118,123
 The second pathway is an HPV-dependent pathway, caused by a persistent 
infection with hrHPV. HrHPV subtypes 16 and 33 are the most commonly seen 
genotypes in vulvar lesions, present in about 60% and 20% of HPV-dependent vulvar 
carcinomas in the general population respectively.121,124-126 The premalignant stage 
for this tumour is uVIN.121,127 The oncogenesis of this type of vulvar SCC has a 
remarkable resemblance to the development of CIN into cervical cancer. The immune 
system seems to play an important role in the progression of uVIN to invasive 
disease.128 HPV-dependent vulvar SCCs primarily affect younger women and 
comprehend the minority of vulvar malignancies in the general population (about 
20%).121,126 Oppositely, HPV-dependent vulvar SCCs seem to comprehend the 
majority of vulvar carcinomas in immunocompromised women.
1.3.5  Genital (pre)malignancies in renal transplant recipients
The role of HPV in the oncogenesis of genital malignancies has urged investigators 
to theorise that the immunosuppressed state poses transplant patients at risk to HPV 
infection with subsequent cancer development. 
 Already in 1975, Porreco et al. described a 14-fold increased incidence of  intrae - 
pithelial lesions of the cervix in RTRs compared with an age matched group in the 
general population.88 In the following years, several other studies showed increased 
 The natural host tissue of HPV is the differentiating epithelial layer of skin or 
mucosa. The life cycle of the virus is initiated when it infects basal epithelial cells, after 
which the virus replicates and produces viral particles during epithelial differentiation. 
The HPV genome encodes for 9 viral proteins; the specific early (‘E’)-region encodes 
for regulatory, transforming and replication viral proteins which are expressed in un- 
to moderately differentiated basal replicating cells. The late (‘L’)-region encodes for 
viral capside proteins which are only expressed in highly differentiated epithelial cells, 
resulting in a high number of HPV copies in superficial epithelial layers (see Figure 1).108 
 A persistent infection with high-risk HPV (hrHPV) may lead to integration of the 
viral DNA into the human genome. Integration is characterised by deletion of the viral 
E2 region, that leads to an over expression of the viral E6 and E7 oncoproteins. These 
proteins are known cancer promoting genes that may inactivate the key cellular 
proteins p53 and retinoblastoma protein which leads to chromosomal instability, 
diminished apoptosis and enhanced cell proliferation. 102,109
1.3.3  Cervical (pre)malignancies
Cervical cancer is a major health problem, with more than 500.000 new cases 
occurring each year worldwide, especially in developing countries. Yearly about 
250.000 deaths from cervical cancer are reported, making it the third leading cause 
of cancer death in women in the world.109 In developed countries, cervical cancer 
has been considered a preventable cancer because of its long pre-invasive state, 
cervical screening cytology programmes to detect pre-invasive lesions at an early 
stage and the possibility to treat these premalignancies. Virtually all cervical cancers 
are caused by hrHPV infection, which implies that cervical cancer does not and will 
not develop in the absence of the persistent presence of HPV.110 HPV 16 accounts 
for 50 – 60% of the cervical cancer cases in most countries, followed by HPV 18 
(10 – 20%).105,110,111 
 The primary site for cervical cancer is the cervical transformation zone (border 
between the glandular and squamous epithelium). The transformation zone is 
assumed to be more susceptible to oncogenic influences, like hrHPV infection, due 
to the high cell-turnover.112 Virtually all cases of cervical cancer develop through the 
following distinct and sequential steps: acute infection with hrHPV followed by 
detectable viral persistence linked to the development of cervical intraepithelial 
neoplasia (CIN) and subsequent invasion.113 About ten percent of the hrHPV 
infections that persist for several years is linked to the development of CIN.114 CIN 
lesions are classified as CIN 1, CIN 2 and CIN 3 on the basis of the presence of 
mitotic activity and nuclear atypia within respectively the basal third, two thirds and 
whole thickness of the epithelium.115
 In general, the prognosis of cervical cancer is good with an overall 5-year survival 
of 65% and for stage I disease a 5-year survival up to 98%.116 On the other hand, the 
120 21
CHAPTER 1 GENERAL INTRODUCTION AND OUTLINE OF THIS THESIS
incidences of CIN and cervical cancer after renal transplantation, with standardised 
incidence rates (SIRs) described between 2.3 and 8.6.70,73,129-131
 Vulvar (pre)malignancies in RTRs are only sparsely described in the current 
literature. However, it is known that RTRs have an obviously increased risk for 
HPV-related vulvar (pre)malignancies.73,75,76 The ANZDATA Registry, which contains 
data of more than 13.000 RTRs (110.395 person years) transplanted between 1980 
and 2003, reported SIRs varying between 45.6 and 55.8 for vulvar cancer.74,132 
1.3.6  Treatment and prevention of genital (pre)malignancies in renal 
transplant recipients
Treatment
Therapeutic concessions are frequently needed in the treatment of genital (pre)
malignant lesions in RTRs, as radiation therapy and extensive surgery may damage 
the renal transplant. Prognosis may therefore be compromised and prevention of 
these lesions in RTRs is of utmost importance. 
Primary prevention
Currently, two vaccines containing immunogens for HPV genotypes 16 and 18 are 
available in many countries. These vaccines may prevent the majority of HPV 16 and 
18 related anogenital (pre)malignancies and have been shown to be highly effective 
in the general population. The vaccines may also be promising for RTRs although 
they may have a decline in vaccine-induced immunity.133
Figure 1  HPV-mediated progression to cervical cancer 
Basal cells in the cervical epithelium rest on the basement membrane, which is supported by 
the dermis. Human papillomavirus (HPV) is thought to access the basal cells through mi-
cro-abrasions in the cervical epithelium. Following infection, the early HPV genes E1, E2, E4, 
E5, E6 and E7 are expressed and the viral DNA replicates from episomal DNA (purple nuclei). 
In the upper layers of epithelium (the midzone and superficial zone) the viral genome is 
replicated further, and the late genes L1 and L2, and E4 are expressed. L1 and L2 encapsidate 
the viral genomes to form progeny virions in the nucleus. The shed virus can then initiate a new 
infection. Low-grade intraepithelial lesions support productive viral replication. The progression 
of untreated lesions to micro invasive and invasive cancer is associated with the integration of 
the HPV genome into the host chromosomes (red nuclei), with associated loss or disruption of 
E2, and subsequent up regulation of E6 and E7 oncogene expression. LCR = Long control 
region.
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer. Woodman CB, Collins SI, 
Young LS. The natural history of cervical HPV infection: unresolved issues. Nature Reviews Cancer 7, 11-22 
(January 2007), copyright 2007.
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Specific themes that were studied in this part include:
- cervical screening in female renal transplant recipients (chapter 6)
- prevalence of gynaecological (pre)malignancies in the female renal transplant 
recipient population (chapter 6)
- clinical overview of anogenital malignancies in female renal transplant recipients 
and HPV genotype distribution in these lesions (chapter 7)
- epidemiology of HPV infections in female renal transplant recipients (chapter 8)
Concluding this thesis, in chapter 9 the main findings of the studies are summarised 
and the implications for patient care are discussed. Future perspectives regarding a 
multidisciplinary approach for anogenital lesions will be given.
Secondary prevention
In the Dutch national cervical cancer screening program, women aged between 30 
and 60 years are invited for cervical screening every five years. Based on the evidence 
of the higher risk for malignancies, it is suggested that this screening in the trans-
plantation population should be intensified, although there is no consistent evidence 
that this will lead to a reduction in cervical cancer incidence and subsequent 
mortality.88,134,135 By now, several European and American guidelines (e.g. the 
European Best Practice Guidelines, the “Kidney Disease: Improving Global Out-
comes”-foundation and the American Society of Transplantation) recommend to 
perform at least annual cervical cancer screening with pelvic examination and 
cervical smear in female RTRs.136-138 According to Wong et al., annual screening for 
cervical cancer using conventional cytology in female RTRs is cost effective when 
compared with no screening.139 Additionally, regular surveillance of the anogenital 
region of female RTRs is important.137,138 Annual screening for cervical cancer 
provides an excellent opportunity to perform a thorough external examination of the 
anal and vulvar regions.
1.4 Outline of this thesis 
This thesis includes clinical studies on genital psoriasis and HPV-related anogenital 
(pre)malignancies in female RTRs. The thesis is divided in two parts.
Part A of this thesis focuses on genital psoriasis. Remarkably little is known about the 
epidemiology, clinical presentation, impact and therapy of genital psoriasis, although 
this hidden skin disease will affect a significant proportion of patients with psoriasis 
at some time during their disease and is a frequent cause of genital complaints. 
Specific themes that were studied in this part include:
- epidemiology of genital psoriasis in the Netherlands (chapter 2)
- impact of genital psoriasis on quality of life and sexual health (chapter 3)
- patients’ experiences of psoriasis in the genital area (chapter 4)
- effects of specialised care for patients with genital psoriasis (chapter 5)
Part B of this thesis focuses on HPV-related anogenital (pre)malignancies in female 
renal transplant recipients. As a consequence of the obviously elevated risk for 
HPV-related anogenital (pre)malignancies in this population and the restrictions in 
treatment of these lesions, additional attention to screening and prevention of these 
lesions is required. 
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Abstract
Background
Psoriatic lesions may involve nearly all sites of the body. Involvement of the genital 
skin is frequently classified as part of intertriginous psoriasis without special 
awareness and treatment for this presentation of the disease. Gaining knowledge 
about the frequency of the involvement of genital skin in these patients will improve 
the overall care for patients with psoriasis.
Objectives
We studied the prevalence of genital psoriasis in the Netherlands and epidemiologi-
cal characteristics of this specific presentation of the disease. Furthermore, we 
studied the relation between flexural and genital psoriasis.
Patients/Methods
A self-administered questionnaire was sent to all 5300 members of the Dutch 
Psoriasis Society. Sociodemographic patient characteristics and disease-related 
data (such as localisation of psoriatic lesions, involvement of the genitalia, age at 
onset of genital psoriasis and severity of genital psoriatic lesions) were collected and 
analysed.
Results
A response rate of 37% was achieved. Almost 46% of the responding patients with 
psoriasis, that is 16.5% of all potential responders (n = 5300), report genital 
involvement at some time during the course of their disease. The genitalia can 
become affected at any age. Many patients with current genital involvement (38%) do 
not have the flexural skin affected. 
Conclusions
A large part of patients with psoriasis suffer from genital psoriasis, which was not 
associated with flexural involvement in at least one third of them. More attention to the 
genital region is required in the current standard treatment of both male and female 
psoriatic patients at any age. 
Introduction
Psoriasis is a multifactorial, chronic, immune-mediated hyperproliferative inflammatory 
skin disease with a relatively high prevalence in the general population of about 2%.1-4 
The most common type of psoriasis is chronic plaque psoriasis which preferentially 
involves the scalp and the outer aspects of the elbows and knees.4 However, psoriatic 
lesions may involve all sites of the body, such as the intertriginous areas (synonym: 
flexures) and the genital skin. 
 Intertriginous psoriasis is diagnosed when the major skin folds of the body are 
affected. Areas that may be involved are the axillae, retroauricular folds, groins, 
gluteal clefts and submammary folds. Involvement of the genital skin is frequently 
classified as part of intertriginous psoriasis and there is often no special awareness 
for this presentation of psoriasis. However, genital psoriasis deserves a distinct 
approach as it may be associated with considerable morbidity, discomfort and 
embarrassment. The genital skin changes from stratified and keratinised squamous 
cell epithelium to mucosa.5-7 Treatment of genital psoriatic lesions deserves special 
attention, as the vulnerable and thin genital skin has a high sensitivity and there might 
be an increased penetration of topical modalities in the genital area.5
 Psoriatic lesions at the genitalia often present as well-demarcated, bright 
erythematous, thin plaques and these usually lack the typical scale which is apparent 
at other parts of the body, because of maceration.8-18 However, scales might be seen 
at the more keratinised surfaces of the genital skin (i.e. penile shaft, scrotum and 
adjacent to the labia majora).18-20 When scaling is present, it is often minimal and can 
easily be scraped off, leaving pinpoint bleedings (Auspitz phenomenon).9,10,21,22 In 
addition to plaque-type genital psoriasis, the genital area might be involved with 
pustular psoriasis as well.23,24 
 Remarkably few data exist on the involvement of the genitalia in patients with 
psoriasis, leaving the current prevalence of genital psoriasis unclear. Three dated 
surveys in populations of patients visiting the dermatologist (conducted between 
1964 and 1974) reported that involvement of the genitalia might occur in 29-40% of 
the patients.25-27 There are only two recent surveys that provide information on the 
prevalence of genital psoriasis while the primary focus of these studies were on other 
issues: the first investigation28 assessed patient compliance in the treatment of 
psoriasis and the other study29 evaluated patient perspectives on the impact of 
psoriasis. Nevertheless, involvement of the genitalia was reported in 29 and 32% of 
the patients respectively.28,29
 Genital psoriasis is probably more common than previously thought. Patients might 
feel embarrassed about genital discomfort (patients’ delay). In addition, anamnesis 
on genital complaints and inspection of intimate body regions of patients are often 
omitted from physical routine examination in dermatological outpatient clinics 
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scales. The involved area of the skin is marked on an anatomical sketch and is 
weighted by an investigator according to the original PASI score.37 The range of 
SAPASI is 0-72, with increasing severity of psoriasis with increasing SAPASI scores. 
Ranges to explain the severity of psoriasis were previously described as: 0, complete 
remission; > 0 to 3, mild; > 3 to 15, moderate; > 15, severe.38
Statistical analysis
All answers were entered in a database and subsequently statistical calculations 
were performed using Statistical Package for Social Sciences 16.0 (SPSS, Chicago, 
IL, USA). Continuous variables were described using median (and ranges) or mean 
(± standard deviation), depending on the (non-) parametric distributions of measured 
variables. Discontinuous variables were described by the total frequencies and 
percentages of each modality. Independent Student’s t-tests were used to calculate 
the significance of differences between numeric variables and chi-square (Χ2) tests 
were used for differences between categorical variables. P-values of <0.05 were 
considered to be statistically significant. Calculations were only performed on the 
total number of patients who answered the concerning queries. Missing values were 
not included in the analysis. 
Results
Of the 5300 questionnaires sent, 1963 were returned, representing an overall 
response rate of 37%. Twenty responses were excluded as the respondents were 
less than 18-years of age (n = 18) or because the gender of the patient was unknown 
(n = 2). The remaining 1943 responses were suitable for analysis. 
Baseline
The distribution of baseline characteristics according to gender, age, BMI and 
SAPASI is reported in Table 1. The respondents comprised 1008 women (51.9%) and 
935 men (48.1%). The mean age of the respondents was 56.3 years (±13.5 years), 
with the men being slightly older [mean age 57.6 years (±12.4 years)] than the female 
patients [mean age 55.1 years (±14.3 years)] (t-test: P < 0.001). The average BMI of 
all the respondents was 26.6 kg/m2 (±4.6 kg/m2). This was comparable for both men 
and women. According to the BMI classification of the World Health Organisation 
(WHO),39 39.6% of the patients had a normal weight (BMI 18.5 – 24.9) and 59.9% had 
overweight (BMI ≥ 25) with 17.6% being (morbid) obese (BMI ≥ 30). 
 The self-reported mean age at onset of psoriasis was 25.4 years (±15.3 years), 
varying between 0 and 79 years of age (see Table 1). The vast majority of the respondents 
(98.6%) (n = 1915) stated that their psoriasis was diagnosed by a general physician 
(doctors’ delay). Similarly, healthcare professionals infrequently initiate a dialogue on 
sexual (dys-) function and the majority of psoriatic patients have never been asked 
about their sexual life by their attending doctor.30-32 Accordingly, the problem of 
genital psoriatic lesions may remain unnoticed in psoriatic patients.
 It is well known that psoriasis may have a major impact on the quality of life.33-36 
Involvement of the genitalia might have a more profound impact on the patient’s 
quality of life with considerable impairment of psychosexual appreciation as well.36
 To improve the care for patients with psoriasis, it is necessary to acquire knowledge 
about the frequency of the involvement of genital skin in these patients. The aim of 
this study is to evaluate the prevalence of genital psoriasis in the Netherlands and to 
describe epidemiological characteristics of this specific presentation of psoriasis.
Materials and Methods
Patients
A self-administered questionnaire was distributed to all members (n = 5300) of the 
Dutch Psoriasis Society together with an introduction letter and reply-paid envelopes. 
The questionnaire could be completed anonymously and no incentives were given. 
A special trained advisor of the Dutch Psoriasis Society could be contacted by 
telephone when patients had questions about the investigation. For difficult issues, 
consultation of one of the investigators was advised. After receiving the questionnaires, 
personal data were separated from the questionnaires and both items were assigned 
an identification number for data handling and control, as well as for storing and retrieving 
the questionnaires during subsequent surveys. Data were analysed anonymously. 
Study design
The investigation was conducted as from the 14th of February 2009 and responses 
were accepted through the first of June 2009. Prior to the distribution of the 
questionnaires, we conducted a pilot study on 10 patients to improve the quality and 
efficiency of the survey. Items about sociodemographic patient variables (age, 
gender, weight and length) and medical data (medical history, age at onset of 
psoriasis and at diagnosis, self-reported localisation and severity of psoriatic lesions, 
type of psoriasis, involvement of the genitalia, age on which genital psoriasis started 
and severity of genital lesions) were covered in the questionnaire. The severity of 
psoriasis was assessed in multiple-choice questions (by using an ordinal scale; 
classification: no, mild, moderate or severe lesions) and by the self-administered 
psoriasis area and severity index (SAPASI). SAPASI is a valid and reliable instrument 
that allows patients to assess the severity of their psoriasis. The redness, induration 
and scaliness of an average psoriatic lesion are rated with three visual analogue 
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patients: 497 (53.3%) patients of the male sample (n = 932) indicated genital 
involvement during the disease, whereas 380 patients (38.2%) of the female sample 
(n = 994) indicated genital involvement (Χ2: P < 0.001).
 More than one-third of the patients (569 of 1621 patients, 35.1%) stated that they 
suffered from genital psoriasis at the moment of this study, with varying degrees of 
severity [mild (82.6%), moderate (15.1%) or severe (2.3%)].
 There were no significant differences in the presence of overweight/obesity (BMI 
≥ 25) for patients with and patients without genital psoriasis (Χ2: P = 0.44).
Age at onset of genital psoriasis
The mean age at onset of genital psoriasis appeared to be 35.3 years (±15.0 years). 
However, psoriatic involvement of the genital skin may begin at almost any age, 
regarding the broad range reported by the patients (range: 3-85 years of age). Figure 1 
shows the distribution of age at onset of genital psoriasis, reflecting that the majority 
of patients had the first genital manifestation between 20 and 40 years. No significant 
differences in age at onset of genital psoriasis existed between men and women 
(t-test: P = 0.80). 
 The median time between the onset of psoriasis and the onset of genital lesions 
appeared to be 8.0 years, ranging from 0 to 66 years. One hundred and thirty-six 
patients (17.7%) had genital involvement as initial presentation of their psoriasis.
or a medical specialist. The remaining 1.4% (n = 28) did not answer this particular 
query. Psoriasis was diagnosed after a mean of 2.1 years after the beginning of 
complaints, with a maximum of 59 years thereafter. Most respondents (90.4%) were 
diagnosed with psoriasis within the first 5 years after the beginning of skin complaints. 
The mean duration of the respondents’ psoriasis was 30.9 years (±16.0 years). 
Patients had a median SAPASI score of 6.0 ranging from 0 to 39.4 (mean: 6.6 ± 4.4). 
Chronic plaque psoriasis was the most common clinical type of psoriasis, which was 
present in 1313 cases (67.6%). More than half of the respondents (51.1%) reported nail 
involvement. In addition, joint complaints were present in 42.4% of the patients.
Genital psoriasis
Of the 1926 respondents, who answered the query, 877 patients (45.5%) stated that 
their genital skin had been affected by psoriasis at sometime during the course of 
their disease. This corresponds to 16.5% of the entire study population (n = 5300). 
Genital psoriasis significantly prevailed in male patients compared with female 
Table 1  Baseline characteristics
Baseline characteristics
Sex, No. (%)
Male 935 48 %
Female 1008 52 %
Age, years
Mean (± SD) 56.3 ± 13.5
Age at onset of psoriasis, years
Mean (± SD) 25.4 ± 15.3
Duration of psoriasis, years
Mean (± SD) 30.9 ± 16.0
BMI, kg/m2
Mean (± SD) 26.6 ± 4.6
SAPASI score
Median (range) 6.0 0-39.4
Psoriasis, No. (%)
With nail involvement 992 51.1 %
With joint complaints 824 42.4 %
No. = Number; SD = Standard deviation; BMI = Body mass index; SAPASI = Self-administered psoriasis 
area and severity index
Figure 1  Age at onset of genital psoriasis
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without ever the genital area having involved. This indicates that flexural and genital 
psoriasis are most probably distinct manifestations of psoriasis.
 The large number of patients responding to our questionnaire (1943 patients) 
provides valuable insights into the epidemiology of genital psoriasis, which is a 
presentation of psoriasis with limited attention of professionals until now. Nearly half 
of our patients reported involvement of the genitalia during the course of their disease, 
which is the highest percentage ever reported in the literature. However, it is remotely 
possible that patients with genital involvement may have returned the questionnaires 
preferentially (sampling bias). Nevertheless, even when we assume that all non-responders 
would have no genital involvement, still 16.5% of the population has genital psoriasis. 
The truth most probably lies somewhere in between. 
 Three previous studies reported genital manifestations of psoriasis in 29–40% of 
the patients.25-27 Remarkably, these studies which were published approximately 40 
years ago have never led to further publications in the field of the genital manifestations 
of psoriasis. Two recent studies report involvement of the external genitalia in 29 and 
32% of the patients, but these numbers were just secondary outcome measures.28,29 
 It is difficult to understand why direct questioning to genital complaints and 
active inspection of the external genital area in patients with psoriasis has not become 
a part of daily practice for dermatologists after the publications about high prevalence 
of genital psoriasis. The impact of genital psoriasis on quality of life and psychosexual 
appreciation may be apparent.36 The negative influence on psychosexual wellbeing 
and quality of life may be caused by either the skin disease itself and/or the localisation 
of psoriatic lesions at genital skin. Unfortunately, the prevalence of genital psoriasis 
is underestimated, because of both patients’ and doctors’ reluctance. The implementation 
of adequate information on genital psoriasis in (self-) educational programmes for 
patients with psoriasis might be of interest to require more common knowledge about 
this intimate manifestation of the disease. Moreover, doctors should be encouraged 
to initiate a dialogue about possible genital complaints to offer adequate treatment 
and psychosexual counselling by professionals.
 Our results showing that almost 60% of the respondents had a BMI ≥ 25 (which 
is defined as overweight by the WHO39) are in agreement with the previous studies 
that have shown a positive association between increased BMI and psoriasis.40,41 
There is no significant difference in the presence of overweight/obesity between 
patients with and patients without genital psoriatic lesions. 
 The mean age at onset for psoriasis in general was 25.4 years. The median time 
between onset of psoriasis in general and onset of genital lesions turned out to be 
8 years, with a broad range. This difference in ages at onset is difficult to explain. 
Apparently, as the peak incidence of genital lesions is after menarche and before 
menopause in females, an association between the occurrence of genital lesions 
and hormonal factors is improbable.
Flexural versus genital psoriasis
Responses of 1558 patients about current involvement of the genitalia and flexures, 
regardless whether other sites of the body (e.g. trunk, extremities or scalp) were 
affected at that time, are shown in Figure 2. This question was answered by 1558 
patients, of which 519 patients (33.3%) currently have genital psoriasis. Of these, 197 
patients (38.0%) had only genital psoriasis without having the flexures affected. 
 Three hundred and four of the 310 patients in whom currently only the flexural 
skin is affected by psoriasis answered the query on whether they had had genital 
involvement during the course of their disease. Two hundred and thirty-four (234) of 
these patients (77.0%) answered that they had never had their genital skin affected 
with psoriasis.
Discussion
Our study illustrates that almost 46% of the patients with psoriasis report genital 
involvement at some time during the course of their skin disease. The mean age at 
onset of genital psoriasis is 35.3 years, but the genitalia may be involved at nearly any 
age. Almost 40% of patients with current genital involvement do not have the flexural 
skin affected. Additionally, a substantial part of the population had flexural psoriasis 
Figure 2  Current genital and/or flexural involvement
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lesions at the genital skin’ instead of ‘genital complaints in general’. At least 98.6% of 
the respondents was diagnosed with psoriasis of their skin by a general physician or 
a medical specialist. We assume that most patients with psoriasis will recognise their 
skin disease on genital skin rather adequate, although it might be possible that other 
skin diseases than psoriasis have been present at the genital skin of the respondents.
 To conclude, our study shows that a large part of patients with psoriasis suffer 
from genital presentation of this disease and that genital psoriasis is most likely 
another entity than flexural psoriasis. To our opinion, these results plead for more 
attention to the genital region in both males and females with psoriasis at any age. 
A challenging task for further research is to conduct a prospective study to investigate 
whether genital complaints in psoriatic patients are actually caused by genital 
psoriasis. Additionally, treatment options for this presentation of psoriasis should be 
studied. Moreover, the impact of genital psoriasis on psychosexual satisfaction and 
quality of life should be part of further research.
 It is evident from this study that there are significantly more male patients with 
psoriasis of the external genitalia (53.3% of the male population) compared with 
female patients (38.2% of the female population). Our data reconfirm the discrepancy 
between male and female genital involvement which is already documented in older 
studies on the epidemiology of psoriasis. Three previous studies reported data on 
male and female genital psoriatic involvement, which appeared to be present in 
33–49% and 21–33% of cases respectively.25-27 Interestingly, our percentages are by 
far the highest percentages ever documented. It is attractive to speculate on the 
preponderance of male patients with genital psoriasis. Male genital skin may be 
affected more often with psoriasis than female genital skin and/or males may report 
these lesions more often. However, two other explanations may be more likely: 
inspection of the external genitalia is easier for males compared with females; 
moreover, complaints of female external genitalia might be more difficult to interpret 
correctly by the women as a result of confusion with other genital dermatoses (like 
non-specific dermatitis or candidiasis). Nevertheless, male and female patients are 
both frequently involved with genital psoriatic lesions.
 The external genital skin is generally classified as flexural skin, although it forms 
a unique area comprising different structures and types of epithelium.5-7 As a 
consequence of local circumstances, the genital skin folds are susceptible to 
maceration and fissuring and the normal characteristics of psoriasis might be lost or 
modified in this region. Additionally, as a result of the localisation, genital lesions 
might be confused with sexually transmitted diseases. The present study revealed 
that flexural and genital psoriasis were separate manifestations in a considerable 
number of patients: 38% of the patients with current genital psoriasis did not have the 
flexures affected and 77% of the patients with current flexural psoriasis had never 
experienced genital lesions. Based on these percentages and the typical presentation 
of psoriasis at genital skin, it is reasonable to assume that flexural and genital 
psoriasis are distinct entities of psoriasis that both require special attention in clinical 
practice. 
 A selection bias might be created by questioning the members of the Dutch 
Psoriasis Society, as members of a patient support association may possibly not 
represent a random sample of patients with psoriasis. It may be speculated that 
these patients are perhaps more interested or worried about their disease or they 
might suffer from more severe psoriasis. The possibility to answer the questionnaire 
anonymously is an important strength of our investigation. Patients probably indicate 
genital symptoms more easily on an anonymous questionnaire than during a visit at 
the outpatient clinic. As our questionnaire based study asked retrospectively for 
information, a slight recall bias might be present in our data, which can cause either 
an over- or underestimation of the results. Bearing in mind the multiple differential 
diagnoses for genital psoriasis, we deliberately asked for the presence of ‘psoriatic 
244 45
CHAPTER 2 EPIDEMIOLOGY OF GENITAL PSORIASIS
32 Niemeier V, Winckelsesser T, Gieler U. Skin disease and sexuality. An empirical study of sex behavior 
or patients with psoriasis vulgaris and neurodermatitis in comparison with skin-healthy probands. 
Hautarzt 1997; 48: 629-33.
33 Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49: S57-S61.
34 Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the 
EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-36.
35 Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National 
Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280-4.
36 Wolkenstein P. Living with psoriasis. J Eur Acad of Dermatol Venereol 2006; 20: 28-32.
37 Feldman SR, Fleischer AB, Jr., Reboussin DM et al. The self-administered psoriasis area and severity 
index is valid and reliable. J Invest Dermatol 1996; 106: 183-6.
38 Fleischer AB, Jr., Feldman SR, Rapp SR et al. Disease severity measures in a population of psoriasis 
patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index 
scores. J Invest Dermatol 1996; 107: 26-9.
39 World Health Organisation Global Database on BMI Classification Available at: http://apps.who.int/
bmi/index.jsp?introPage=intro_3.html (Last accessed: 30 December 2009) 
40 Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as 
risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-7.
41 Wolk K, Mallbris L, Larsson P et al. Excessive body weight and smoking associates with a high risk of 
onset of plaque psoriasis. Acta Derm Venereol 2009; 89: 492-7.
References
1 Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-20.
2 Myers WA, Gottlieb AB, Mease P. Psoriasis and psoriatic arthritis: clinical features and disease 
mechanisms. Clin Dermatol 2006; 24: 438-47.
3 Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 
2001; 15: 16-7.
4 Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71.
5 Bunker CB, Neill SM. The Genital, Perianal and Umbilical Regions. In: Rook A, Burns T, Breathnach SM 
et al., Rook’s Textbook of Dermatology, Seventh edn. Blackwell publishing, Oxford, 2004; 68. 1-11, 68. 
49-52.
6 Cold CJ, Taylor JR. The prepuce. BJU Int 1999; 83 Suppl 1: 34-44.
7 Stoof TJ, van der Meijden WI. Psoriasis. In van der Meijden WI, ter Harmsel WA, eds. Vulvapathologie, 
1st edn.Koninklijke van Gorcum B.V., Assen, 2007: 137-46.
8 Buechner SA. Common skin disorders of the penis. BJU Int 2002; 90: 498-506.
9 Goldman BD. Common dermatoses of the male genitalia. Recognition of differences in genital rashes 
and lesions is essential and attainable. Postgrad Med 2000; 108: 89-91, 95-96.
10 Golombowski G, Anthuber S, Anthuber C. Vulva diseases in childhood. [German]. Gynakologe 1998; 
31: 558-65.
11 Gross G. Dermatological findings on the breast and vulva. [German]. Gynakologe 2001; 34: 940-8.
12 Mroczkowski TF. Common nonvenereal genital lesions. Med Clin North Am 1990; 74: 1507-28.
13 Pincus SH. Vulvar dermatoses and pruritus vulvae. Dermatol Clin 1992; 10: 297-308.
14 Rosen T. Update on Genital Lesions. JAMA 2003; 290: 1001-5.
15 Salim A, Wojnarowska F. Skin diseases affecting the vulva. Curr Obstet Gynaecol 2002; 12: 81-9.
16 Trager JDK. What’s your diagnosis? Well-demarcated vulvar erythema in two girls. Pediatr Adolesc 
Gynecol 2005; 18: 43-6.
17 van Dijk F, Thio HB, Neumann HAM. Non-oncological and non-infectious diseases of the penis (Penile 
Lesions). EAU-EBU Update Series 2006; 4: 13-9.
18 Varghese M, Kindel S. Pigmentary disorders and inflammatory lesions of the external genitalia. Urol 
Clin North Am 1992; 19: 111-21.
19 Farber EM, Nall L. Genital psoriasis. Cutis 1992; 50: 263-6.
20 Coldiron BM, Jacobson C. Common penile lesions. Urol Clin North Am 1988; 15: 671-85.
21 Weinrauch L, Katz M. Psoriasis vulgaris of labium majus. Cutis 1986; 38: 333-4.
22 Fiumara NJ. Psoriasis of the penis: Koebner reaction. Following oral genital exposure. J Am Vener Dis 
Assoc 1976; 3: 59-60.
23 Quan MB, Ruben BS. Pustular psoriasis limited to the penis. Int J Dermatol 1996; 35: 202-4.
24 Singh N, Thappa DM. Circinate pustular psoriasis localized to glans penis mimicking ‘circinate 
balanitis’ and responsive to dapsone. Indian J Dermatol Venereol Leprol 2008; 74: 388-9.
25 Hellgren L. Psoriasis. A statistical, clinical and laboratory investigation of 255 psoriatics and matched 
healthy controls. Acta Derm Venereol 1964; 44: 191-207.
26 Farber EM, Bright RD, Nall ML. Psoriasis. A questionnaire survey of 2,144 patients. Arch Dermatol 
1968; 98: 248-59.
27 Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica 1974; 148: 1-18.
28 van de Kerkhof PC, de Hoop D, de Korte J et al. Patient compliance and disease management in the 
treatment of psoriasis in the Netherlands. Dermatology 2000; 200: 292-8.
29 Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. J Eur 
Acad Dermatol Venereol 2005; 19 Suppl 3: 2-6.
30 Bachmann G. Female sexuality and sexual dysfunction: are we stuck on the learning curve? J Sex Med 
2006; 3: 639-45.
31 Wendt E, Hildingh C, Lidell E et al. Young women’s sexual health and their views on dialogue with 
health professionals. Acta Obstet Gynecol Scand 2007; 86: 590-5.
Quality of life 
and sexual health in patients 
with genital psoriasis
K.A.P. Meeuwis
J.A. de Hullu
H.P. van de Nieuwenhof
A.W.M. Evers
L.F.A.G. Massuger
P.C.M. van de Kerkhof
M.M. van Rossum
British Journal of Dermatology
2011; 164: 1247 – 1255
CHAPTER
3
348 49
CHAPTER 3 GENITAL PSORIASIS: QUALITY OF LIFE AND SEXUAL HEALTH
Abstract
Background
Knowledge about quality of life and sexual health in patients with genital psoriasis is 
limited.
Objectives
We studied quality of life and sexual function in a large group of patients with genital 
psoriasis by means of validated questionnaires. In addition, we evaluated whether 
sufficient attention is given by healthcare professionals to sexual problems in patients 
with psoriasis, as perceived by the patients.
Methods
A self-administered questionnaire was sent to 1579 members of the Dutch Psoriasis 
Association. Sociodemographic patient characteristics, medical data and scores of 
several validated questionnaires regarding quality of life (Dermatology Life Quality 
Index) and sexual health (Sexual Quality of Life Questionnaire for use in Men, 
International Index of Erectile Function, Female Sexual Distress Scale and Female 
Sexual Function Index) were collected and analyzed.
Results 
This study (n = 487) shows that psoriasis has a detrimental effect on quality of life 
and sexual health. Patients with genital lesions reported even significantly worse 
quality of life than patients without genital lesions (mean ±SD quality of life scores 8.5 
± 6.5 vs. 5.5 ± 4.6, respectively, P < 0.0001). Sexual distress and dysfunction are 
particularly prominent in women (reported by 37.7% and 48.7% of the female patients, 
respectively). Sexual distress is especially high when genital skin is affected (mean 
±SD sexual distress score in patients with genital lesions 16.1 ± 12.1 vs. 10.1 ± 9.7 in 
patients without genital lesions, P = 0.001). The attention given to possible sexual 
problems in the psoriasis population by healthcare professionals is perceived as 
insufficient by patients. 
Conclusions
In addition to quality of life, sexual health is diminished in a considerable number of 
patients with psoriasis and particularly women with genital lesions have on average 
high levels of sexual distress. We underscore the need for physicians to pay attention 
to the impact of psoriasis on psychosocial and sexual health when treating patients 
for this skin disease.
Introduction
Psoriasis may involve all sites of the body, including the genital skin. Psoriatic lesions 
at the genitalia often present as well-demarcated, bright erythematous, thin plaques 
and these usually lack the typical scale which is apparent at other parts of the body, 
due to maceration.1-7 Only rarely may scaling be seen at the genital skin. Then, it is 
often minimal and can easily be scraped off, leaving pinpoint bleeding.7-9 In addition 
to plaque-type genital psoriasis, the genital area might also be involved with pustular 
psoriasis.10,11 Treatment of genital psoriatic lesions deserves special attention, as the 
vulnerable and thin genital skin is highly sensitive and there might be an increased 
penetration of topical treatment agents in the genital area.12 Despite the possibility of 
adequate treatment, (genital) psoriasis is characterised by exacerbations and 
remissions. A substantial number of patients with psoriasis have genital psoriatic 
lesions. We recently published data on the prevalence of this particular localisation of 
psoriasis in patients in the Netherlands. Of 1943 patients with psoriasis, over 45% 
reported genital presentations of psoriasis at some time during the course of their 
disease.13 
 It is well known that psoriasis may have a substantial negative impact on physical, 
psychological and social dimensions of quality of life.14-18 The impact of psoriasis on 
sexual health, which is an integral part of general health and quality of life, is an 
underexplored area. There are only few studies on this topic, relying on data from 
small samples. According to these studies, sexual health may frequently be impaired 
in patients with psoriasis compared with people with healthy skin.19-24 Although the 
literature is not uniform, it is conceivable that when psoriasis is present on the more 
sensitive areas of the body, like the genital skin, the negative effect on sexual quality 
of life is more profound. This was established by Buckwalter in 1982.25 However, van 
Dorssen et al. found no correlation between diminished sexual satisfaction and 
localisation of psoriasis on genital skin.26 One more recent publication denotes that 
patients with a decreased sexual activity since the onset of psoriasis reported a 
marginally, but not significantly, greater psoriasis severity affecting the genital area 
compared with patients without a decreased sexual activity.20 Not only psoriasis itself 
but also the treatments as used by the patients may cause sexual dysfunction; some 
publications report that antipsoriatic medication (i.e. methotrexate and etretinate) 
might cause sexual impotence and erectile dysfunction.27-29 In addition, itch and 
related scratching behaviour might have a particular worsening impact on the genital 
skin, resulting in a vicious itch-scratch circle that worsens the condition of the affected 
psoriatic genital skin.30 Despite this possible impact of psoriasis on intimate 
relationships and sexuality, the vast majority of patients with a chronic skin disease 
like psoriasis reported that they had never been asked about their sexual life by their 
attending doctor.22 
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several sociodemographic patient characteristics (age, gender and marital status) 
and subjective feelings regarding sexuality and having psoriasis: whether there is 
sufficient attention given to possible sexual problems and whether more attention to 
these problems is required (by checking ‘yes’, ‘no’, ‘unknown’). Moreover, patients 
were asked whether they believe that since the onset of psoriasis sexual activity has 
declined. If yes, we asked the patients to rate (using a four-point scale of ‘never’, 
‘sometimes’, ‘often’, and ‘always’) the frequency with which several factors affected 
their sexual functioning, as was previously described by Gupta and Gupta.20
Scoring systems
See Table 1 for an overview of all scoring systems used. 
Dermatology Life Quality Index
The DLQI is a commonly used 10-item questionnaire regarding the quality of life in 
patients with a skin disease, comprising the following six domains: symptoms and 
feelings, daily activities, leisure, work and school, personal relationships and treatment. 
The total score is calculated by summing the score of each question, resulting in a 
minimum of 0 and a maximum of 30. In cases of missing answers, we calculated the 
scores according to the manual. The higher the DLQI score, the more quality of life 
is impaired.34 
Self-administered Psoriasis Area and Severity Index
This instrument allows patients to assess the severity of their psoriasis. Patients rate 
the redness, induration and scaliness of an average psoriatic lesion with three visual 
 The aim of our study was to gain more knowledge about quality of life and sexual 
function by means of validated questionnaires in a large group of patients with genital 
psoriasis. In addition, we evaluated whether sufficient attention is given by health care 
professionals to sexual problems in patients with psoriasis, as perceived by the patients.
Materials and methods
Subjects and procedure
In total, 1579 members of the Dutch Psoriasis Association were asked to participate 
in the study. These patients were involved in a previous study on epidemiology of 
genital psoriasis13 and had given their permission to participate in a consecutive 
questionnaire-based study on quality of life and sexual health. Medical ethics review 
was not required according to the local Medical Review Ethics Committee. All patients 
were ≥ 18 years of age. Participants had the opportunity to consult one of the 
investigators by e-mail for questions regarding the study. Repeat mailings were 
made for unreturned surveys. We introduced a secured digital answering system for 
electronic completion of the questionnaire. Besides, a paper version was available for 
those patients without access to the internet. Results were collected between 24 
September 2009 and 31 December 2009. Answers were processed anonymously 
and data were linked to the corresponding answers of the preceding survey by an 
identification number.
Study design
Contents of the first questionnaire have previously been described in detail.13 The 
following items of that questionnaire were used for the current study: medical data 
(background information on psoriasis, severity of psoriasis and current or previous 
genital involvement), Dermatology Life Quality Index (DLQI) scores and Self- 
Administered Psoriasis Area and Severity Index (SAPASI) scores. As psoriasis is a 
chronic and fluctuating skin disease, we modified the time frame of the DLQI towards 
1 year. Therefore, all DLQI scores mentioned are for the modified 1-year basis DLQI.
 The secondary questionnaire comprised several validated instruments to 
measure sexual health [Sexual Quality of Life Questionnaire for use in Men (SQoL-M), 
International Index of Erectile Function (IIEF), Female Sexual Distress Scale (FSDS) 
and Female Sexual Function Index (FSFI)]. ter Kuile et al. replicated the adequate 
psychometric properties of the FSDS and FSFI within a Dutch population and the 
SQoL-M and IIEF have also been validated in the Dutch population.31-33 All 
questionnaires are based on the patients’ experiences over the previous 4 weeks. 
Just like the DLQI, we deliberately modified all questionnaires so that all responses 
were based on the experiences over the previous year. Patients were also asked for 
Table 1  Scoring systems
Scoring 
System
Measure Interpretation
DLQI Dermatology-specific QoL ↑ score = ↓ QoL
SAPASI Severity of psoriasis ↑ score = ↑ severity
SQoL-M Male sexual QoL ↑ score = ↑ QoL
IIEF Male sexual function ↑ score = better sexual function
FSDS Female sexually related personal dis-
tress
↑ score = ↑ distress
FSFI Female sexual function ↑ score = better sexual function
QoL  = Quality of life
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allowed to be missing. The full-scale score ranges between 2 and 36. Higher scores 
of the FSFI mean better sexual functioning. A FSFI total score of 26.55 or less is the 
cutoff point for differentiating women with and without sexual dysfunction.40
Statistical analysis
All answers were entered in a computerised database. Subsequently, statistical 
calculations were performed using Statistical Package for Social Sciences 16.0 
(SPSS, Chicago, IL, USA). Data of all measured variables were checked for their 
distribution pattern.
 Continuous variables were described as median and range or mean ±SD, 
depending on the (non)parametric distributions of variables measured. Discontinuous 
variables were described by the total frequencies and percentages of each modality. 
Missing values were processed as described in the section ‘scoring systems’; for 
other variables the missing data were not included in the analysis. 
 Differences between groups were examined using a chi-square test for categorical 
variables. Parametric distributed continuous variables were compared by using 
independent Student’s t-tests and nonparametric distributed continuous variables 
were compared using the Mann-Whitney U-test. Correlations between different 
variables were calculated using Pearson or point-biserial correlation tests. We used a 
partial correlation test, controlling for SAPASI scores, for calculation of the correlation 
coefficients between scores of questionnaires and having current genital psoriasis. 
Statistical significance was achieved at P < 0.05.
Results
Baseline
In total, 487 questionnaires were returned, resulting in a response rate of 31%. 
Baseline characteristics are shown in Table 2.
 Significantly more men (278 responders out of 776; 35.8%) responded to our 
questionnaire compared with women (209 responders out of 803; 26.0%) [X2: P < 
0.0001]. Respondents were significantly younger (53.3 vs. 57.3 years; independent 
Student’s t-test: P < 0.0001), were diagnosed with psoriasis at a significantly younger 
age (24.5 vs. 26.2 years; independent Student’s t-test: P = 0.03) and had a significantly 
higher SAPASI score (7.1 vs. 6.6; independent Student’s t-test: P = 0.04) compared 
with non-respondents. 
 The mean ± SD age of the patients at the time of the second questionnaire was 
53.9 ± 12.3 years. The mean ± SD age at disease onset was 24.5 ± 14.0 years. More 
than one-third of the patients (38.2%) experienced psoriatic skin lesions before the 
age of 18 years. The majority of respondents had chronic plaque psoriasis (69.6%), 
analogue scales and shade the involved area of their skin on a silhouette of the 
human body. Based on the silhouette shading, an investigator assigns a value for 
each area.35 The SAPASI weights the involved area as in the original Psoriasis Area 
and Severity Index36 score. The range of SAPASI is 0–72, increasing SAPASI scores 
indicating increasing severity of psoriasis. Ranges to explain the severity of psoriasis 
were previously described as: 0, complete remission; >0 to 3, mild; > 3 to 15, 
moderate; > 15, severe.37
Sexual Quality of Life Questionnaire for use in Men
The SQoL-M is a self-administered instrument which assesses sexual quality of life 
in men.32 The instrument contains 11 items, each with a response scale ranging 
between ‘completely agree’ (1 point) and ‘completely disagree’ (6 points). Total scores 
were calculated according to the SQoL-M scoring manual.32 The total score ranges 
from 0 to 100; increasing scores indicate increase in quality of life. 
International Index of Erectile Function
The IIEF is a multidimensional, 15-item questionnaire scale for the assessment of 
relevant domains of male sexual function (erectile function, orgasmic function, sexual 
desire, intercourse satisfaction and overall satisfaction), with good psychometric 
properties.33 The five domains are each set up by a different cluster of items and 
summing the scores for individual items computes domain scores.33 
 Any missing response resulted in the questionnaire being excluded from the final 
calculation of the questionnaire, according to the IIEF scoring manual. The total score 
ranges between 5 and 75; higher scores indicate better sexual function. 
Female Sexual Distress Scale
The FSDS is a reliable and psychometric valid 12-item scale that assesses sexually 
related personal distress in women.31,38 The total score ranges from 0 to 48, with 
higher scores indicating a higher level of sexual distress. Questionnaires were excluded 
from analyses when more than 10% of the answers were missing. A total score of 
≥ 15 on the FSDS is the recommended cutoff score to establish the presence of 
sexually related personal distress.38
Female Sexual Function Index
The FSFI measures key dimensions of female sexual function.31,39 The questionnaire 
is composed of 19 items, with six individual domains (sexual desire, arousal, 
lubrication, orgasm, satisfaction and pain). Calculations were performed as previously 
described by Rosen et al.39 A domain score was not calculated whenever one or 
more items of the domain were missing. Full-scale scores were calculated by adding 
the six domain scores. To calculate this score, a maximum of one domain score was 
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lesions (GEN group) and 296 patients did not have current genital lesions (NGEN 
group). Within the NGEN group 86 patients had had genital lesions in the past. In 19 
patients we lack information on the presence of current genital lesions; these patients 
were excluded from comparative analysis between the two groups. Respondents 
appeared to have current genital involvement significantly more often (172 of 468; 
36.8%) compared with nonrespondents (284 of 1053; 27.0%) [X2: P < 0.0001].
Quality of life
The mean ± SD DLQI score of all patients was 6.6 ± 5.5. Table 3 shows the DLQI 
scores of both groups. Both the total DLQI score as well as all domain scores indicate 
that patients with current genital lesions experienced significantly worse quality of life 
than patients without genital psoriatic lesions. There was a small but significant 
correlation between the DLQI scores and having genital psoriatic lesions [r = 0.26, P 
(two-tailed) < 0.0001]. 
 The responses of the patients on the particular DLQI item concerning sexual life 
(‘Over the last year, how much has your skin caused any sexual difficulties?’) showed 
a significant difference between the GEN group (mean ± SD 0.7 ± 0.9) and the 
NGEN group (mean ± SD 0.3 ± 0.6) (independent Student’s t-test: P < 0.0001). Male 
and female respondents did not respond differently to this query (independent 
Student’s t-test: P = 0.22).
 Mean ± SD SAPASI scores differed significantly between the GEN (8.7 ± 5.5) 
and NGEN (6.1 ± 3.9) group (Mann-Whitney U-test: P < 0.0001). Nevertheless, the 
correlation between DLQI scores and having current genital lesions was significant (r 
= 0.17, P (two-tailed) < 0.0001), even when correcting for SAPASI scores. This 
indicates that genital psoriasis can significantly affect quality of life, independent 
from the SAPASI score.
 Patients from the NGEN group who had had genital psoriatic lesions in the past 
had the same mean ± SD DLQI score (5.6 ± 4.3) as the patients from the NGEN 
group who had never had genital lesions (5.5 ± 4.7) (independent Student’s t-test: P 
= 0.87). Their mean score differed significantly from the mean DLQI scores of the 
GEN group (5.6 vs. 8.5, P < 0.0001). 
Sexual health
Men with psoriasis had mean ± SD total scores for the SQoL-M and for the IIEF of 
77.2 ± 24.1 and 55.7 ± 17.2, respectively. Patients with genital lesions showed no 
significantly different scores on both questionnaires compared with patients without 
current genital lesions. Also, evaluation of domain scores of the IIEF showed no 
significant differences between both male groups. 
 Using the FSDS cutoff score of ≥ 15, 37.7% of the women with psoriasis showed 
sexual distress. Women with current genital lesions showed significantly more sexual 
followed by guttate psoriasis in 183 (37.6%) patients. The current SAPASI score 
ranged between 0 and 39.4 (median 6.4). This is comparable with the SAPASI score 
of the patients in the previous study (n = 1579).
 In total, 277 patients (56.9%) had their genital skin involved with psoriasis during 
the course of their disease. The reported mean ± SD age at onset of genital lesions 
was 34.7 ± 14.1 years (range 3-74). The total group of respondents was divided into 
two groups according to the presence of current genital lesions. ‘Current genital 
lesions’ was defined as follows: genital skin affected by psoriasis at least 6 months 
before the second questionnaire (i.e. at the time of the first questionnaire). Of the 468 
patients who answered the query, 172 patients stated that they had current genital 
Table 2  Baseline characteristics
Sex, n (%)
Male
Female
278 
209 
(57.1%)
(42.9%)
Marital status, n (%)
Single
Married/cohabiting
Othera
42 
406 
39 
(8.6%)
(83.4%)
(8.1%)
Age (years), mean ± SD 53.9 (± 12.3)
Psoriasis, n (%)b
Plaque
Guttate
Pustular
Erythrodermic
With joint involvement
With nail involvement
339 
183 
23 
28 
208 
270 
(69.6%)
(37.6%)
(4.7%)
(5.7%)
(42.7%)
(55.4%)
Age at onset of psoriasis (years), mean ± SD 24.5 (± 14.0)
SAPASI score, median (range) 6.4 (0 - 39.4)
Ever had genital psoriasis, n (%)
Yes
No
277 
210 
(56.9%)
(43.1%)
Age at onset of genital psoriasis (years), mean ± SD 34.7 (± 14.1)
Current genital psoriasis, n (%)
Yes (GEN)
No (NGEN)
172
296
(36.8%)
(63.2%)
a Divorced, widowed, separated or living apart together
b One patient may have several types of psoriasis
N =  Number; SD = Standard deviation; SAPASI = Self-administered psoriasis area and severity index; 
GEN = Group with current genital lesions; NGEN = Group without current genital lesions
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distress (mean ± SD FSDS score 16.1 ± 12.1) compared with women without current 
genital lesions (mean ± SD FSDS score 10.1 ± 9.7) (independent Student’s t-test: P 
= 0.001). Besides, the prevalence of sexually related personal distress (FSDS score 
≥ 15) was 50.8% in the GEN women and 32.1% in the NGEN women (X²: P = 0.01). 
SAPASI scores did not influence the correlation between FSDS scores and having 
current genital lesions. Although not statistically significant, patients from the NGEN 
group who had had genital psoriatic lesions in the past had a mean ± SD FSDS 
score (12.9 ± 11.5) between that of patients who had never had genital lesions (9.2 ± 
9.1) (independent Student’s t-test: P = 0.07] and that of patients with current genital 
lesions (independent Student’s t-test: P = 0.25).
 The FSFI cutoff score of ≤ 26.55 shows that 48.7% of the women with psoriasis 
had sexual dysfunction. The presence of sexual dysfunction was equally distributed 
between the women with genital lesions (31 of 56 patients; 55.4%) and those without 
genital lesions (57 of 125 patients; 45.6%) (X2: P = 0.23). Besides, the mean scores 
on the FSFI questionnaire (both total score as well as domain scores) did not show 
significant differences between both patient groups. See Table 4 for all sexual health 
scores.
 Patient age at onset of genital psoriasis showed a negative correlation with the 
total scores of the FSFI (r = -0.24, P = 0.03) and the IIEF (r = -0.41, P < 0.0001), 
indicating that patients who were older at onset of genital psoriasis had lower mean 
scores on these questionnaires, meaning worse sexual functioning. The age at onset 
of genital psoriasis did not correlate with the mean total scores of the FSDS, SQoL-M 
and the DLQI questionnaires. 
Decline of sexual activity
Of the 481 patients with psoriasis who answered the query concerned, 120 patients 
(24.9%) answered that their sexual activity declined after the onset of psoriasis. This 
was seen more in women (32.8%) than in men (19.1%) (X²: P < 0.0001). Table 5 
reflects the different factors associated with this decline in sexual activity according 
to the patients. ‘Negative effect of psoriasis on physical appearance’, ‘diminished 
sexual desire of the patient’, ‘inconvenience caused by scaliness of skin’ and 
‘inconvenience caused by topical therapy’ were mentioned most frequently. 
Attention given to possible sexual problems
Table 6 shows that not more than 9% of the responders (n = 44) believe that there is 
sufficient attention given to possible sexual problems by their doctor. In contrast, at 
least 43% of all patients (n = 211) think that it might be desirable during consultations 
for healthcare professionals to direct more attention to and more frequently ask about 
possible sexual problems.
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Discussion
The present study shows that psoriasis has a detrimental effect on both general 
quality of life and sexual health. When genital lesions are present, quality of life is 
even worse. Sexual dysfunction and distress are particularly prominent in half of all 
women with psoriasis, and distress is particular high when genital skin is affected. 
The attention given to possible sexual problems in the psoriasis population by health 
care professionals is perceived by patients as insufficient. 
 It is known that psoriasis can have a substantial impact on health-related quality 
of life.14,15,18 Our results showing that patients with genital psoriasis have a significantly 
worse quality of life compared with patients without genital lesions are in agreement 
with previous studies.17,41 The most significant predictor of quality of life associated 
with psoriasis appeared to be the self-assessed psoriasis severity score (SAPASI)42, 
but even when we corrected for the higher SAPASI score in the patients with genital 
psoriasis, this group still had a worse quality of life compared with the group without 
genital lesions. These findings are, to a certain extent, in accordance with the results 
of Schmid-Ott et al.43 who found that patients with the ‘sensitive’ regions (lower 
abdomen and genitals) affected felt significantly more stigmatised and that they 
concealed their symptoms more often than those with other regions (both visible and 
invisible) affected. These feelings and concerns might have serious consequences 
for an individual’s psychosocial well being. 
 Patients who had had genital psoriasis in the past had the same DLQI scores as 
patients who had never had genital lesions, and patients who had had genital lesions 
in the past had a better quality of life compared with patients with current genital 
lesions. This implicates amelioration in quality of life when recovering from genital 
psoriatic lesions. Likewise, there seems to be a trend towards improvement of the 
FSDS scores for women recovering from genital psoriasis. 
 Almost 40% of the women with psoriasis showed sexually related personal 
distress, which was present in the patients with genital lesions particularly. However, 
a significant proportion of patients without genital lesions experienced sexual distress 
as well. In addition, half of the women had sexual dysfunction as defined by the FSFI 
cutoff score, demonstrating that women with psoriasis particularly suffer from 
limitations in their sexual life and intimate relationships. Descriptive results from 
reasons for lower sexual activity after the onset of psoriasis (Table 5) further suggest 
that feelings of shame and embarrassment about physical appearance, scaling of 
the skin and topical therapy as well as reduced sexual desire might play a major role 
in these high distress and dysfunction scores in women. In contrast, the two groups 
of men showed no differences in sexual quality of life scores.
 The mean SQoL-M scores incline towards normal sexual quality of life, when we 
compare them with the scores of 101 men who self-reported to have no problems 
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the meantime little has improved. Over 60% of the patients indicated that they did not 
know whether sufficient attention was given or not. It may be speculated that patients 
have never realised that doctors could also care for sexual health. In addition, it is 
possible that patients never made a specific demand for care regarding their sexuality, 
purely because they did not know what they might expect.
 Among our patients almost 25% reported a decline in sexual activity since the 
onset of psoriasis, induced by different factors. This percentage is somewhat lower 
than reported in another publication, which found a decline in sexual activity in more 
than 40% of patients with moderate to severe psoriasis.20 It is possible that the 
difference in severity of psoriasis (moderate in our group) explains this difference in 
percentages. Nevertheless, many patients (women in particular) indicated a negative 
impact of psoriasis on sexual activity and this is certainly something which medical 
professionals should discuss with their patients. Ideally, the physician takes the 
initiative to ask about quality of life and sexuality. Optionally, a very short disease-spe-
cific questionnaire such as the DLQI, which is practical and of clinical value when 
used in a busy clinical setting,34 may be used. When indicated, motivated patients 
could be referred to a (dermato)psychologist or sexologist. For patients whose genital 
problems are not limited to dermatological pathology (e.g. erectile dysfunction or 
dyspareunia), a multidisciplinary approach with consultation of a urologist or 
gynaecologist is advised. We believe that better communication and counselling 
about (sexual) quality of life may help to improve acceptance of the skin disease and 
may ameliorate therapeutic results. 
 Limitations of our study deserve comment. A preselection bias might have been 
introduced because we approached a subpopulation of patients who had previously 
participated in research and who were all members of the Dutch Psoriasis Society. It 
may be hypothesised that these patients do not represent a random sample of 
patients with psoriasis, as they might be more interested or worried about their 
disease and additional (sexual) health problems. Also, respondents were younger 
and had more severe psoriasis compared with the nonrespondents. Given the highly 
intimate and personal questions it is possible that a response bias exists as 
particularly patients most bothered by their (genital) symptoms might have returned 
the questionnaires. Older patients were overrepresented, so the observed results 
may possibly not be extrapolated to other age groups. However, the mean DLQI 
scores of our study population, as well as of both separate groups (GEN and NGEN), 
are classified as having a ‘moderate effect on patient’s life’ according to the manual 
of the DLQI. Basra et al.48 recently published data which show that our mean score 
is within the range of the mean scores of patients with psoriasis in many other 
publications. Nevertheless, we used a time-modified version of the DLQI and, in 
consequence, the DLQI scores in the present study cannot be completely compared 
with existing DLQI norm scores. Unfortunately, as both male sexual health questionnaires 
with their sexual function (mean ± SD: 87.13 ± 13.72).32 Several possible factors 
might play a role in these gender differences: men might be less open about their 
sexual problems, resulting in incorrect ‘normal’ scores. However, the questionnaires 
used have been validated in Dutch men populations and showed a considerable 
number of men with lower scores on sexual dysfunction.32,33 Furthermore, one might 
postulate that differences in sexual desire between men with psoriasis and their 
female partners are smaller than the differences between female patients and their 
male partners, making men with psoriasis less concerned about their sex life. 
Moreover, older women’s sexual health (age ≥ 57 years; comprising a large part of 
our study population) appears to be more sensitive to physical health and possibly 
also physical appearance compared with that of older men.44 
 The results of both questionnaires regarding sexual functioning (FSFI and IIEF) 
indicate that sexual functioning is diminished in a large proportion of both men and 
women with psoriasis. Our findings correspond with other studies in small samples.21,45 
Additionally, Goulding et al.46 recently published that erectile dysfunction is increased 
in patients with psoriasis, although psoriasis was no independent risk factor for 
erectile dysfunction in their study population. It is interesting that we did not find any 
differences in sexual function between patients with and patients without genital 
localisation of their psoriasis, while sexual distress was higher in women who had 
more affected genital skin. Apparently, localisation of the lesions at genital skin does 
not provoke worse sexual function in itself, but might have an impact on the subjective 
experience of sexual distress in women, e.g. feelings of reduced physical 
attractiveness because of scaling skin. This is supported by van Dorssen et al.26 who 
state that sexual motivation and satisfaction did not correlate with localisation of the 
disease around the genital skin. A more recent publication denoted that the number 
of patients who report difficulties in sexual life seemed higher in patients with psoriatic 
lesions in the genital area. However, when considering several other variables of 
psoriasis, localisation on the genital area no longer had a significant effect on sexual 
life.24 
 Our finding that the older the patient at onset of genital psoriasis the worse sexual 
function, correlates with a recent publication on sexual function following vulvar 
excision, indicating that older women are at more risk for poor sexual function and 
quality of life following vulvar excision.47 These findings highlight the need to 
distinguish differences in normal changes in sexual function with aging from those 
that may be attributed to the skin lesions. In addition, older women might also have 
more problems with coping adequately with possible sexual and intimate problems 
due to the psoriasis. 
 We showed that the attention given to possible sexual problems in patients with 
psoriasis is seriously insufficient. van Dorssen et al.26 pleaded in 1992 for more 
attention to be paid to potential sexual problems in these patients, but apparently in 
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psychosocial and sexual health when treating patients for psoriasis.
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Abstract
Background 
Psoriasis in the genital area is often neglected, although it bothers a substantial 
number of patients. 
Objective
To study both the role of the physician in the treatment of genital psoriasis and the 
symptom intensity of these lesions as experienced by the patients.
Methods 
A detailed self-administered questionnaire (containing items on the role of the 
physician and genital symptom intensity, range 0–10) was filled in by members of the 
Dutch Psoriasis Society.
Results  
Data of 277 patients with genital psoriasis were analyzed. A total of 45.8% did not 
discuss the presence of genital psoriasis with their physician, 25% believed that the 
physician paid sufficient attention to genital lesions, and 67.8% never applied 
treatment for genital lesions. Mean symptom intensity ranged from 2.4 to 5.1, all 
scores being significantly higher for women compared to men. Severe symptoms 
were present in up to 43.5% of patients. Of these patients, up to 38.1% did not discuss 
the symptoms with their physician. 
Conclusion 
The consultation rate for genital lesions is low, while numerous patients report a 
significant burden of disease. 
Introduction
Psoriasis may involve all sites of the skin, including the genital area. Psoriasis in this area 
has long been neglected in the treatment of patients with psoriasis, whereas several 
reports have shown that it may represent an important problem for a substantial number 
of patients.1-3 Recently, we published data on the prevalence of genital psoriasis in 
patients in the Netherlands. Of 1943 patients with psoriasis, over 45% reported genital 
presentations of psoriasis at any time during the course of their disease.4 
 It is known that healthcare professionals infrequently initiate a dialogue on sexual 
(dys-) function with their patients. The majority of psoriatic patients have never been 
asked about their sexual health by their attending doctor, and it appears that the vast 
majority of psoriatic patients believe that the attention for possible sexual problems is 
insufficient.5-8 Likewise, the problem of genital psoriatic lesions may remain unnoticed 
in patients with psoriasis, whereas involvement of the genital skin may have a 
profound impact on quality of life and sexual health.8
 The experience of symptoms, minor to severe, may create serious distress and 
may disrupt social functioning.9 Understanding the burden of symptoms is crucial to 
identify a focus for intervention strategies.9 Patients with psoriasis frequently 
experience physical symptoms such as skin pain and skin discomfort (e.g. itch, 
irritation or burning).10,11 However, patients’ experience concerning the presence and 
intensity of genital symptoms is only sparsely described in the current literature. 
Some expert opinion-based publications state that pain, pruritus and/or burning 
sensation, ranging from minimal to marked, may be present in patients with genital 
psoriasis.12-15 However, the gold standard for the study of symptoms is based on the 
perception of the individual experiencing the symptom and his/her self-report.9 One 
recent publication16 denotes that there is a significant correlation between the 
presence of vulvar discomfort (considered as itching and/or burning) and vulvar 
localisation of psoriasis. The intensity of vulvar discomfort assessed according to a 
visual analogue scale was 3.8 (range 1–10 points). Unfortunately, the authors did not 
specify the intensity of different symptoms and pain was not measured at all.
 General psoriatic lesions show a dynamic behaviour. Well-known deteriorating 
factors are stress, trauma, infections and specific medications (i.e. beta-blockers and 
lithium).17 For genital psoriasis, the clinical behaviour and possible triggering factors 
are largely unknown. 
 To improve the care of patients with genital psoriasis, it is important to get an 
impression of the current role of the physician in the treatment of genital psoriasis. 
Moreover, the experience of patients regarding physical symptom characteristics of 
genital psoriasis (including intensity and fluctuation) will be clarified in this study. 
Finally, we give recommendations to optimise future care of patients with genital 
psoriatic lesions.
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 Moreover, physical symptoms caused by the genital psoriatic lesions were 
measured. Therefore, the average intensity of itch, pain, burning sensation, scaliness, 
redness and induration was rated using a numeric rating scale, (‘0’ reflecting no 
symptom and ‘10’ reflecting the worst symptom conceivable. Previously suggested 
ranges to explain the intensity of chronic non-malignant pain were used to classify 
the intensity of the physical symptoms of our interest: mild 1–3, moderate 4–6 and 
severe 7–10.10
 Patients’ experience concerning deterioration of genital psoriatic lesions in 
comparison with worsening of non-genital lesions was assessed in a multiple choice 
questionnaire by using an ordinal scale [classification: ‘never’, ‘sometimes’, ‘often’, 
‘always’ and ‘unknown’]. Patients were asked which of the following items may have 
a possible influence on worsening of their genital psoriatic lesions: emotional stress, 
trauma to genital skin (e.g. during depilation), infection on genital skin (e.g. 
dermatomycosis), urinary infection, hormone fluctuations (e.g. menstrual cycle or 
pregnancy) and use of medication. 
Statistical Analysis
All data were entered in a computerised database. Subsequently, statistical calculations 
were performed using Statistical Package for Social Sciences 16.0 (SPSS, Chicago, 
IL, USA). Data of all measured variables were checked for their distribution pattern. 
Continuous variables were described as medians (range) or means (± standard 
deviation), depending on the (non‐) parametric distributions of measured variables. 
Discontinuous variables were described by the total frequencies and percentages of 
each modality. X2 test was used to calculate the significance of differences between 
categorical variables; independent Student’s t-test was used for differences between 
numerical variables. Paired samples t-test was used to calculate differences between 
the intensity of different symptoms. Missing values were not included in the analyses. 
P-values of < 0.05 were considered to be statistically significant.
Results
Baseline
An overall response rate of 31% (487 out of 1579) was achieved for our second 
questionnaire. All questionnaires were suitable for analysis. A total number of 210 
patients never had genital psoriasis. On the other hand, 277 patients (56.9%) 
indicated that their genital skin had been affected by psoriasis at some time during 
the course of their disease. For this study, we focus on the patients who suffer(ed) 
from genital psoriasis (n = 277). Baseline characteristics of all these patients are 
reflected in Table 1.
Patients and Methods
Patients and Study Design
A self-administered questionnaire was distributed to a number of members of the 
Dutch Psoriasis Society (n = 1579). These patients had been involved in a previous 
study on epidemiology of genital psoriasis4 and had given their permission to 
participate in a consecutive questionnaire‐based study on genital psoriasis. All 
patients were ≥ 18 years of age. Participants had the opportunity to consult one of the 
investigators by e‐mail for questions regarding the study. Repeat mailings were made 
for unreturned surveys. A secured digital answering system was introduced to 
complete the questionnaire electronically. Additionally, a paper version was available 
for those patients who did not have internet available. Results were collected from 24 
September 2009 until 31 December 2009. The answers were processed anonymously 
and data were linked to the corresponding answers of the preceding survey by an 
identification number. Medical ethics review was not required according to the local 
Medical Review Ethics Committee. 
Questionnaires
The contents of the questionnaire regarding the previous study have formerly been 
described in detail.4 The following items of that questionnaire were used for the 
current study: sociodemographic characteristics (age, gender and marital status) 
and medical data (age at onset of psoriasis, type and severity of psoriasis, current or 
past involvement of genital skin and age at which genital psoriasis started). The 
severity of psoriasis was assessed by the self-administered psoriasis area and 
severity index (SAPASI).18
 The questionnaire used in the present study asked patients whether they ever 
experienced genital psoriasis during the course of their disease. To be able to define 
patients with current genital lesions and genital lesions in the past, we used the information 
obtained from the first questionnaire about current or past involvement. Therefore, 
‘current genital psoriasis’ was defined as ‘genital skin involved with psoriasis at least 
6 months before the second questionnaire’ (i.e. at the time of the first questionnaire). 
 If patients ever had genital psoriasis, they were asked to answer subsequent 
questions on their experience regarding the role of the physician involved in the care 
of their (genital) psoriasis (either their general practitioner or their dermatologist, 
gynaecologist, urologist or other physician) in this localisation of psoriasis: whether 
they discussed the presence of genital lesions with their physician, whether they 
thought that there was sufficient attention for this presentation of psoriasis and 
whether a biopsy was performed in the genital region to establish the diagnosis of 
psoriasis (by checking ‘yes’, ‘no’ or ‘unknown’). In addition, we asked whether they 
received treatment for their genital lesions and by whom the treatment was prescribed. 
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 Of the 277 patients, 172 patients (66.7%) stated that they suffered from current 
genital lesions, and 86 patients (33.3%) had had genital lesions in the past. In 19 patients 
we lack information on the presence of current genital lesions. 
Patients’ Experience: Role of the Physician 
Almost half of the patients (n = 127, 45.8%) did not discuss the presence of genital 
lesions with their physician; another 127 patients indicated that they discussed this 
issue. Age had no effect on whether or not genital lesions were discussed. Only 
25.3% of all patients mentioned that their physician paid sufficient attention to their 
genital lesions. No significant differences were found between male and female 
patients for both discussion of the genital lesions and perceived attention for those 
lesions (P = 0.51 and P = 0.20, respectively). The vast majority of patients (92.4%) 
stated that a biopsy was never taken to confirm the diagnosis of genital psoriasis. 
 A total of 273 patients responded to the question regarding treatment of genital 
lesions. Over two thirds of patients (n = 185, 67.8%) responded that no treatment for 
their genital lesions was ever applied. Seventy out of the 88 patients who were treated 
for genital lesions indicated that they discussed the genital lesions with their physician. 
Half of the remaining 18 patients who received treatment did not discuss the presence 
of genital lesions with their physician, and for the other half this is unknown. In the 
vast majority of cases (81.4%), the treatment was prescribed by a dermatologist. 
Fifty-seven out of the 127 patients (44.9%) who discussed the presence of genital 
psoriatic lesions with their physician indicated that they did not receive any treatment. 
Patients’ Experience: Genital Symptoms
Table 2 shows the means and standard deviations of the genital symptom intensity 
scores (0–10 numeric rating scale) for the total group, the subgroup of patients with 
current genital psoriasis and the subgroup of patients with genital psoriasis in the past. 
All scores ranged between 0 and 10. Among the total group of patients, it was found 
that the mean intensity scores of itch, burning and pain all differed significantly (4.2 ± 
2.9 vs. 3.5 ± 2.9 vs. 2.8 ± 2.7, P < 0.0001); thus, patients with genital psoriasis have 
significantly more itch than burning skin than pain. Also, the mean intensity scores of 
redness, scaliness and induration differed significantly (5.1 ± 2.5 vs. 3.7 ± 2.8 vs. 2.4 
± 2.6, P < 0.0001), meaning that patients with genital psoriasis have significantly more 
redness than scaliness than induration. The intensity of all symptoms was significantly 
higher for women compared to men (P < 0.0001 for all variables except for pain: 
P = 0.006). Patients with genital psoriasis in the past reported significantly lower 
intensity scores than patients with current genital psoriasis (P < 0.0001 for itch, pain, 
burning sensation, scaliness and redness; P = 0.006 for induration).
 Table 3 shows that redness and itch are indicated as ‘severe’ in most cases and 
pain and induration are usually mild. Depending on the kind of symptoms, up to 
 The present cohort studied (n = 277) consisted of significantly more male 
patients (62.8%) compared to female patients (37.2%) (X2: P = 0.003). The mean age 
of the patients at the time of the questionnaire was 52.2 (± 12.2) years and patients 
reported an average age at onset of genital psoriasis of 34.7 (± 14.1) years. Plaque 
psoriasis (n = 199, 71.8%) was the most common type of psoriasis, followed by 
guttate psoriasis in 117 patients (42.2%). Patients with genital psoriasis appeared to 
have nail involvement significantly more often (177 out of 277, 63.9%) compared to 
the patients without genital involvement (89 out of 210, 42.4%) (X2: P < 0.0001). There 
was no significant difference between the presence of joint complaints between the 
patients with and without genital psoriasis (X2: P = 0.98]
Table 1  Patients’ characteristics (N = 277)
Sex ratio
Male
Female
174 
103 
(62.8%)
(37.2%)
Marital status 
Single
Married/cohabiting
Othera
26 
228 
23 
(9.4%)
(82.3%)
(8.3%)
Age, yearsb 52.2 ± 12.2
Type of psoriasisc
Plaque
Guttate
Pustular
Erythroderma
With joint complaints
With nail involvement
199 
117 
13 
17 
119 
177 
(71.8%)
(42.2%)
(4.7%)
(6.1%)
(43.0%)
(63.9%)
Age at onset of psoriasis, yearsb 24.0 ± 13.2
Median SAPASI score 6.9 (0-39.4)
Age at onset of genital psoriasis, yearsb 34.7 ± 14.1
Current genital psoriasis
Yes
No
Unknown
172
86
19
(62.1%)
(31.0%)
(6.9%)
SAPASI = Self-administered psoriasis area and severity index.
a Divorced, widowed or separated, living apart together.
b Mean ± standard deviation
c Self-reported type of psoriasis. One patient may have indicated several types of psoriasis.
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their non-genital lesions. Forty-one patients (14.8%) answered ‘never’, 46 patients 
(16.6%) ‘often’ and 40 patients (14.4%) ‘unknown’ to this particular query. 
 Patients attributed emotional stress most frequently to worsening of genital 
lesions (n = 194, 70.0%). Trauma to genital skin, infection on genital skin and hormone 
fluctuations may affect progression of genital lesions according to 15.9, 10.5 and 
8.7% of patients, respectively. Urinary infection and the use of medication (NSAIDs, 
beta-blockers or others) were indicated as deteriorating factors only by 2.5 and 4.3% 
of patients, respectively. 
Discussion
This exploratory study provides insight into the experience of patients with genital 
psoriasis. Almost half of the patients did not discuss the presence of genital lesions 
with their physician, and over two thirds of the patients never received treatment for 
these lesions. A comprehensive outline of the genital symptom intensity and 
fluctuation was provided.
 A remarkably large group of patients (45.8%) did not discuss genital psoriasis 
symptoms with their physician. Among these patients, even 20–40% are classified as 
having ‘severe’ symptoms. No differences between men and women were found. It is 
possible that patients may have fear or shyness for genital examination and that they 
are therefore reluctant in starting the conversation about their complaints. 
Unfortunately, we do not know who initiated the dialogue in the cases who did discuss 
the genital symptoms. However, we think that it is justified to advocate a more 
proactive approach of possible genital psoriasis in general practice. 
 A noteworthy number of patients indicated that they never received treatment for 
their genital lesions. Within this group there are patients who did not discuss the 
presence of the lesions with their physician, but also a significant proportion of 
patients who actually did discuss their complaints. This finding may be attributed to 
the fact that during busy outpatient consulting hours, attention is focused on 
non-genital skin and that genital complaints are being overlooked. 
 A number of patients stated that they did not discuss the symptoms, but did 
receive treatment. Therefore, it is very likely that a considerable number of patients 
practice self-treatment, which is an unfavourable situation since the genital skin has 
a high sensitivity and there might be an increased penetration of topical treatment 
modalities in the genital area. Otherwise, it is also possible that patients are treated 
with systemic medication which certainly may have beneficial effects on genital 
psoriatic lesions while not necessarily prescribed for those particular lesions.19 
 At least 80% of the patients studied in this investigation reported genital sensory 
skin symptoms (itch, pain or burning sensation), which corresponds with findings in 
38.1% of the patients with severe genital symptoms indicated that they did not discuss 
the symptoms with their physician. 
 Patients’ experience concerning deterioration of genital psoriatic lesions in 
comparison with worsening of non-genital lesions is diverse. The majority of patients 
(n = 115, 41.5%) indicated that sometimes their genital lesions worsened parallel to 
Table 2  Total and subgroup scores of genital psoriasis symptom intensity  
(0-10 numeric rating scale)
Symptoms Genital psoriasis P-valueb
Total group
(N = 277)a
Current group 
(N = 172)a
Past group
(N = 86)a
Itch 4.2 ± 2.9 4.8 ± 2.9 3.1 ± 2.8 < 0.0001
Pain 2.8 ± 2.7 3.2 ± 2.6 1.9 ± 2.6 < 0.0001
Burning 3.5 ± 2.9 3.9 ± 2.8 2.6 ± 2.8 < 0.0001
Scaliness 3.7 ± 2.8 4.1 ± 2.8 2.8 ± 2.4 < 0.0001
Redness 5.1 ± 2.5 5.6 ± 2.5 4.0 ± 2.3 < 0.0001
Induration 2.4 ± 2.6 2.7 ± 2.7 1.8 ± 2.2 0.006
Data are given as mean ± SD. Missing values were not included in the analysis.
a Number of missing responses: total group (5–12), current group (1–4), past group (4).
b  Independent Student’s t-test. Comparison between patients with current genital psoriasis and those 
with genital psoriasis in the past.
Table 3  Classification of self-reported intensity of genital symptoms
Symptoms None
(NRS: 0)
Mild 
(NRS: 1–3)
Moderate 
(NRS: 4–6)
Severe 
(NRS: 7–10)
Itch 16 (9.4%) 52 (30.4%) 39 (22.8%) 64 (37.4%)
Pain 37 (21.9%) 67 (39.6%) 38 (22.5%) 27 (16.0%)
Burning 32 (18.8%) 43 (25.3%) 54 (31.8%) 41 (24.1%)
Scaliness 20 (11.8%) 59 (34.9%) 46 (27.2%) 44 (26.0%)
Redness 2 (1.2%) 35 (20.6%) 59 (34.7%) 74 (43.5%)
Induration 43 (25.6%) 76 (45.2%) 28 (16.7%) 21 (12.5%)
Total numbers on which percentages are based vary because of missing data for some subjects. 
NRS = Numeric rating scale
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 This study, with an overall response rate of 31%, has uncovered several important 
findings. However, we acknowledge certain limitations of our study. The population 
studied may possibly not reflect a random sample of psoriatic patients, as only 
patients who previously participated in research and who are all members of the 
Dutch Psoriasis Society were included. These patients may be more bothered by 
their genital symptoms compared to the general psoriatic population. Besides, we 
were not able to compare our results with an age- and gender-matched control group 
with genital disease different from psoriasis. Also, male patients predominated in this 
investigation. This is a logical consequence of the fact that the present cohort is a 
selection of the respondents to our second questionnaire. Significantly more male 
patients responded to that questionnaire.8 Moreover, in the study population of the 
first questionnaire, significantly more male patients compared to female patients 
reported genital psoriasis.4 Also, the retrospective design of this study might have 
caused a recall bias, which may have resulted in an over- or underestimation of the 
calculated results, e.g. the difference between symptom intensity in patients with 
current genital psoriasis and those with genital psoriasis in the past. We are aware of 
the multiple differential diagnoses for genital psoriasis, and although we deliberately 
asked for the presence of ‘psoriatic lesions at the genital skin’, it is insuperable that in 
this questionnaire-based study some inaccurate cases have been included. Despite 
these possible biases, the current study is the first describing subjective patients’ 
experience regarding the role of the physician and genital psoriasis symptoms of a 
large number of patients.  
 The consultation rate for genital psoriasis lesions is low, while numerous patients 
report a significant burden of disease. We recommend a proactive and patient-cen-
tred approach to identify and treat patients with genital psoriasis. Based on the 
results of this investigation, we started a specialised outpatient clinic for patients with 
genital psoriasis. The future will learn whether this approach, with focus on treatment 
and improvement of (sexual) quality of life, contributes to the well-being of patients 
with psoriasis. 
another publication on skin pain and discomfort in non-genital psoriasis.10 Sampogna 
et al. published somewhat lower percentages; however, their numbers might be 
underestimated as only patients who reported symptoms ‘often’ or ‘all the time’ were 
counted.11 For all symptoms, patients reported mean genital intensity scores in the 
mild to moderate range, which is equivalent to pain and discomfort intensity scores 
in non-genital psoriasis.10 Zamirska et al. also found mild to moderate vulvar 
symptoms in their population of psoriatic women with vulvar discomfort (n = 41). Only 
22 patients in that study had psoriatic lesions on the vulva.16
 It is known that psoriatic patients with pain experience significantly more often 
and more severe interference with function compared to patients with skin discomfort.10 
We did not investigate to what extent different genital symptoms interfered with daily 
functioning. Nevertheless, we do know that our patients experience a considerable 
impact on quality of life and on sexual health.8 Besides, it is known that in patients 
with vulvar lichen sclerosus, which like psoriasis is clinically characterised by itching 
and burning and has also a chronic nature, there is a correlation between the intensity 
and/or frequency of vulvar symptoms (pain, burning, itching, dryness) and a poorer 
quality of life.20 Also, patients with vulvar lichen sclerosus who experience more itch 
and/or pain report more sexual distress and more problems regarding several 
dimensions of sexual functioning.21 
 Interestingly, all reported symptoms were more severe in women than in men, 
which is also found in other publications on non-genital psoriasis.11,22 When we 
speculate, this finding may reflect biological or psychological differences between 
both genders (women have different pain perception or pain threshold and tolerance 
levels compared to men and maybe this is also the case for other symptoms 
measured in our investigation).23,24 Besides, maybe women are less aggressively 
treated for their genital psoriasis than men. 
 It is remarkable that patients with current genital psoriasis reported significantly 
more intense symptoms compared to patients with genital psoriasis in the past. 
Possibly, patients might forget symptom intensity when genital lesions have resolved. 
 We found no relationship between the deterioration of genital psoriatic lesions 
and worsening of non-genital lesions. This may possibly be due to variance in 
applying treatment to the different skin regions (treating non-genital lesions and not 
treating genital lesions). 
 A very large group of patients indicated stress as aggravating factor for their 
genital lesions. If stress causes worsening of genital psoriasis, then a vicious circle is 
easily created: stress worsens genital psoriasis, which in itself creates a large amount 
of distress.8 We think that starting a dialogue about possible genital complaints and 
(multidisciplinary) treatment of these lesions may relatively easily break through this 
circle. 
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Abstract
Genital psoriasis is a neglected manifestation of psoriasis, although it affects 
numerous patients and has impressive effects on (sexual) quality of life ((S)QoL). We 
aimed to assess the value of specialised care for patients with genital psoriasis. 
Patients were treated for at least one year at a specialised research outpatient clinic 
with extensive attention for genital lesions and (S)QoL. The genital lesions were 
treated according to a stepwise algorithm. First follow-up was planned after six 
weeks; subsequent follow-up visits were scheduled basically every three months. At 
every visit, psoriasis severity and (S)QoL were measured with validated tools. 
Differences in scores between visits were analysed by a mixed model for repeated 
measures. Forty-two patients were included (M:F = 25:17). All objective and 
subjective genital psoriasis severity and QoL parameters improved significantly 
within the first follow-up period of approximately six weeks. In female patients, sexual 
QoL also significantly improved. In conclusion, genital psoriasis can relatively easy 
be treated within limited time exposure, resulting in significant improvement of QoL. 
Prompt and simple adjustments in the provided care are enough to accomplish this. 
Introduction
Psoriasis in the genital area is a rather neglected manifestation of psoriasis. However, 
the number of patients affected with genital psoriasis is considerable. Several studies 
show that involvement of the genital skin occurs in 29-46% of psoriasis patients 
sometime during the course of the disease.1-6
 Most patients with genital psoriasis experience localised mild to moderate sensory 
skin symptoms such as itch, pain and/or burning.7-10 Diagnosis of genital psoriasis 
can usually be made on the basis of its typical clinical appearance that includes 
symmetrical, well-demarcated, brightly erythematous thin plaques that usually lack 
the typical dry scaling.11 Sometimes, evident scaling is seen on the more keratinising 
regions of the genital skin and lesions may be accompanied by painful rhagades or 
fissures.12-15
 Patients with genital psoriasis have significantly worse quality of life (QoL) scores 
compared with patients without genital lesions.16-18 In addition, numerous patients 
with psoriasis have sexual dysfunction.16,19,20 Out of all patients with psoriasis, 25 – 
40% report a decline of sexual activity since the onset of psoriasis, mainly due to 
diminished sexual desire, embarrassment of physical appearance and inconvenience 
caused by scaliness of the skin or topical therapy.16,21 Particularly in women, there is 
evidently more sexual distress and probably also sexual dysfunction when genital 
skin is affected.16,22 
 Treatment of genital lesions is challenging, as the genital skin is thin and sensitive. 
Based on a systematic literature review about this topic, there is room for mild to 
moderate potent corticosteroids, possibly combined with vitamin D analogues or 
tar-based treatment.11 A third-line treatment option is the use of an immunomodulator, 
although evidence is still scarce. Systemic treatment is generally not used solely for 
genital psoriasis11; however, when prescribed it can also improve genital lesions.23,24 
 Genital lesions and the accompanying deterioration of (sexual) QoL ((S)QoL) are 
seldom subject of discussion at the outpatient clinic.1,25 An earlier study showed that 
less than 10% of the patients believe that sufficient attention is given to sexual 
problems by their doctors, while many patients believe that it would have been 
beneficial to have received more care in this area.16,26 A possible explanation for this 
incongruence is that patients might be uncomfortable about or unaware of the 
possibility of discussing sexual problems with their clinicians.27 
 It is clear that there is room for improvement in physical and psychological care 
for patients with genital psoriasis. Therefore, a research outpatient clinic with extensive 
attention for (S)QoL and topical therapy for patients with genital psoriasis was introduced. 
Based on the data collected from this clinic, this study will provide an overview of 
the changes in disease severity and (S)QoL parameters during follow-up. Additionally, 
results of the evaluation of the clinic by the patients after follow-up are presented.
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Methods
Study population
Patients with psoriasis and genital symptoms who participated in a previous questionnaire- 
based study on (S)QoL in patients with genital psoriasis16 or who visited the regular 
dermatology outpatient clinic of the Radboud university medical center were invited 
during March 2010 and October 2011 to visit our research outpatient clinic. 
 Patients were included for follow-up when they had clinically (confirmed by a 
dermatologist) or histopathologically confirmed genital psoriasis, were aged over 18 
years and consented to participation. According to the local Medical Research Ethics 
Committee, medical ethical review was not required for this study. 
Study design
We conducted a cohort study between March 2010 and September 2012. Patients 
were assessed for eligibility at baseline and, when included, followed for at least 
one year. The first follow-up visit (V1) was planned 6 weeks after baseline visit. Further 
follow-up visits were basically scheduled every 3 months during one year. However, 
the schedule was intensified when medically needed (i.e. when treatment was adjusted). 
Also, when patients did not comply with the exact scheme, data were taken into 
account. All patients were followed and all data were collected by one of the clinical 
investigators (KM). 
 At every visit, measurements determining psoriasis severity and (S)QoL were 
completed. In case of possible sexual dysfunction or impaired QoL, patients were 
offered referral to a sexologist or (dermato-)psychologist. 
 After completing follow-up, patients were requested to evaluate the care offered 
at the outpatient clinic by filling in an anonymous evaluation form. This form contained 
questions about change of physical complaints during follow-up, attention for (S)QoL 
at the outpatient clinic and the overall benefit from visiting the outpatient clinic. 
Treatment algorithm 
At baseline, topical therapy was selected according to a stepwise treatment algorithm, 
which we published in 2011.11 An overview of the prescribed treatments is shown 
in Table I. Additionally, the daily use of an emollient was advised to all patients. When 
the patient was already effectively treating the genital psoriasis with treatment comparable 
to our algorithm, this was continued. When, according to the clinical investigator, at 
follow-up there was insufficient clinical improvement in spite of compliance we 
prescribed the next step in the algorithm.
 We considered the use of systemic medication for non-genital psoriatic lesions 
relevant when started during the study period and duration was sufficient to have 
possible systemic effects on genital lesions. 
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Outcome measures
Psoriasis severity and (S)QoL assessments were conducted at baseline and every 
follow-up visit (see Table II and Appendix). 
Statistical analysis
All data were stored in an electronic database and statistical analysis was performed 
using IBM SPSS Statistics 20. Data for all included patients were analysed. Two-sided 
P-values < 0.05 were considered significant. Continuous variables were presented 
as median (range) or mean ±SD, depending on their distribution pattern. Categorical 
variables were summarised by counts and percentages. Missing values were processed 
as described for the different scoring systems. For other variables, missing data 
remained missing. 
 Differences between men and women at baseline were tested with Students’ 
t-test or Mann-Whitney U test. The association between variables was evaluated with 
Spearman’s or Pearson’s (two-tailed) correlation coefficient, depending on the distribution 
of the data. 
 The course of psoriasis severity and (S)QoL during the study period was 
modelled with a restricted maximum likelihood-based linear mixed model for repeated 
measures, using an autoregressive correlation structure with lag 1 and custom 
hypothesis testing. This model corrects for missing data and variation in follow-up 
interval. Skewed variables were log transformed before analysis. In order to evaluate 
whether psoriasis severity and (S)QoL improved after the baseline visit, mean scores 
of variables during the total follow-up period were compared to scores at baseline. In 
order to evaluate whether there was additional improvement after V1, mean scores of 
variables at follow-up visits 2-6 were compared with V1. In a similar way, we evaluated 
whether there were additional benefits in the treatment period between follow-up visit 
2 and follow-up visits 3-6. 
Results
Baseline characteristics
Fifty-one patients who visited the outpatient clinic were screened for inclusion. Nine 
patients appeared to have other diagnoses than genital psoriasis (eczema n = 3, 
lichen sclerosus n = 1, lichen simplex n = 1, unspecified n = 1) or had no visible skin 
lesions and had no previous diagnosis of genital psoriasis (n = 3) and were therefore 
excluded. As a result, data of 42 patients were eligible for inclusion. Characteristics of 
these patients are depicted in Table III. 
 The median interval between baseline and V1 was 6 weeks (range 4-24 weeks) 
and the median interval between the follow-up visits was 13 weeks (range 4-43 
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corticosteroid cream combined with either silver sulfadiazine or fucidic acid cream 
and calcineurin inhibitor cream whether or not combined with fucidic acid cream.
 During the study, all 42 patients received topical therapy for their genital psoriasis, 
see Table I. The vast majority of patients (n = 34, 81%) showed adequate improvement 
with the use of a mild potent corticosteroid cream with or without the addition of 
Vitamin D analogue ointment. Two of those patients were also prescribed 5% or 10% 
salicylic acid because of substantial desquamation of keratinised skin. Higher potent 
corticosteroid cream was prescribed in 5 patients. Two of them started with this high 
potent therapy followed by milder corticosteroid and Vitamin D analogue, because of 
the severity of genital lesions at baseline visit. Three patients used other topical therapies.
 Eight patients used relevant systemic therapy for their non-genital psoriasis during 
the study: UVB (n = 5), methotrexate (n = 2) and fumaric acid (n = 1). In addition to 
treatment at the research outpatient clinic, one patient was referred to a sexologist 
and six patients consulted a dermato-psychologist.
Psoriasis severity and (sexual) quality of life
Psoriasis severity and (S)QoL data at baseline are summarised in Table IV. Severity 
of psoriasis in general was moderate (PASI 5.7, SD 4.1). There were no significant 
differences between men and women concerning baseline scores of psoriasis severity 
and (dermatological) QoL. 
 The investigator classified the severity of genital psoriasis as mild to moderate in 
the vast majority of patients (n = 29, 69%) (Investigators Global Assessment (IGA): 
mean 2.5). Most patients (n = 24, 57%) experienced the genital psoriasis as being (very) 
mild (Patient Global Assessment (PGA): mean 2.2). Two patients had no visible lesions 
at baseline. IGA and PGA showed to be moderately correlated (r = 0.50, P = 0.001). 
 Median EQ-5D index and average EQ-VAS were 0.84 (similar to age matched norm 
score of general population)28 and 72.7 (slightly lower than age matched general 
population)28, respectively. Mean DLQI score was 9.1, indicating a moderate adverse 
effect on patient’s life.29 EQ-5D index and DLQI showed a very weak negative 
association at baseline (r = -0.3, P = 0.060). Patients had mean scores for sexual 
QoL of 22.8 (Female Sexual Distress Scale [FSDS]) and 70.7 (SQoL Questionnaire for use 
in Men [SQoL-M]). There was hardly any association between the duration of genital 
psoriasis and sexual QoL (FSDS: r = 0.06, P = 0.844. SQoL-M: r = 0.39, P = 0.056). 
Eight of the thirteen women with baseline FSDS data (62%) were identified as having 
sexually-related personal distress. No cut-off values are available for the SQoL-M. 
Follow-up data
As shown in Table IV, a significant improvement in all variables, except for EQ-VAS 
and SQoL-M was obtained between the baseline visit and V1. For all variables, except 
for BSA, VAS Itch, DLQI and FSDS no further significant changes were found after V1. 
weeks). Patients had a median number of 5 follow-up visits. Two patients were lost to 
follow-up before V1.
 The cohort consisted of 25 (60%) men and 17 (40%) women. Mean age at inclusion 
was 50 years, ranged between 20 and 80 years and was similar for both genders. 
Patients had a mean ±SD age of 40.7 ±15.1 at diagnosis of genital psoriasis and the 
median duration of genital psoriasis was 7.7 years, range 0.7 - 52.2 years. In addition 
to genital psoriasis, 22 patients (55%) had also perianal psoriatic lesions; men and 
women were equally affected. 
 Thirty patients (71%) were using therapy for genital psoriasis at baseline; six were 
treated with mild potent corticosteroid cream, in accordance with our protocol. The 
remaining 24 patients used either too potent (n = 10) or too mild (n = 2) cortico-
steroids, solely vitamin D analogues (n = 3) or emollients (n = 3). Six patients received 
other therapies such as coal tar ointment with precipitated sulphur, mild potent 
Table III   Baseline characteristics
N (%)
Inclusion 42
Men
Women
25
17
(60)
(40)
Clinically confirmed 
Histologically confirmed
41
1
(98)
(2)
Cigarette use
- Current smoker
- Never smoker
- Former smoker
17
14
11
(40)
(33)
(26)
Therapy for genital psoriasis at baseline
- Mild potent CS 
- Low potent CS
- Moderate - high potent CS
- Vitamin D analogue 
- Emollient
- Other
30
6
10
2
3
3
6
(71)
Age at inclusion (Years, mean ± SD) 50.1 ±13.7
Age at diagnosis psoriasis (Years, mean ± SD) 29.4 ±17.4
Duration of psoriasis (Years, mean ± SD) 20.7 ±14.0
Age at diagnosis genital psoriasis (Years, mean ± SD) 40.7 ±15.1
Duration of genital psoriasis (Years, median, range) 7.7 0.7 – 52.2
N = Number; SD = Standard deviation; CS = Corticosteroid 
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Scores of BSA, VAS Itch (Fig. 1), DLQI and FSDS showed also significant changes 
after V1 with no further significant changes after V2. Women showed significant 
improvement on more parameters (BSA, PASI, IA, SUM, IGA, PGA, VAS Itch, VAS 
Pain, VAS Burning, DLQI and FSDS) compared to men (BSA, IA, SUM, IGA, VAS Itch, 
DLQI) (detailed data not shown).
 Of all included patients, 27 (mean age 54.4 years; 18 men, 9 women) filled in the 
evaluation form regarding their visits to the research outpatient clinic. Sixteen patients 
(59%) experienced an improvement of their complaints, eight (30%) remained stable 
and three (11%) reported deterioration of genital psoriasis. All 27 patients rated the 
attention for QoL as sufficient. Twenty-four patients gave their opinion about the 
attention for sexual QoL: 22/24 (92%) defined this as sufficient. Of the 24 patients who 
answered the question, 22 (92%) indicated that they benefitted from visiting the 
research outpatient clinic.
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Figure 1  Visual analogue scale (VAS) itch during follow-up
Illustration of mean VAS Itch (95% CI) scores during follow-up. Significant improvement between 
Baseline and first follow-up visit (V1)* and between V1 and second-sixth follow-up visit (V2-6)**. 
V6 is not shown because of extensive confidence interval (CI). 
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consultation in daily clinical practice. It is also worthwhile to invest time and promptly 
address sensitive issues like impact on QoL and sexual health as this can have major 
and rapid beneficial effects for psoriasis patients. 
 There might be a role for a dedicated nurse practitioner in the care for patients 
with (genital) psoriasis focusing on education, treatment support and psychosocial 
needs.36,37 It is proven that visiting a dedicated, multidisciplinary clinic is associated 
with an improvement in QoL.38 Therefore, a multidisciplinary, well-trained health 
care team of a dermatologist collaborating with a gynaecologist, urologist, (dermato-)
psychologist or sexologist would be of excellent value for the comprehensive 
management of genital psoriasis and its implications. 
 Eight patients used relevant systemic medication for their non-genital psoriasis, 
which may have biased the study outcomes we presented. However, analysis without 
those patients, showed roughly similar effects during follow-up. It can be stated that 
whether or not treated with systemic psoriatic medication, genital psoriasis severity, 
disease-specific QoL and female sexual health significantly improve within the first 
follow-up period with focusing on care for genital psoriasis and its possible additional 
psycho-sexual effects.
 The average baseline EQ-5D index value was similar to that of the age-matched 
general population28. Nevertheless, improvement of this value was seen during 
follow-up. However, there appeared to be one patient with a very influential outlying 
EQ-5D index value at baseline, which affected the outcome of the follow-up data. 
Remarkably, when excluding this patient from analysis, EQ-5D index showed no 
significant improvement during follow-up. Also, there was only a slight association 
between EQ-5D index and DLQI. Considering these findings, the EQ-5D index and 
DLQI obviously capture different aspects of health-related QoL, which was also 
concluded by Nordin et al.39 We agree with their hypothesis that the DLQI may be more 
sensitive to detect change in QoL of psoriasis patients, as the DLQI is dermatology 
specific whereas the EQ-5D measures health-related QoL for health-economic 
analyses. Additionally, sexual health is completely missing in the EQ-5D measurement, 
notwithstanding the fact that it is frequently affected in psoriasis patients. It is 
important to realise the purpose of using a health measurement tool, avoiding that 
such a tool is randomly selected.
 Although this study reveals a number of interesting points regarding the care for 
patients with genital psoriasis, certain limitations have to be acknowledged. As 
patients were members of the Dutch Psoriasis Society or visited a tertiary care facility, 
it may be argued that the study population does not represent a random sample of 
psoriasis patients. It is also possible that response bias i.e. wanting to meet the 
expectations of the researcher influenced the answers given by patients to some 
extent. Besides, we acknowledge that life events and the natural course of psoriasis 
may have influenced the outcome. As blinding was not feasible, observer bias could 
Discussion
This unique cohort study following patients with genital psoriasis who visited a research 
outpatient clinic focusing on care for genital psoriasis and possible additional psycho- 
sexual effects provided new insights in the value of such specialised care. Objective 
and subjective genital psoriasis severity and QoL significantly improved within the 
first follow-up period of approximately six weeks. In female patients, sexual QoL also 
significantly improved. Furthermore, the majority of patients highly appreciated this 
specialised care. 
 The studied cohort, consisting of patients with a diagnosis of genital psoriasis, 
had moderate to severe psoriasis in general and mild to moderate genital lesions. 
Dermatological QoL was moderately affected, as shown by the mean DLQI score of 
9.1.29 Besides, sexual QoL was highly devastated in female patients (over 60% of the 
patients were classified as having distress; mean FSDS was 22.8). In men, the 
SQoL-M data (mean 70.7) indicated slightly diminished sexual QoL when compared 
to the normal value of 87.1.30 These findings are in accordance with prior studies. 
Indeed, involvement of genital skin in patients with psoriasis is one of the situations 
that lead to a significantly impaired (S)QoL despite relatively mild psoriasis severity 
scores. 16,31 Particularly in women with genital psoriasis, sexual distress is higher and 
sexual function is more significantly impaired compared to those without genital 
lesions.16,22 These findings are confirmed in several other studies that show an impact 
of (genital) psoriasis on sexual function in 30-70% of patients with psoriasis.21,32-35
 It is interesting that both the objective and subjective severity of genital psoriasis 
as well as DLQI-scores show significant and clinically relevant improvement between 
baseline and V1 after approximately six weeks, when topical therapy for genital 
lesions is prescribed and attention is given to problems causing (sexual) dysfunction. 
Women showed improvement on more parameters than men. However, significant 
improvement on several disease severity and QoL parameters was seen in both 
genders. It should be remarked that study groups in this gender specific analysis 
were small and that analysis therefore may not have shown significant improvement 
for some variables in men. For most parameters a plateau was reached already after 
V1 (six weeks interval). BSA, VAS itch, DLQI and FSDS improved even further, up to 
the second follow-up visit at 19 weeks, after which a plateau was reached. In women, 
sexual QoL improved, while in men it did not improve notably. An explanation for this 
may be that the sexual QoL in men was not severely enough affected, so there was 
less room for improvement.
 The fact that clinical improvement has a substantial beneficial effect on sexual 
life and that time dedicated to explanation of disease as well as treatment support is 
associated with improved QoL in a very short time was described before.33,36 These 
findings suggest a need for attention for possible genital psoriasis during the first 
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Appendix: outcome measures
Psoriasis severity
We used the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA) 
to score the clinical severity of psoriasis in general. PASI assesses the severity of 
psoriasis on a scale ranging from 0 (no psoriasis) to 72 (severe psoriasis)40 and BSA 
describes the percentage of surface skin affected by psoriasis ranging from 0 to 100%.
 The clinical severity of genital psoriasis was assessed by the Investigators Global 
Assessment (IGA), SUM score and the Investigators Assessment of the extent of 
genital psoriasis (IA: surface of affected genital skin in cm2). The IGA-score is 
depending on whether genital psoriasis is cleared (0), minimal (1), mild (2), moderate 
(3), severe (4) or very severe (5). The SUM score of genital psoriasis is calculated as 
the sum of the severity scores for erythema, desquamation and induration using the 
scoring system from the PASI (range 0-4 per item). The total SUM score ranges 
between 0 (no lesions) and 12 (very severe lesions).
 Severity of genital psoriasis as experienced by the patient was measured by the 
Patient Global Assessment (PGA) ranging between clear (0) and severe (4), and 
Visual Analogue Scales (VAS) on itch, pain and burning of genital skin (range 0-100). 
(Sexual) quality of life
The 5-Dimension European QoL (EQ-5D) health survey was used to measure generic 
QoL. This survey has two parts. The first part assigns an index-score for the self- 
reported health state, including five domains. This index-score ranges between 0 and 1, 
where 0 represents death and 1 represents perfect health. Total scores were calculated 
by using the Dutch EQ-5D Tariff.41 When responses were missing for one or more of 
the domains, index scores were not calculated. The second part is a VAS, ranging 
between 0 (worst imaginable health state) and 100 (best imaginable health state).
 The Dermatology Life Quality Index (DLQI) was used to assess the extent of the 
effect of psoriasis on daily living, with overall scores ranging from 0 (‘not at all’) to 30 
(‘very much’). In case of missing data, scores were calculated according to the 
manual.29
 Sexual QoL in female patients was measured by the Female Sexual Distress 
Scale (FSDS).42 The total scores range from 0 to 48, with higher scores corresponding 
to higher levels of sexual distress. A score of ≥ 15 is the recommended cut-off value 
to establish the presence of sexually related personal distress. With more than 10% 
of answers missing, questionnaires were excluded. The Sexual QoL Questionnaire 
for use in Men (SQoL-M) measures sexual QoL in men. Total scores range from 0 to 
100, with higher scores corresponding with a better sexual QoL.30 According to the 
manual, with over 50% missing answers, the questionnaire was excluded from 
analysis.
have influenced the severity scores. Only a limited number of patients participated in 
this study. Nevertheless, the significant results found in the current small study group 
are supportive for the validity of our findings. The introduction of a control group 
would have provided more insight in the real value of intensified care compared to 
standard daily clinical practice. However, it is hardly possible to monitor daily clinical 
care for genital psoriasis without the awareness of patients and physicians of being 
studied. 
 To conclude, this study showed that genital psoriasis, though devastating for 
QoL and (particularly in women) for sexual health, can be treated relatively easy 
within limited time exposure. Prompt and simple adjustments in the provided care 
are enough to accomplish this. Routine attention for possible genital psoriasis and 
accompanying impact on (S)QoL is imperative. Therefore, we highlight the need for 
well-trained and motivated clinicians.
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Abstract
Immunosuppressive therapy in renal transplant recipients (RTR) is associated with an 
increased risk for the development of (pre)malignancies involving the skin and the 
female lower genital tract. We assessed whether yearly cervical screening was 
performed and evaluated the development of skin cancer and gynaecological (pre)
malignancies in RTRs. Female RTRs (n = 224), transplanted between 1991 and 1995, 
were analysed retrospectively. Sociodemographic patient characteristics, frequency 
and results of cervical smears and prevalence of cutaneous, cervical, vaginal or 
vulvar (pre)malignancies were investigated and compared with that in the general 
population. A mean of 0.2 cervical smears per patient per year was found to have 
been performed in RTRs, which is significantly less than the recommended screening 
ratio of 1.0 for female RTRs (P < 0.001). The risk for RTRs to develop malignancies of 
the female lower genital tract was increased: twofold to sixfold for cervical intrae-
pithelial neoplasia, threefold for cervical carcinoma and 50-fold for vulvar carcinoma. 
Cervical screening is not performed in accordance with the advised yearly intervals, 
and the risk for RTRs to develop vulvar and cervical (pre)malignancies is increased. 
More attention should be paid to the vulvar and cervical surveillance of RTRs by both 
medical specialists and general physicians.
Introduction 
Each year, more than 800 renal transplantations (RT) are performed in the Netherlands 
according to the Netherlands Organ Transplantation Registration (NOTR). Solid organ 
transplantation requires the administration of lifelong intense immunosuppressive 
therapy. The strategies to reduce graft rejection have improved considerably since 
the first successful kidney transplantation in 1954.1,2 At present, most immuno-
suppressive regimens combine a calcineurin inhibitor (ciclosporin or tacrolimus) with 
an adjunctive agent (azathioprine, mycophenolate mofetil or sirolimus) and cortico-
steroids, resulting in a remarkable increase of patient survival.2 The current immuno-
suppressive regimes have led to a 1-year patient and graft survival of more than 90% 
and the incidence of acute rejection has fallen to 10–15%.2 This high survival rate has 
made it incumbent on the medical specialists to pay increasing attention to the 
long-term side-effects of immunosuppressive medication.
 It is known that renal transplant recipients (RTRs) have at least a threefold to 
fivefold increase of risk to develop any kind of cancer compared with the general 
population.1,3-5 The relative risk with respect to specific cancers, such as skin cancer, 
post-transplant lymphoproliferative disorders, Kaposi’s sarcoma and human papilloma - 
virus (HPV)-related malignancies of the lower genital tract e.g. cervix, vulva and anus 
may be even higher.4,6-8
 The appearance of malignancies after RT is obviously related to the duration and 
dose of immunosuppressive medication.6,9-11 Immunosuppressants may influence 
different mechanisms resulting in an increased risk for the development of cancer 
after RT. Immunosuppressive medication can directly affect DNA by inhibiting repair 
mechanisms and by causing chromosome strand breaks. This may lead to irreversible 
DNA alterations and subsequent cancer development.6,12 Additionally, an immuno-
suppressive state potentiates oncogenic stimuli such as ultraviolet (UV) light, viruses 
and chemical carcinogens. UV-radiation can lead to mutations in proto-oncogenes 
and tumour-suppressor genes. Moreover, it can suppress the local cutaneous 
immune response by depletion of Langerhans’ cells with less antigen presentation 
and recognition as a result.13-15 HPV is an important factor in the development of 
lower genital tract malignancies and might also play a role in the development of 
cutaneous malignancies (http://www.rivm.nl).13,15-18 The viral E6 protein inactivates 
p53 (a tumour-suppressor protein), which results in chromosomal instability and 
diminished apoptosis. The E7 protein suppresses the retinoblastoma protein pathway, 
which leads to enhanced cell proliferation.17,19 In the pathogenesis of skin cancer, 
E6-proteins can inhibit UV-induced apoptosis by a p53-independent mechanism, 
which results in accumulation of UV-induced mutations.13,15-17 
 Skin cancer is the most commonly encountered malignancy in RTRs, with 
37.4–63% of all post-transplantation tumours.1,4,6,12,20 In countries with a temperate 
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 The follow-up period was defined as the period between transplantation and any 
of the following dates whichever is earlier: the first of August 2008, date of death or 
date denominated as ‘lost to follow-up’. Patients with failure of renal graft function (n 
= 73) and therefore restart of dialysis were also followed until the first of August 2008. 
Variables recorded included sociodemographic patient characteristics (i.e. race, age 
at transplantation, decease) and background information on renal medical history, 
transplantation, and restart of haemodialysis.
 We collected the dates and results of cervical smears and the development of 
skin cancer and cervical, vaginal or vulvar (pre)malignancies after RT. Whenever a 
malignancy developed, we registered additional clinical and pathological data. The 
duration of immunosuppression was calculated from the date of transplantation to 
either the end of the study period, the date of death, or the date of definitive transplant 
failure when dialysis was resumed. When a patient used immunosuppression during 
more than one period, the duration of all such periods were aggregated.
 We counted the total number of cervical smears performed in female RTRs from 
their 18th year of life. As the advised screening frequency is once a year, we excluded 
the patients with less than 1 year of follow-up after their transplantation from further 
analysis. To calculate the number of patient-years after transplantation, we also 
corrected the years after the transplantation for incomplete follow-up, death, and 
childhood (<18 years). The mean number of cervical smears per patient per year was 
calculated by dividing the total number of cervical smears by the total number of 
patient-years after transplantation. We compared this ratio with the advised ratio of 
1.0 smear per patient-year. The ratio of cervical smears performed before the first 
low- or high-grade squamous intraepithelial lesion (SIL; after which patients get more 
frequent follow-up smears according to national guidelines) was calculated by 
dividing the total number of cervical smears until the first pathological smear by the 
number of patient-years in that period. Age-adjusted prevalence rates of (pre)
malignancies in the studied cohort were calculated per 100.000 individuals using the 
European Standard Population (as defined by the WHO) for comparative purposes. 
Data on prevalence of (pre)malignancies in the general population were obtained 
from national and international literature and from the Netherlands Cancer Registry. 
Statistical analysis
Descriptive statistics were used to reproduce study results as percentages, means, 
medians and standard deviations. To test the correlation between the occurrence of 
skin cancer and lower genital tract malignancies in female RTRs, a Spearman Rho 
correlation coefficient was determined. Different ratios of smears per patient-year 
were compared using Student’s t-tests. Calculations were performed using Statistical 
Package for Social Sciences 16.0 (SPSS, Chicago, IL, USA). P-values of <0.05 were 
considered statistically significant.
climate, the incidence of skin cancer within 10 years after RT is 10–15%. After 20 
years, this percentage increases to 40%.7,21 More than 90% of all skin cancers are 
non-melanoma skin cancers, which are predominantly squamous cell carcinomas 
(SCCs) (up to 250-fold increased risk), followed by basal cell carcinomas (BCCs) (up 
to 10-fold increased risk).3,7,11,22,23 As BCCs prevail in the general population, the 
SCC/BCC ratio is reversed in RTRs (http://www.rivm.nl).7,24 
 It is generally accepted that lower genital tract neoplasms in female RTRs are 
fully related to high-risk HPV (hrHPV). Accordingly, immunosuppressed female RTRs 
are at a significantly increased risk for abnormal cervical smears, cervical/vulvar  intra- 
epithelial neoplasia (CIN/VIN) and lower genital tract malignancies. As a consequence, 
prevention and early treatment of (pre)malignancies is important. Earlier publications 
have suggested conducting physical examinations and cervical smears with smaller 
intervals than common in the national screening programmes (target population in 
the Netherlands: 30–60 years of age; interval 5 years), although there is a lack of evidence 
for this policy.25-27 In 2000, The American Society of Transplantation advised yearly 
cervical screening for female RTRs.26 
 In our study, we investigated whether cervical smears were performed in 
accordance with the advised yearly interval. In addition, we analysed the development 
of vulvar, vaginal and cervical (pre)malignancies in female RTRs to determine their 
prevalence in our RTR-population. Moreover, as both cutaneous and female lower 
genital tract (pre)malignancies are probably associated with HPV infections, we 
studied the correlation between these (pre)malignancies in the RTR-population. We 
formulated recommendations to optimise the follow-up concerning lower genital tract 
(pre)malignancies in female RTRs.
Patients and Methods
Data on all consecutive female patients who underwent a RT between January 1991 
and December 1995 at the Radboud University Nijmegen Medical Centre, the 
Netherlands, were included in this analysis. Identities of all 224 patients were extracted 
from the local RT registry of this academic centre. Clinical data of the patients were 
abstracted from the patient hospital charts and the electronic patient files, up to the 
first of August 2008. To complete the histo- and cytopathological data, we used 
PALGA (Pathologisch Anatomisch Landelijk Geautomatiseerd Archief), which is a 
nationwide histo- and cytopathology network and archive that achieved complete 
national coverage since 1991.28 All patients started with triple immunosuppressive 
therapy (calcineurin inhibitor, mycophenolate mofetil and prednisolone). Six months 
after transplantation, almost all patients were treated with double immunosuppressive 
therapy [in most instances azathioprine (2-3 mg/kg) and prednisolone (10 mg)].
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available for further analysis. Of these patients, 128 women (63.4%) underwent at 
least one cervical smear while 74 patients (36.6%) never had a cervical smear after 
their transplantation. There was only one patient who had a mean screening ratio of 
1.0, which implies that the cervical smears were performed at least once a year. 
Seventy-four patients were screened in accordance with the recommended screening 
in the general population (once in five years). A mean screening ratio lower than 0.2 
was seen in 53 patients, which means that these patients were screened with an 
interval greater than the recommended population screening interval. Taking all 
cervical smears (449) and patient-years after transplantation (2198) into account, the 
overall cervical smear/patient-year ratio after transplantation was 0.2. This ratio is 
significantly less than the recommended screening ratio of 1.0 for female RTRs (P < 
0.001), but comparable with the national guidelines for women aged 30–60 years. 
The mean screening ratio in all RTRs (n = 202) before the detection of any low- or 
high-grade SIL was 0.13. 
 We counted 17 histopathological examinations of the cervix performed after an 
abnormal cervical smear in 11 patients. See Figure 1 for an overview. CIN after renal 
transplantation was detected in eight patients (3.6%). One patient developed CIN 3 
and subsequently CIN 1, a year later. One patient of our cohort developed cervical 
carcinoma (0.4%). Two patients developed meta- or hyperplasia of the uterine cervix 
and were excluded from further analysis on cervical pathology. The median interval 
between first transplantation and the development of CIN was 12.3 years (range: 3.5 
– 13.7 years). In the eight RTRs with CIN, the median interval between the first trans-
plantation and the first smear performed was 1.2 years (range: 0.2 – 12.5 years). 
Results
The baseline characteristics of the 224 female RTRs are shown in Table 1. The number 
of transplantations was almost equally divided over the years, and predominantly 
carried out between the age of 41 and 60 years: the median age of patients at trans-
plantation in our cohort was 44.6 years (range: 5.1 – 74.6 years). 
 A minority of patients (n = 49, 21.9%) went through more than one RT. Ten 
patients were lost to follow-up because of transplantation in another transplantation 
centre (n = 5), emigration (n = 1) or unknown reasons (n = 4). Median duration of 
follow-up was 12.8 years (range: 0 – 17.6 years) and the median duration of immuno-
suppression was 11.0 years (range: 0 – 29.6 years). At the end of the follow-up period, 
123 patients (55%) were still alive. One hundred and one patients (45%) were 
deceased, particularly because of fulminant infections and cardiovascular diseases. 
Median time between transplantation and death was 6.0 years (range: 0 – 14.9 years). 
 Our cohort consisted of 21 RTRs with less than 1 year follow-up after their 18th 
year of life. One patient died before the age of 18. Consequently, 202 RTRs remained 
Table 1   Baseline characteristics of renal transplant recipients
Number of patients
N %
Age at transplantation (years)
0-18 19 8.5
19-40 79 35.3
41-60 104 46.4
> 60 22 9.8
Year of transplantation
1991 47 21.0
1992 38 17.0
1993 37 16.5
1994 51 22.8
1995 51 22.8
Total renal transplantations
1 175 78.1
2 43 19.2
> 2 6 2.7
Figure 1  Cervical histopathological examinations in 11 patients after renal  
transplantation
CIN1 = Cervical intraepithelial neoplasia grade 1. CIN2 = Cervical intraepithelial neoplasia grade 2. CIN3 = 
Cervical intraepithelial neoplasia grade 3
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 The cervical carcinoma developed 5 years after transplantation at the age of 
38 years. The first cervical smear in this patient was performed because of irregular 
blood loss. Histopathology of a biopsy after colposcopy showed a cervical cancer. 
The screening ratio before the detection of any low- or high-grade SIL was 0.08 in the 
RTRs with cervical pathology (n = 9), which did not differ significantly from the ratio 
in RTRs without cervical pathology (0.13; n = 193) (P = 0.60). The mean number of 
cervical smears per patient-year after RT was 0.53 (SD ± 0.31, range: 0.1 – 1.0), 
which is significantly higher when compared with RTRs without cervical pathology 
(P < 0.001). No information is available about possible complaints that may have led 
to cervical cytology.
 Eight VIN lesions were detected in four of our RTRs during the study period. All 
of these lesions were HPV-related VIN types (usual VIN). The mean age at presentation 
of the first VIN lesion was 40.3 years (SD ± 4.6 years). The median interval between 
first RT and first VIN lesion was 13.3 years (range: 5.1 – 14.4 years). SCC of the vulva 
developed in two patients of our cohort: 10.2 and 13.8 years after transplantation. No 
cases of vaginal carcinoma occurred in the female RTRs. There was only one patient 
Table 2   Comparison of different prevalence rates between renal transplant 
recipients and the general population 
Comparison of prevalence rates
Transplant  
recipients
General  
population
Increased  
risk
N % Prevalence(a) Prevalence(a) Rate ratio(d)
CIN 8 3.6 3454.8 600 - 2000 (b) 1.7 – 5.8
Cervical carcinoma 1 0.4 280.0 88.9 (c) 3.2
Vulvar carcinoma 2 0.9 717.5 14.4 (c) 49.8
CIN, cervical intraepithelial neoplasia
a: European Standardized Rate, per 100.000
b: Obtained from literature references 25,30,31
c: Obtained from the Netherlands Cancer Registry
d:  Rate ratio is the age-adjusted rate in renal transplant recipients divided by the rate in the general population
Table 3   Cervical smears and histology of cervix and vulva after transplantation 
Years after Tx
3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 10.5 11 11.5 12 12.5 13 13.5 14 14.5 15 15.5 16
Pt
1 L L-CIN3
2 N L-CIN0 N L-CIN3 N N N
3 L-CIN3 N N     N N N
4 AU N AU AU-CIN3 N N N-VIN3 VIN3 N-VIN3 N N ||
5 AU N L AU-CIN1 L L L L L L-CINnVIN3-N L-VIN3-L L ||
6 N N H-CIN3 AU AU-CIN1VIN2 AU     L ||
7 L-CIN0-L L-CIN1 N ||
8 AU   AU   L-CIN2 ||
9 L H CxCa ||
10 VIN1 N VIN3 L VCa ||
11 N N L Vca+VAIN ||
N = Normal smear result; AU = Cytologically determined atypical squamous cells of undetermined 
significance; L = Cytologically determined low-grade squamous intraepithelial lesion of the cervix; H = 
Cytologically determined high-grade squamous intraepithelial lesion of the cervix; CINn = Histologically 
determined normal cervix; CIN0 = Histologically determined meta- or hyperplasia of the cervix; CIN1 = 
Histologically determined cervical intraepithelial neoplasia grade 1; CIN2 = Histologically determined 
cervical intraepithelial neoplasia grade 2; CIN3 = Histologically determined cervical intraepithelial 
neoplasia grade 3; VIN1 = Vulvar intraepithelial neoplasia grade 1; VIN2 = Vulvar intraepithelial neoplasia 
grade 2; VIN3 = Vulvar intraepithelial neoplasia grade 3; VCa = Vulvar carcinoma; CxCa = Cervical 
carcinoma; | = Deceased; || = End of follow up.
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Discussion
Our study shows that cervical screening smears in RTRs are not being performed in 
accordance with the recommended interval of once a year. We confirmed the elevated 
risk for RTRs to develop vulvar and cervical (pre)malignancies, which developed 5 – 
13 years after transplantation. It appears that skin malignancies and gynaecological 
(pre)malignancies, which are both considered to be related to HPV and more frequent 
after RT, are not related with each other; of all women who developed skin malignancies 
(19%), only one vulvar carcinoma combined with vaginal dysplasia was diagnosed.
 We investigated the performance of cervical smears in RTRs. The recommended 
screening interval for RTRs as suggested in previous publications varies between 6 
and 12 months (1–2 smears per patient per year)25-27, although there is no evidence 
that cervical screening with a short interval (when compared with the national 
screening programme in the Netherlands: between age of 30 – 60; once in 5 years) 
will either decrease the incidence of lower genital tract (pre)malignancies or improve 
the prognosis.
 The interval of the smears performed in our cohort was comparable with the 
national screening programme in the Netherlands, with a mean number of 0.2 smears 
per patient per year (one smear once in 5 years for each patient). This low number of 
smears (when compared with the guideline of yearly smears) might be explained by 
several factors. First, the coverage rate of the national screening programme only 
with vaginal intraepithelial neoplasia (VAIN), which occurred simultaneously with SCC 
of the vulva. Table 2 compares the standardized, age-adjusted prevalence rates of 
CIN, cervical carcinoma and vulvar carcinoma between transplant recipients and the 
general population. We were not able to present this comparison for VIN, as no 
publications concerning prevalence rates of VIN in the general population exist.
 Table 3 shows an evaluation of the cervical smears and histology of cervix and 
vulva after transplantation. The majority of the lower genital tract (pre)malignancies 
occur after a median interval of 11.5 years (range: 5 – 13.5 years). At least seven RTRs 
hardly received screening smears before the development of serious cervical/vulvar 
pathology. In three patients, a relatively short period of time (approximately 2 years) 
elapsed between the transformation of benign cervical smears to low-grade SIL, 
leading to CIN in two patients. In the third patient, a vulvar carcinoma and VAIN were 
diagnosed after the low-grade SIL was detected.
 Forty-two out of 224 RTRs (18.8%) developed at least one cutaneous malignancy. 
Twenty-nine RTRs developed 63 SCCs on non-genital skin. The remaining part of the 
skin tumours were mostly BCCs. The median interval between transplantation and 
the first skin malignancy was 6.2 years (range 0.3 – 16.5 years).
 There was only one patient with skin cancer who also had vulvar pathology in 
combination with a VAIN lesion. No significant correlation between skin cancer and 
lower genital tract (pre)malignancies was found in our RTR population (Spearman 
Rho = -0.044, SD ± 0.058; P = 0.508). The absolute numbers of (pre)malignancies 
can be found in Table 4.
Table 4   Correlation between lower genital tract (pre)malignancies and skin 
cancer in renal transplant recipients (absolute count) 
Type Patients
(N)
VIN CIN VAIN CxCa VulvaCa SkinCa
VIN 4 3 0 0 1 0
CIN 8 3 0 0 0 0
VAIN 1 0 0 0 1 1
CxCa 1 0 0 0 0 0
VulvaCa 2 1 0 1 0 1
SkinCa 42 0 0 1 0 1
VIN = Vulvar intraepithelial neoplasia; CIN = Cervical intraepithelial neoplasia; VAIN = Vaginal intrae pithelial 
neoplasia; CxCa = Cervical carcinoma; VulvaCa = Vulvar carcinoma; SkinCa = Skin cancer
Table 5   Suggested gynaecological standard screening procedure of cervix 
and vulva for female renal transplant recipients 
Pre-transplantation Post-transplantation
Normal 1 Abnormal 2
Start 0-6 months  
before RT 
Approximately 3 years 
after RT 
Immediate  
after RT 
Frequency Once Once a year Once a year
Screening Routine* Routine* According to  current 
 gynaecological  guidelines; 
thereafter routine*
RT = Renal transplantation
1: In case of normal pre-transplant screening result.
2: In case of abnormal pre-transplant screening result.
* Routine screening comprises anamnesis, inspection and cytology (smear).
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 Two patients were diagnosed with SCCs of the vulva, which is an extremely rare 
disease. This is a 50-fold increased risk compared with the European Standardized 
Rate of vulvar carcinomas in the general population. Both vulvar carcinomas had 
usual VIN (related to HPV infection) in the adjacent tissue, which proves a causal 
relationship between HPV and vulvar carcinoma just like in cervical cancer. Two 
studies concerning solely vulvar carcinomas demonstrated a 25- to 40-fold increased 
risk for RTRs to develop vulvar carcinomas.5,6 An epidemiologic study from Sweden 
published in 1986 documented a 100-fold increased risk of developing carcinomas 
of the vulva and anus compared with the general population.8
 We observed a median interval of 12.3 years (range: 3.5 – 13.7 years) between 
the first transplantation and the development of CIN. Three earlier studies found an 
average interval between the beginning of immunosuppressive medication and CIN 
to be between 38 and 47 months.25,27,34 The longer interval in our study might be 
partly explained by demographic differences of the patients in the cohorts studied 
and use of other immunosuppressive medication. The vulvar SCCs of our cohort 
developed after an average interval of 144 months (SD ± 30.5 months), which seems 
to correspond with data reported in the literature.5,8
 In the nine patients with CIN and cervical carcinoma significantly more cervical 
smears were performed (0.53 per patient per year; P < 0.001) compared with the 
RTRs without cervical (pre)malignancies. Two explanations for this result can be 
given. First, a considerable number of low- and high-grade SILs originated in these 
patients before the CIN lesions were diagnosed; all patients with abnormal cytology 
or histology will undergo more frequent follow-up smears. Second, patients with 
cervical dysplasia might have had more gynaecological complaints when compared 
with the general population. Unfortunately, no information is available on possible 
gynaecological complaints in this cohort. The screening ratio before the detection of 
any low- or high-grade SIL in this group of RTRs did not differ significantly from the 
ratio in RTRs without cervical pathology. Nevertheless, at least five RTRs were 
screened only barely before the diagnose of serious cervical pathology. Through 
more frequent follow-up with more smears some of these cervical (pre)malignancies 
could have been detected earlier. 
 Immunosuppression has direct carcinogenic effects; it predisposes patients to 
develop infections and potentiates oncogenic viruses like HPV. Based on the results 
of earlier publications, it is very likely that HPV infections play a prominent role in the 
higher incidence of lower genital tract (pre)malignancies in RTRs.8,25,32,35,36 Halpert 
et al.25 presented higher rates of HPV infections in transplant patients (8.5 – 17.1%) 
compared to the general population (1.85%). This finding was confirmed by Brown et 
al., who reported a significant difference in the presence of HPV-positive lower genital 
tract neoplasms between female RTRs and an immunocompetent group. For 
example, 100% of the vulvar lesions in RTRs were HPV-positive compared to 21–57% 
reaches 77%29, which might be explained by lack of motivation or fear for screening. 
Therefore, we could not expect a 100% coverage rate in our RTR population. 
Furthermore, it might be possible that the advice for yearly cervical smears is not well 
implemented in the daily practice of the nephrologist or the general practitioner, 
because of lack of evidence for this policy or because of plain inattention. Moreover, 
patients may avoid cervical screening either because they underestimate the 
importance of screening or because they find the investigation aggravating. 
 The ratio of the smears that were performed before the first low- or high-grade 
SIL was lower (0.13) than the overall screening ratio (0.2). In the years after an 
abnormal smear, the ratio of smears was higher attributable to the follow-up smears 
that are required to be performed with more regular intervals according to national 
guidelines.
 We detected CIN lesions in eight patients (3.6%). Previous publications reported 
the occurrence of cervical dysplasia in 1.28%, 2.0% and 0.6% of the general 
population in the Netherlands, USA and Canada respectively.25,30,31 On the basis of 
these percentages, it seems that our RTRs have at least a twofold to sixfold increased 
risk of developing CIN, when compared with the general population. This result 
supports the findings of earlier investigations that showed that the prevalence of CIN 
is increased in RTRs.27,32
 Only four patients with dysplasia of the vulva were found. All of the lesions were 
HPV-related VIN types. Likely, VIN is underreported, because there is no screening 
instrument for VIN resulting from its low incidence with limited malignant potential. 
Moreover, RTRs are not routinely asked for vulvar complaints and no standard 
gynaecological examination is performed. Although pruritus is the most common 
symptom of VIN, this symptom is frequently misclassified, as RTRs are prone to 
develop candidiasis, which is the most frequently made diagnosis in case of pruritus. 
Finally, it might be possible that suspicious lesions are not always histopathologically 
examined. 
 Cervical carcinoma was diagnosed in only one patient. Comparing this number 
with the rates of cervical carcinomas in the age-adjusted standardized general 
population, the RTRs in the studied cohort have at least a threefold higher risk for 
developing cervical carcinomas than the general population. A limited number of 
earlier studies report comparable standardized incidence rates between 3.3 and 
8.5.5,6,33 The cervical carcinoma in our study developed 60 months after transplanta-
tion, which agrees with the data reflected in other studies (38–102 months).5,34
 Carcinomas of the vagina are rare, with a prevalence of 1.7 per 100.000 in the 
Dutch general population. Based on recently published standardized incidence rates 
for RTRs for developing vaginal carcinomas (15.8 and 36.0)5,6, we could have 
expected 0.06 to 0.14 cases of vaginal carcinoma in our cohort. It is therefore not 
surprising that we did not diagnose any patients with a vaginal malignancy. 
6114 115
CHAPTER 6 GYNAECOLOGICAL (PRE)MALIGNANCIES AND SKIN CANCER IN RTRs
 Annual screening for cervical cancer in RTRs using conventional cytology 
recently proved to be cost-effective.39 Yearly cervical smears might be combined 
with a thorough vulvar inspection. Our data suggest that the majority of patients with 
cervical pathology is diagnosed 9 years after RT. Therefore, it is justified, in our 
opinion, to postpone the recommended yearly screening to approximately 3 years 
after RT. This is allowed under the condition that patients are screened on cervical 
and vulvar pathology and HPV infections before their RT, as pre-RT cervical/vulvar 
pathology might worsen when immunosuppression is started. This way the ‘doctor-
density’ can be limited in the first years after transplantation when patients and 
doctors are focussed on preservation of kidney function. If RTRs have abnormal 
screening results before transplantation, a more intense follow-up schedule should 
be carried out immediately after RT. Table 5 recapitulates the suggested 
gynaecological standard screening procedure for female RTRs. It is important to 
keep in mind that there is no evidence yet that this schedule will decrease the 
incidence of female genital malignancies.
 To conclude, this study emphasises the need for more regular screening for 
potentially lethal malignancies of the lower genital tract in RTRs, as close and careful 
monitoring and treatment of suspected lesions may prevent more serious pathology. 
Additionally, RTRs have to be advised properly about the importance of regular 
screening and self-examination of the vulvar region. 
in immunocompetent individuals.35 Furthermore, several studies showed a significantly 
higher rate of infections with hrHPV subtypes 16 and 18 in lower genital tract 
malignancies of RTRs when compared with the general population.32,35 Paternoster 
et al.36 noted a constant association between those hrHPV types and lower genital 
tract intraepithelial lesions. 
 Screening for cervical/vulvar pathology and hrHPV infections just before trans-
plantation is not a common procedure, because the exact timing of transplantation is 
not planned ahead. As more and more elective kidney transplantations with a kidney 
from a living donor are performed, it might be possible to introduce a screening just 
before the date of transplantation for cervical/vulvar pathology and presence of 
hrHPV infections.
 The exact mechanism underlying the high prevalence of HPV infections in 
RTRs remains unclear. Normally, the majority of HPV infections are transient resulting 
from clearance from the HPV-infected epithelium. It might be possible that RTRs 
have a diminished ability to clear new HPV infections because of the impairment 
of immunological surveillance. This, in combination with high prevalence of HPV 
subtypes 16 and 18, might additionally lead to more aggressive growth of 
malignancies. However, it is not likely that RTRs acquire new HPV infections as, 
based on the average age at transplantation, the majority of the RTRs already had 
their sexarche long before transplantation. Besides, transplant recipients may be 
sexually less active than the average population as a result of the burden of their 
disease. Another, more plausible explanation might be that the beginning of immuno-
suppressive medication may activate a latent HPV infection, resulting in a rise of the 
viral load.37  
 The development of cutaneous malignancies, and the interval after which they 
develop, does not seem to be associated with the development of lower genital tract 
malignancies and vice versa. It might be possible that different HPV types are 
responsible for the occurrence of malignancies in the genital area and for neoplasms 
of other skin areas, although the role of HPV in skin cancer remains unclear.38 
Furthermore, other factors (like UV radiation) might play a more important role in the 
development of non-genital skin malignancies. 
 Our investigation was conducted as a single-centre study, which implicates a 
relatively small number of patients. On the other hand, the relatively long follow-up 
after transplantation is an important strength of our study, as malignancies such 
as lower genital tract (pre)malignancies hardly occur in the first 5 years after trans-
plantation. A limitation of the retrospective design of our study is the lack of data 
about lifestyle risk factors (e.g. smoking, riskful sexual behaviour and skin 
cancer-related risks) and the exact medication schedules (many different schedules 
with multiple conversions during follow-up). Further prospective investigations and 
the use of a standardized questionnaire might eliminate this possible bias.  
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Abstract 
Background
Renal transplant recipients have an increased risk to develop human papillomavirus 
(HPV)-related anogenital malignancies. A clinical overview of female anogenital 
posttransplantation malignancies and possible multifocal premalignancies over a 
period of 40 years renal transplantation is presented. Additionally, the genotype- 
specific prevalence of HPV in these (pre)malignancies was investigated.
Methods
Data of 1023 women, who underwent a renal transplantation between 1968 and 2008, 
were collected. Clinical data of all female renal transplant recipients who developed 
anogenital malignancies were retrospectively analysed. The histology, cytology, 
and distribution of genotype-specific HPV infections were analysed in all primary 
anogenital tumours and possible (multifocal) premalignancies. 
Results
Sixteen anogenital malignancies (1.6%) were found: vulva (n = 6), cervix (n = 5), and 
anus (n = 5). Twelve of 16 patients never had a cervical smear before transplantation. 
The median interval between transplantation and diagnosis of malignancy was 136 
months (range: 16 – 288 months). High-risk HPV was detected in 91.7% of investigated 
lesions, HPV subtype 16 predominated (54.5%). Four of seven patients with two 
distinct anogenital lesions had different HPV types in the lesions. 
Conclusions
A high number of anogenital malignancies developed in our cohort, which are nearly 
all caused by HPV. Multifocal lesions within one patient frequently contained different 
high-risk HPV genotypes in both lesions. Our results underline the importance of 
anogenital screening and monitoring before and periodically after renal transplantation 
to prevent morbidity and mortality from anogenital malignancies. 
Introduction
Renal transplantations (RTs) account for the major part of solid organ transplantations 
that are performed worldwide. In 2010, more than 850 RTs were performed in the 
Netherlands (16 million inhabitants) according to the Netherlands Organ Transplantation 
Registration.1 
 In general, solid organ transplantation requires the use of lifelong immunosup-
pressive medication. Because of the improvement of immunosuppressive regimens, 
the current 1-year patient and graft survival is more than 90% and the incidence of 
acute rejection has decreased to 10-15%.2,3 As a result of the enhanced long-term 
transplant survival and the increasing age of renal transplant recipients (RTRs), the 
development of cancer is becoming a major cause of morbidity and mortality after 
RT. A clear association between the duration and dose of immunosuppressive 
medication and post-transplant malignancies is known.4-7 
 RTRs have at least a threefold to fivefold increased risk to develop any type of 
cancer compared with the general population.7-10 The relative risk for specific 
cancers, such as skin cancer, Kaposi’s sarcoma, and post-transplant lymphoprolifer-
ative disorders may even be higher.7-9,11-13 Moreover, many authors have established 
a significantly increased risk for human papillomavirus (HPV)-associated dysplasia 
and cancers of the anogenital tract (cervix, vagina, vulva, and anus) in female 
RTRs.7-9,14-24 Recently, we found a remarkably increased risk for cervical intraepithe-
lial neoplasia (CIN) (twofold to sixfold), cervical carcinoma (threefold), and vulvar 
carcinoma (50-fold) in a population of 224 female RTRs who underwent a RT between 
1991 and 1995 in our centre.18 As a consequence of this increased risk, several 
publications and international guidelines17,18,25-28 have implemented the advice to 
intensify cervical screening in those patients by means of smaller intervals than common 
in many national screening programmes (target population in the Netherlands since 
1996: 30 – 60 years of age; interval 5 years). 
 It was previously documented that RTRs are more often affected with (multifocal; 
i.e. having two or more localisations of the anogenital tract, synchronously or 
metachronously within a single patient) HPV infections compared with the general 
population.14,15,17,27,29,30 Persistent infections with high-risk HPV (hrHPV) types (the 
majority HPV 16 and 18) are important risk factors for cervical cancer development.31 
Additionally, HPV is etiologically related to a number of cancers of the anus and 
vulva.31-37 Of all anal carcinomas, 71% to 88% are positive for HPV, with a 
preponderance of hrHPV types.38-40 Vulvar squamous cell carcinoma (SCC) and its 
precursor lesions may originate from an HPV-independent or an HPV-dependent 
pathway. Carcinogenesis of the HPV-dependent (generally HPV type 16 and 18) 
pathway largely resembles that of cervical SCCs. This type of vulvar cancer primarily 
affects younger women and encompasses the minority of vulvar SCCs in the general 
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Patients with malignancy of the lower anogenital tract:  
clinical characteristics
Data of female RTRs with a malignancy of the lower anogenital tract were registered: 
localisation and histopathological type of malignancy, date of diagnosis, history of 
(pre)malignancies and cervical smears, treatment, recurrence or metastases of the 
tumour after treatment. In case of development of anogenital premalignancies pre- or 
post-malignancy, the histopathological type, localisation, and date of diagnosis were 
registered. If applicable, we also collected the date and cause of death. Patients were 
followed until the date denominated as ‘lost to follow-up’, date of decease, or the end 
of July 2010. 
HPV presence and genotyping
Specimens of all primary anogenital tumours were available for detection of geno-
type-specific HPV infections. Whenever there was an interval of at least 6 months 
between diagnose of the tumour and of previous or subsequent (multifocal) 
premalignant lesions, we also determined the distribution of HPV genotypes in these 
lesions. We choose an interval of 6 months to make probable that both lesions were 
separate entities.
 DNA was isolated from formalin-fixed, paraffin-embedded tissue sections (6 mm) 
with the EZ1 robot (with the DNA tissue kit of Qiagen) according to standard 
procedures44 and used for polymerase chain reaction (PCR) analysis. A negative 
water control was included with each batch of 10 samples. Broad-spectrum HPV 
DNA amplification was performed using a short PCR fragment (SPF-PCR) assay. The 
SPF-PCR system amplifies a 65-bp fragment of the L1 open reading frame, allowing 
the detection of at least 43 HPV types. In case of a positive PCR result, subsequent 
HPV genotyping was performed using a reverse hybridisation line probe assay (LiPA), 
allowing simultaneous typing of 25 HPV genotypes. The combined SPF-PCR-LiPA 
system for detection and genotyping of HPV has been described in detail elsewhere.44 
As a quality control for the presence of DNA and absence of PCR inhibitors in the 
isolated material, a ‐-globin PCR was performed as described earlier.45 
Statistical analysis
Descriptive statistics were used to reproduce study results as percentages, means, 
medians, standard deviations, and ranges. Calculations were performed using 
Statistical Package for Social Sciences 16.0 (SPSS, Chicago, IL, USA).
population (only ~20%). Conversely, HPV-dependent vulvar SCCs seem to comprise 
the majority of vulvar carcinomas in immunocompromised women.33,41
 A long-standing hrHPV infection may cause multifocal (pre)malignancies of the 
anogenital tract.31 It was recently shown that in the general population frequently 
identical HPV types are found in both vulvar and cervical (pre)malignancies within 
the same patient, even after an interval of more than 10 years.42 Hence, a patient with 
a hrHPV-related anogenital (pre)malignancy is at higher risk to develop other hrHPV- 
related anogenital (pre)malignancies. 
 The elevated risk for RTRs to develop HPV-related anogenital (pre)malignancies 
may result in severe morbidity and mortality, mainly as these lesions may give rise to 
major dilemmas regarding therapy as radiation therapy or extensive surgery may 
harm the renal transplant. Therefore, understanding the elevated risk, the role of HPV, 
prevention and early treatment of premalignant lesions in this vulnerable patient 
population is important. 
 In this report we aim to give a clinical overview (including treatment) of all incident 
cases of anogenital malignancies after RT in our centre which has 40 years of experience 
with RT. Additionally, the HPV genotype distribution in all these malignancies and 
possible (multifocal) premalignancies within the same patient will be determined. 
Finally, we offer practical advice to improve the future health and quality of life of 
female RTRs.
Materials and Methods
Data sources
Data of all consecutive female RTRs who underwent a RT in the Radboud University 
Nijmegen Medical Centre, the Netherlands, between January 1968 and December 
2008 were collected. We assembled sociodemographic patient characteristics, 
medical data on RT, and on incident cases of malignancies of the female lower 
anogenital tract (i.e. cervix, vagina, vulva and anal canal), up to the end of July 2010. 
Total duration of transplant function of all patients of our cohort was analysed, taking 
into account repeated RTs in one patient. Patients with a total duration of transplant 
function less than 90 days were excluded from further analyses.
 Histo- and cytological data were obtained from the Pathological Anatomical 
National Automated Archive, which is a nationwide histo- and cytopathology network 
and archive that covers the entire country since 1991.43 Medical charts and electronic 
patient files were used to complete medical data. 
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Results
Baseline
During the study period, 1253 RTs were performed on female patients at the Radboud 
University Nijmegen Medical Centre. One hundred twenty-seven patients were 
transplanted more than once, with a maximum of four RTs per patient. For this 
analysis, patients were considered only once, whether they received multiple RTs or 
not. A total duration of renal transplant function less than 90 days was seen in 81 
patients, who were excluded from further analysis. Consequently, the final cohort 
included a total of 1023 consecutive female patients whose data were suitable 
for analysis. Baseline characteristics are reflected in Table 1. Transplantations were 
predominantly carried out between the age of 40 and 60 years. The median age at 
first RT was 44.5 years (range: 3.5 – 74.6 years). 
Malignancies of the Female Lower Anogenital Tract
Sixteen patients in our cohort (1.6 %) developed an anogenital malignancy (see Table 2 
for a detailed overview of all patients). All but one of these patients were transplanted 
once; patient 6 went through two RTs. The majority of the patients started with 
double immunosuppressive therapy (prednisolone and azathioprine or cyclosporine). 
Seven patients who experienced acute rejections were all successfully treated with 
prednisolone or antithymocyte globulin. 
 Six vulvar, five cervical, and five anal de novo carcinomas were diagnosed. The 
majority of the malignancies were SCCs. One adenocarcinoma of the anus was 
observed (patient 12). One patient (patient 12) developed a high-grade liposarcoma 
with unknown localisation 18 years before transplantation. This tumour was excised 
without any recurrence or metastases. Five patients (patient 1, 2, 4, 10, and 15) 
developed multiple post-transplant (pre)malignant skin lesions on non-genital skin 
before and after the diagnosis of their anogenital malignancy. Patient 1 and 14 
developed a Merkel cell carcinoma of the skin and an adenocarcinoma of the colon, 
respectively, 3 months and 5 years before the diagnosis of their vulvar carcinomas. 
The colon carcinoma showed local recurrence without metastases 2 years after initial 
treatment and was treated with local resection. Patient 15 had been successfully 
treated for breast cancer 13 years before the diagnosis of her anal carcinoma.
 The median age at diagnosis of the anogenital malignancies in our cohort was 
45 years (range: 37.2 – 72.5 years). The median interval between RT and diagnosis of 
malignancy was 136 months (range: 16 – 288 months). At the end of our study, seven 
patients were free of disease, five patients died of the disease, and four patients died 
of another cause. The median age at death was 53.2 years (range: 40.4 – 79.9 years). 
Table 3 presents data separated for the various types of the anogenital malignancies 
in our cohort.
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Table 2   Detailed information on female renal transplant recipients with anogenital  
malignancies 
Patient Age at first RT  
(yr)
Localisation Tumour  
Type
Age at  
diagnosis (yr)
Other  
malignancies
Therapy Recurrence Follow up since diagnosis 
1 19.1 Vulva SCC 43.1 Skin and MCC Radical vulvectomy and lymphadenectomy - FU 19 M
COD: metastatic MCC
2 23.5 Vulva SCC 41.4 Skin Partial vulvectomy and lymphadenectomy Vulva FU 141 M
DOD
3 24.9 Vulva SCC 44.7 - Radical vulvectomy and lymphadenectomy - FU 138 M
NED
4 34.0 Anus SCC 44.3 Skin RT Anus FU 37 M
DOD
5 56.9 Anus SCC 69.3 - External + internal RT and Chemo - FU 127 M
COD: Unknown
6 29.4 Anus SCC 45.3 - Excision - FU 138 M
NED
7 65.4 Cervix SCC 69.7 - Wertheim-Okabayashi + RT Vagina FU 32 M
DOD
8 29.1 Vulva SCC 39.3 - Radical vulvectomy and lymphadenectomy + partial 
sigmoid resection +rectumamputation 
- FU 13 M
COD: Acute myelofibrosis
9 33.6 Cervix SCC 38.6 - Wertheim-Meigs with ovariectomy - FU 132 M
COD: Myocardial infarction
10 28.9 Vulva SCC 42.8 Skin Partial vulvectomy - FU: 24 M
NED 
11 49.5 Cervix SCC 59.3 - Wertheim-Meigs with ovariectomy - FU: 2 M
DOD
12 71.2 Anus a AC 72.5 Liposarcoma RT, chemo and rectum amputation - FU: 13 M
DOD
13 58.1 Cervix SCC 60.2 - Wertheim-Meigs + RT - FU: 47 M
NED 
14 46.6 Vulva SCC 68.1 Colon Partial vulvectomy and lymphadenectomy - FU: 4 M
NED
15 34.8 Anus SCC 52.7 Skin & Mamma Rectum amputation - FU: 13 M
NED
16 29.6 Cervix SCC 37.2 - Wertheim-Meigs - FU: 7 M
NED
a Liver metastasis was already present at time of diagnosis AnusCa. RT = Renal transplantation; FU = 
Follow-up; M = Months; COD = Cause of death; NED = No evidence of disease; SCC = Squamous cell 
carcinoma; MCC = Merkel cell carcinoma; DOD = Dead of disease; AC = Adenocarcinoma; VCa = 
Vulvar carcinoma; CxCa = Cervical carcinoma; AnusCa = Anus carcinoma; RT = Radiotherapy; Chemo 
= Chemotherapy
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 Four of five patients with cervical cancer (patient 7, 11, 13, and 16) had modified 
surgical procedures, with only unilaterally removed pelvic lymph nodes and parametric 
tissue because of the presence of the renal transplant on the other side of the pelvis. 
Radiotherapy was indicated but abandoned to preserve renal function in patient 16. 
Patient 13 lost renal transplant function as a result of radiotherapy and is currently on 
dialysis. 
 Evaluation of last cervical smear before and first cervical smear after RT in the 16 
patients is presented in Table 4. It shows that 12 of 16 patients never had a cervical 
smear before their transplantation. Among the four patients who underwent at least 
one cervical smear before transplantation (interval between last smear and RT 
ranging between 1 and 7 years), there was one patient with a cytological normal 
cervix 3 years before RT that was diagnosed with a cervical carcinoma approximately 
2 years after RT. Patient 11 was diagnosed with a CIN 3 lesion before RT. After RT, a 
cytological high-grade squamous intraepithelial lesion of the cervix was diagnosed 
again. However, an intentional wait-and-see policy was carried out, and she was 
diagnosed with a cervical carcinoma 118 months after her RT.
 Nine patients only had cervical smears after RT; in three of them, the first cervical 
smear was even more than 10 years after transplantation. Five patients were diagnosed 
with a high-grade cervical lesion (CIN 3) at the moment of first cytological cervical 
screening after RT (interval between RT and first smear ranging between 3 and 
17 years).
HPV Prevalence and Genotype
An overview of the distribution of HPV genotypes in (multifocal) anogenital (pre)
malignancies of female RTRs related to time periods before and after renal transplantation 
is given in Table 5. Of the 16 patients with anogenital malignancies, seven patients 
developed a premalignant lesion in the anogenital region as well. Of these seven 
patients, six developed CIN before their malignancy and one (patient 2) developed 
Table 3   Characteristics of post-transplant anogenital malignancies 
Location Median age at diagnosis,  
years (range)
Median interval RT- malignancy, 
years (range)
Anus 52.7 (44.3-72.5) 12.4 (1.3-17.8)
Vulva 42.9 (39.3-68.1) 18.8 (10.2-24.0)
Cervix 59.3 (37.2-69.7) 5.0 (2.2-9.8)
RT = Renal transplantation
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CIN afterward. Patient 10 was diagnosed with an additional CIN 1 lesion at the time 
of diagnosis of her vulvar carcinoma as well.
 Of the 24 investigated (pre)malignant lesions, HPV was detected in 22 (91.7%). 
HPV type 16 predominated, with 12 of 22 lesions being positive for this type of HPV 
(54.5%). Nine lesions contained other hrHPV types. One vulvar carcinoma (patient 
14) showed HPV positive for an unknown HPV genotype. Four of the seven patients 
with multifocal anogenital lesions had different HPV genotypes in the different lesions 
(57.1%). Two of the seven patients had the same HPV types in both lesions and in one 
patient (patient 3), one of the lesions showed repeatedly ‐-globin negative after DNA 
extraction. Therefore, the HPV status could not be determined. 
Discussion
This long term follow-up study on a large cohort of female RTRs gives an overview of 
the development of anogenital malignancies after transplantation. We found five 
cervical, six vulvar, and five anal carcinomas. Especially vulvar carcinomas developed 
more often and at a younger age compared with the general population. Analysis 
showed presence of HPV in nearly all lesions, all concerning high-risk genotypes. 
Multifocal lesions within one patient frequently contained different hrHPV genotypes 
in both lesions.
 The cases in our study had a significantly longer duration of transplant function 
compared with the other RTRs, and probably longer immunosuppressive use as a 
consequence. Also, the high number of other (second or third) carcinomas in our 
cohort is remarkable, which is probably also a consequence of long-term immuno-
suppression use. The incidence of 1.6% that was found in our cohort seems higher 
than the overall occurrence of anogenital malignancies in the general population. 
A rough calculation, not adjusted for age or follow-up years, with the numbers 
recorded by the Netherlands Cancer Registry shows an estimated raised risk of 
fivefold for cervical, 41-fold for vulvar, and 122-fold for anal carcinoma in our cohort. 
If age-adjusted calculations had been performed, the risks would probably even be 
higher, because of the relatively young age at diagnosis of anogenital malignancies 
in our cohort. Moreover, as the Pathological Anatomical National Automated Archive 
has only complete national coverage since 1991, it is possible that the total number 
of anogenital (pre)malignancies in our cohort is even underreported. 
 The median age at diagnosis of vulvar SCC in the Dutch general population is 
70.4 years.46 In the current study, five of six RTRs developed a vulvar carcinoma at 
approximately 40 years of age, which is remarkably young. However, this young age 
is in agreement with the finding that all these vulvar carcinomas originated from the 
HPV-dependent pathway. Comparably, an earlier publication reported a 100% HPV 
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smear after RT point at the importance of regular cervical screening in RTRs. 
Especially because the treatment of these malignancies in RTRs frequently requires 
concessions such as modified surgery or omission of radiotherapy, which may result 
in a negative outcome. 
 The observation of HPV infection in women at older ages may be explained by 
true new infections or by reactivation of a latent infection.51 It is known that reduced 
immune surveillance secondary to HIV progression may trigger viral reactivation and 
may ultimately lead to progression of dysplasia.52 Presumably, the beginning of 
 immunosuppressive medication in RTRs probably has the same effect, resulting in a 
rise of the viral load and progression to (pre)malignancies.
 Almost 92% of our investigated samples showed a hrHPV infection. hrHPV type 
16 was detected in particular (12 of 22; 54.5%), which corresponds with the 
preponderance of HPV subtype 16 in cervical, vulvar, and anal cancer in the immuno-
competent population (50% – 70%).33,42,47,53 However, less common hrHPV types 
(e.g. 52, 56, and 58) were present as well. Brown et al.27 found an obviously higher 
HPV prevalence in specimens of RTRs (65%) compared with specimens of immuno-
competent patients (38%). The high number of hrHPV-positive cases in our study 
emphasises this finding. Because only specimens of histopathologically proven (pre)
malignant lesions were analysed in our study, a large number of female RTRs 
probably have undetected HPV infections or even (pre)malignant anogenital lesions; 
in particular, when considering that vulvar- and anal intraepithelial neoplasia (AIN) 
were frequently not histopathologically examined in earlier daily practice. This 
emphasises the importance of regular cervical surveillance combined with close 
inspection of the anogenital area for female RTRs, as we recently advised18,54; 
especially as 11 of the 16 diagnosed malignancies in our cohort developed in the 
external anogenital area that should be suitable for close observation. 
  Anal SCC is biologically very similar to cervical cancer. Its precursor lesion 
(high-grade AIN) is analogue to high-grade CIN. Besides, both anal cancer and AIN 
are strongly associated with HPV infection. Several studies reported a detection rate 
of HPV in invasive anal cancers between 71% and 88%.38-40 Oncogenic HPV subtype 
16 predominates, detected in approximately 70% of the HPV-positive anal 
tumours.38-40 RTRs are obviously at higher risk of developing anal HPV infection and 
neoplasia compared with the general population.55 It is interesting to note that, in this 
study, hrHPV subtypes (16 [66.7%] and 58 [33.3%]) were present in all three anal 
SCCs. The only HPV-negative anal carcinoma found was of the adenocarcinoma 
type. This corresponds with other studies that suggest that a large part of anal ade-
nocarcinomas are not HPV-related.38-40 
 Seven RTRs developed a second anogenital lesion at least 6 months before or 
after the diagnosis of their anogenital malignancies. Of these patients, only two 
showed identical hrHPV types in both lesions. In contrast, four patients (57.1%) had 
infection rate among RTRs with vulvar carcinomas, compared with a 20% to 57% HPV 
infection rate in vulvar neoplasms of immunocompetent patients.27,47 Generally, HPV 
types 16 and 33 are considered to be the most common genotypes in vulvar lesions 
(present in ~60% and 20% of vulvar carcinomas in the general population, 
respectively), although other hrHPV subtypes such as 18, 52, and 58 also have been 
reported.33,42,47 This corresponds to the types that predominantly have been 
detected in our cohort (HPV type 16 [50%], 33 [17%], and 58 [17%]). 
 Surprisingly, there is a difference in the interval times between transplantation 
and malignancy between the different anogenital cancer types in our cohort. 
It seems that, in the general population, the rate of malignant transformation of 
HPV-related vulvar and anal premalignancies is much lower compared with cervical 
premalignancies.41,48,49 However, as there are no screening programmes and 
frequently no  histopathological examination is performed for vulvar and anal intrae-
pithelial lesions, the mean interval times between HPV infection and the development 
of these malignancies remain largely unknown. The median interval between RT and the 
diagnosis of cervical carcinoma in our cohort appeared to be very short. As anogenital 
malignancies do not develop over such a short period in general, it is attractive to 
speculate that those RTRs already had asymptomatic dysplastic cervical lesions at 
the time of their RT, followed by rapid progression towards invasive carcinoma after 
the beginning of immunosuppressive therapy. Evaluation of cytological cervical 
screening in the cases with anogenital malignancies showed that only occasionally 
cervical smears were performed before RT. Screening of all women before RT would 
enable to diagnose possible anogenital (pre)malignancies at an early stage and 
provide adequate treatment for these lesions. However, it may also be possible that 
HPV-related cervical cancer develops faster in immunosuppressed patients compared 
with the general population. Because the majority of the cases were diagnosed with 
invasive lesions, it is difficult to draw a conclusion with respect to transformation rate 
in these cases. 
 Various publications and international guidelines advise at least yearly cervical 
screening with pelvic examination and cervical smear after RT.17,18,25-28 Wong et al.50 
have shown that this policy is effective in reducing cancer-specific mortality in RTRs. 
However, yearly follow-up smears were by no means regular in our cohort. This is in 
concordance with the low cervical screening rate in a previously studied larger cohort 
of female RTRs.18 In that study, no differences in screening rate before the detection 
of any low- or high-grade cervical lesion were seen between RTRs with cervical 
pathology and those without.18 The disappointing screening intensity may possibly 
be explained by the fact that these relatively recent guidelines were not well 
implemented in the former cohort. However, even though our overview of cervical 
screening is limited to a subgroup of RTRs with proven anogenital disease, we believe 
that the high number of high-grade cervical lesions at the time of the first cervical 
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Frequent complete gynaecological examination, including inspection of the anogenital 
area, may contribute to early detection of these (pre)malignancies of the anogenital 
tract of women. These relatively simple tools should therefore be implemented both 
before and periodically after RT to improve general health and quality of life of female 
RTRs. Besides, our findings give rise to further research into the course of HPV 
infections in a larger cohort of RTRs, preferentially in a prospective setting.
different hrHPV genotypes in both lesions. Compared with earlier research in our 
centre on nearly only immunocompetent patients with HPV-related vulvar cancer and 
additional cervical abnormalities (89% of patients with identical, and no patients with 
different HPV types in both lesions)42, our immunocompromised cohort showed 
a remarkably high number of patients with different hrHPV genotypes in both 
lesions. As time intervals and severity of the lesions did not differ significantly between 
both cohorts, it is highly possible that the difference in immune status causes the 
dissimilarities found.
 Hampl et al.56 recently published a hypothesis regarding different pathogenetic 
mechanisms leading to the development of multifocal anogenital lesions. They stated 
that immunocompromised patients are characterised by multiple genital lesions 
caused by different HPV types, including types that are untypical for high-grade 
lesions. So, an immunocompromised host would be target for repeated independent 
infections with various HPV types that induce independent lesions.56 Our findings 
support this hypothesis. 
 As we stated earlier, the major role of HPV in the oncogenesis of anogenital (pre)
malignancies and the increased risk for these lesions in RTRs strengthen the 
importance of studying the role of hrHPV vaccination for women before transplanta-
tion.54 The available vaccines (containing hrHPV types 16 and 18) seem to have great 
potential in the prevention of hrHPV-related anogenital (pre)malignancies in transplant 
recipients. The present study shows that the relative contribution (= the percentage 
of positive samples for a specific HPV type in relation to all the HPV-positive samples) 
of hrHPV genotypes 16 and 18 in anogenital lesions of female RTRs (13 of 22; 60%) 
approaches the relative contribution of these genotypes in invasive cervical cancer in 
the general population (71%).57 Nevertheless, it is conceivable that patients with 
end-stage renal disease and transplant recipients may be less responsive to the 
vaccine than immunocompetent individuals, as they may not produce the required 
protective immune response.50,58 At present, no data about effectiveness or safety of 
the HPV vaccination in RTRs are available and prospective studies to elucidate 
possible clinical benefits of this vaccination in RTRs are needed.  
 A high number of RTRs was included in our study. Although the follow-up period 
was extensive for most patients, we must acknowledge that recently transplanted 
patients had a relatively short period of follow-up. It is known that anogenital 
malignancies do not develop over such a short period in general. Therefore, the 
numbers of anogenital malignancies in our cohort can be underestimated and may 
rise in the future. Nonetheless, we believe that our large and representative population 
of female RTRs, despite the lack of a control group, gives important insights in the 
problem of post-transplantation anogenital malignancies.
 To conclude, anogenital malignancies are relatively frequently seen in female 
RTRs, with a crucial role for infections with various (uncommon) hrHPV subtypes. 
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Abstract 
Immunosuppressive treatment of organ transplant recipients is associated with an 
increase in the occurrence of human papillomavirus (HPV) related anogenital (pre)
malignancies. This cohort study investigated the genotype-specific prevalence of 
HPV infections in a large cohort of female renal transplant recipients (RTRs). 
Participants self-collected a cervicovaginal sample for detection and genotyping of 
HPV. Besides, they completed a questionnaire regarding sociodemographic variables, 
medical data and sexual behaviour. Anogenital screening was offered to all HPV 
positive participants. A total number of 218 female RTRs was included. The prevalence 
of mucosal HPV infections was 27.1% and 17.4% for high risk HPV in particular. The 
studied cohort showed a broad range of HPV genotypes and multiple HPV genotypes 
were found in 27.1% of HPV-positive patients. Seven participants were identified with 
occult premalignant anogenital lesions. In conclusion, this study shows a high 
point-prevalence of HPV in female RTRs (age-matched West-European general 
population: 9-10%) with a shift in the distribution of genotypes as compared with 
the general population. Moreover, a substantial number of patients with occult pre-
malignancies was identified. The introduction of self-sampling for HPV positivity 
can help in early detection of (pre)malignant anogenital lesions in this vulnerable 
population. 
Introduction
Current immunosuppressive regimens have improved long-term graft and patient 
survival after renal transplantation. The down-side of prolonged immunosuppressive 
treatment is an increase in the cumulative occurrence of (pre)malignancies, especially 
those associated with viral infections.1,2 
 Previous studies reported an increased risk for human papillomavirus (HPV) 
related anogenital (pre)malignancies in renal transplant recipients (RTRs). A three to 
six-fold increased risk was found for cervical cancer, a ten-fold increased risk for anal 
cancer, and even a 31 to 100-fold increased risk for cancer of the vulva.1,3-5 
 Although data on the prevalence of HPV infections in RTRs are scarce, an evident 
increase compared to healthy immunocompetent individuals has not been found in 
previous studies.6-8 Therefore, it is assumed that the elevated risk for developing HPV- 
related lesions after renal transplantation mainly results from the declined cell-mediated 
immunity caused by the use of immunosuppressive therapy. However, detailed data on 
the genotype-specific prevalence of HPV, risk factors for HPV infection, and the 
relationship between HPV genotypes and anogenital lesions in RTRs are not available.
 Recently, a self-sampling technique for HPV detection has been introduced. 
A number of studies showed that there is a high level of concordance between the 
results obtained with self-collected samples and physician collected samples.9-12 
Advantages of self-sampling are that it is easy to use, inexpensive, and highly accepted 
by women.9-12 
 In the present study we employed self-sampling to investigate the genotype- 
specific prevalence of HPV infections and to offer HPV-based screening for anogenital 
lesions in a large cohort of female RTRs. 
Methods
Study population
Female RTRs that fulfilled the following criteria were invited to participate in this study: 
(1) transplantation at the Radboud university medical center (RUMC), Nijmegen, or 
the Maastricht University Medical Centre (MUMC), Maastricht, the Netherlands, in the 
period 1968-2008, (2) a functioning donor kidney on February 2012, (3) living in the 
Netherlands, and (4) aged above 18 years. This study was approved by the local 
medical ethics committees of both participating centres [protocol number: 2011/268] 
and was conducted according to the Good Clinical Practice guidelines of the 
International Conference on Harmonization (ICH).
 A total of 407 (RUMC) and 219 (MUMC) patients were eligible for participation 
and were sent written information regarding the study. Of the 626 invited participants, 
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Ijssel, The Netherlands). The sequences were used as a query for screening of the 
sequences in the GenBank database (www.ncbi.nlm.nih.gov) with BLAST software.16 
HPV genotypes were assigned when a complete match between the 22-bp interprimer 
region and an HPV sequence in GenBank was found. 
 Genotypes not available on the LiPA strip and without a complete match in 
GenBank were considered HPV genotype ‘X’. Low risk HPV (lrHPV) genotypes were 
defined as genotype 6, 11, 34, 40, 42, 43, 44, 54, 74, 89, 90 and ‘X’. High risk HPV 
genotypes were defined as genotype 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59. 
HPV genotypes 53, 66, 68, 69, 70 and 73 are nowadays classified as possible/
probable high risk HPV (phrHPV) genotypes.17 For analytical purposes, they were 
defined as hrHPV genotypes in this study. HPV genotypes 3, 12, 20 and 76 were 
identified as cutaneous genotypes. These HPV genotypes were regarded as 
contamination during sampling handling and were not taken into account in the 
calculation of HPV prevalence rates. 
Questionnaire
All participants were asked to complete a questionnaire, which was divided in three 
parts. The first part existed of questions concerning sociodemographic characteristics 
(i.e. ethnicity, educational level, religion, and marital status). The second part asked 
for medical data, regarding both general (i.e. weight and length) and gynaecological 
health. The third part included questions on past and present sexual behaviour, to 
gain insight into risk factors for positive genital HPV status. Sexual contact was 
defined as oral, vaginal, or anal sex or genital contact. 
 The distribution of the questionnaires was preceded by a pilot study among eight 
volunteers to optimise the quality of the survey. Questionnaires could be filled in by 
using a digital (secured) system or via a paper version. All questionnaires were 
provided and saved with the unique study code.
Anogenital screening
Patients positive for either cutaneous type or mucosal type HPV were offered an 
anogenital screening visit at the outpatient clinic of the Department of Obstetrics & 
Gynaecology of one of the participating centres. Screening comprised an extensive 
inspection of the anogenital area and a smear of the cervix or vaginal vault in case of 
hysterectomy in the past. Cervical and vaginal cytology results are reported according 
to the Bethesda System. In case of any abnormal finding during this screening visit, 
patients were referred for further gynaecological examination (i.e. vulvar biopsy, 
colposcopy) and treatment according to local guidelines. 
 Patients with negative HPV-DNA test results were advised to have regular 
anogenital inspection and cervical cytology (performed by their own general 
practitioner), according to international guidelines.18-20 
253 RTRs (40%) (172 RUMC and 81 MUMC) gave their written informed consent for 
this study. To ensure pseudonymous data handling, all participants were given a 
unique study code.
 Clinical data of the participants regarding the underlying renal disease, dialysis, 
renal transplantation, immunosuppressive medication, acute rejection episodes and 
creatinine level at the time of participation were abstracted from the local renal trans-
plantation registries of the two centres. 
Sampling technique
All participants were asked to self-collect a cervicovaginal sample in the privacy of 
their own home with the dry Evalyn Brush® system (Rovers Medical Devices B.V., 
Oss, the Netherlands), which was proven to provide similar results as a physician- 
taken sample for high risk HPV (hrHPV) detection.9 Patients received the collection 
device, written instructions with illustrations and a return package comprising a leak 
proof seal bag, absorption sheet and a plastic return envelope complying with the 
packing instruction for the sending of biological substances (category B) per mail. 
All samples were stored dry and certified with the unique study code. Specimens were 
collected from April – November 2012 (RUMC) and January – March 2013 (MUMC). 
Specimen preparation and DNA extraction
The dry Evalyn Brush was resuspended in 1·5 ml Thin Prep. The vials were vortexed 
for 3x15s, stored overnight at 4°C, and again vortexed for 2x15s. From each 
resuspended dry specimen, 200 μl was used for DNA extraction with the MagNaPure 
96 (Roche Molecular Diagnostics). The purified DNA was eluated in 50μl TE-buffer.
HPV detection and genotyping
For detection and genotyping of HPV, broad spectrum HPV amplification was 
performed using a highly sensitive short-PCR-fragment assay (SPF10 -LiPA25; Labo 
Bio-medical Products B.V., Rijswijk, The Netherlands). This assay amplifies a small 
fragment of 65-bp from the L1 open reading frame and allows detection of a broad 
range of HPV genotypes.13-15 HPV-DNA detection was performed by using an HPV 
DNA enzyme immunoassay (DEIA), which uses a defined cocktail of digoxigenin- 
labeled probes to detect a broad spectrum of HPV mucosal genotypes.
 All HPV DNA-positive samples were genotyped subsequently with a line probe 
assay (LiPA25) by reverse hybridization with type-specific probes for mucosal HPV 
genotypes 6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 
59, 66, 68/73, 70, 74.13 The LiPA strips were interpreted visually, using the standard 
reference guide. When samples tested positive using the DEIA, but showed no results 
on the LiPA strip, the SPF10 amplimer was analysed by direct sequence analysis with 
the BigDye Terminator cycle sequencing kit (Applied Biosystems, Nieuwerkerk a/d 
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Data and statistical analysis
All data were pseudonymously stored in an electronic database for data collection 
and statistical analysis (IBM SPSS Statistics 20, New York, USA). For continuous 
variables, medians (range) or means (±SD) were calculated, depending on the distribution 
of the parameters. For categorical variables, total numbers and percentages were 
calculated for each modality. The modified Wald method was used to compute 95% 
confidence intervals (CI) for the HPV-prevalence. Missing answers were not included 
in the analysis. 
 The duration of immunosuppressive therapy was calculated as the time between 
date of transplantation and date of participation in the study. This variable was not 
calculated in patients with retransplantations since data on the use of immuno-
suppressive drugs after previous graft failure were not available. 
 We compared the prevalence of any-type of mucosal HPV between different 
groups of participants by means of crude risk ratio’s (RR), estimated with log-binominal 
generalised linear models. To identify the variables that contributed independently to 
the risk of any-type mucosal HPV positivity, all variables that showed a significantly 
elevated RR in the univariable analysis were included in a multivariable analysis. 
Statistical significance was defined as a two sided P value < 0·05. 
Results
Participants 
Study materials were sent to the 253 women who gave their informed consent; 218 
(86.2%) returned the self-sample and were included in this study. See Figure 1 for an 
overview of study procedures. 
Baseline 
Table 1 shows baseline data of all included participants. Mean age at participation for 
this study was 55.4 years (SD 12.2) and women were on average 43.1 (SD 14.0) years 
of age at their first renal transplantation. The median duration of immunosuppressive 
therapy was 8.5 (range: 3.2-37.7) years. The majority of patients was treated with a 
calcineurin inhibitor (88% at time of transplantation; 67% at time of investigation). 
Induction therapy with antibodies against T-cells or the interleukin-2 receptor was 
used in a few patients only. Participants had a median BMI of 24.5 kg/m2 (range: 16.8 
– 48.3). The vast majority of participants (93%) did not smoke at the time of the study. 
None of the participants had been vaccinated against HPV prior to this investigation. 
There were no significant differences between responders and non-responders 
regarding both the mean age at participation (55.4 vs. 54.6 years, P = 0.45) and 
mean time since renal transplantation (12.4 vs. 12.2 years, P = 0.77).
Figure 1  
Advise for regular anogenital screening 
(n = 147)  
Invitation for anogenital screening visit
(n = 71) 
HPV negative (n =  147) 
HPV positive (n = 71)
• Mucosal HPV (n = 59)
• Cutaneous HPV (n = 12) 
Written informed consent
(n = 253, 40%)
Included:
Returning self-sample (n = 218)   
Invitation of RTRs
eligible for participation
(n = 626)   
Excluded:
Declined to participate (n = 373)  
Excluded:
Not returning self-sample (n = 35)  
Lost to follow-up (n = 4) 
Anogenital screening (n = 67) 
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 An overview of sexual behaviour of included women is given in Table 2. The majority 
of women was married or living together (74%) and almost all women had been 
sexually active (95%), mostly with male sex partners (98%). About half of the women 
(49%) had no sexual contact during the last six months preceding the study. 
 Twenty-six women (12%) underwent hysterectomy before the study. Participant- 
reported data on the performance of cytological cervical screening were available in 184 
(96%) of the remaining subjects and showed that on average 2.6 (SD 2.0) cervical smears 
were performed during the last five years preceding entry into this study. Twenty-two 
percent of the women reported to have undergone at least one smear per year, 24% 
reported one smear in five years and 12% underwent no cervical screening at all. 
HPV data 
Of the 218 samples analysed, 59 (27.1%, CI 21.6-33.3%) tested positive for one or 
more mucosal HPV genotypes. The overall prevalence of lrHPV genotypes in our 
study cohort was 9.6% (CI 6.3-14.3%, n = 21) and hrHPV genotype prevalence was 
17.4% (CI 12.9-23.1%, n = 38). 
 Table 3 shows an overview of any-type mucosal HPV prevalence and risk ratios 
for HPV prevalence between various subgroups of participants. Factors associated 
with an elevated risk on any-type mucosal HPV, according to the univariable analysis, 
were: transplantation in MUMC, younger age at study, non-Dutch ethnicity, younger 
age at transplantation, not being married, younger age at first intercourse, higher 
number of lifetime sexual partners, and higher number of sexual partners during the 
last six months. Time on immunosuppressive medication and the type of immuno-
suppressive treatment were not related to HPV prevalence.
Table 1   Baseline data of participants 
Sample size  
(N)
Age at study (years) 218 55.4 (SD12.2)
Age at transplantation (years) 218 43.1 (SD14.0)
Time on immunosuppression (years) 182 8.5 (3.2 – 37.7)
Time on dialysis (years) 218 1.7 (0 – 14.6)
Number of Tx
 1
 2
 ≥3
218
182 (83.5%)
29 (13.3%)
7 (3.2%)
Current immunosuppressive therapy
Mono
Tac
Mono-other
Duo
Ste-Tac
Ste-Aza
Ste-MMF
MMF-Tac
MMF-CsA
Sir-other
Duo-other
Triple
Sir-other
Triple-other
218
49 ( 22.5%)
8 (3.7%)
40 (18.3%)
37 (17.0%)
22 (10.1%)
18 (8.3%)
6 (2.8%)
12 (5.5%)
16 (7.3%)
2 (0.9%)
8 (3.7%)
Creatinine (μmol/L) 218 113 (52 – 447)
Rejections (N)
 0
 1
 2-3
 >3
218
170 (78%)
30 (13.8%)
14 (6.4%)
4 (1.8%)
BMI
<18·5
 18·5 – 25
>25
211
8 (3.8%)
106 (50.2%)
97 (46%)
Ethnicity
Dutch / Other
213
203 (95.3%) / 10 (4.7%)
Current smoking
Yes / No
213
15 (7%) / 198 (93%)
Education
Primary / No education
Lower secondary / Lower vocational training
Higher secondary / Vocational training
Higher vocational training / University
213
20 (9.4%)
99 (46.5%)
58 (27.2)
36 (16.9%)
Table 1   Continued 
Sample size  
(N)
Cause of ESRD
Chronic glomerulonephritis
Pyelonephritis
Diabetic nephropathy
Nephrosclerosis
Polycystic renal disease
Other
218
36 (16.5%)
18 (8.3%)
7 (3.2%)
9 (4.1%)
42 (19.3%)
106 (48.6%)
Data are reflected as means (±SD) or medians (range). 
N = Number; Tx = Transplantation; Ste = Corticosteroids; MMF = Mycophenolate mofetil; Tac = 
Tacrolimus; CsA = Cyclosporine A; Sir = Sirolimus; Aza = Azathioprine; BMI = Body Mass Index; ESDR 
= End stage renal disease
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Table 2   Sexual behaviour 
Sample size (N) Total cohort
Relationship
Married
Living together
Widowed / Divorced
LAT
Single
213
143 (67.1%)
15 (7.0%)
18 (8.5%)
8 (3.8%)
29 (13.6%)
Sexual activity ever
Yes
No
209
198 (94.7%)
11 (5.3%)
Age at first intercourse (years) 198 18 (11 – 58)
Ever diagnosed with STI
Yes
No
196
16 (8.2%)
180 (91.8%)
Gender sex partner
Male
Female
Both
195
192 (98.5%)
1 (0.5%)
2 (1.0%)
Lifetime sex partners (N)
 1
 2-5
 6-10
>10
186
82 (44.1%)
82(44.1%)
16 (8.6%)
6 (3.2%)
Sex partners last 6 months (N)
 0
 1
 2
>2
196
97 (49.5%)
93 (47.4%)
3 (1.5%)
3 (1.5%)
Sexual contact last 6 months 
Never
Monthly
Weekly
Daily
197
97 (49.2%)
56 (28.4%)
43 (21.8%)
1 (0.5%)
LAT = Living apart together; N = Number; STI = Sexually transmitted infection
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 Additional univariable analyses on different anti-rejection therapies showed no 
significant risk-ratio’s for the different modalities of rejection therapy (lymphocytic 
depleting agents, pulse steroids, or both; P = 0.92). However, the power of this test 
was low due to small study numbers and the results should be interpreted with 
caution. 
 Multivariable analysis with all variables that significantly contributed to an elevated 
risk on any-type mucosal HPV in the univariable analyses showed transplantation 
in MUMC and a higher number of lifetime sexual partners as factors that were 
independently associated with a raised risk of being mucosal HPV positive. Similar 
analyses on contributors to hrHPV infections showed no independent factors predicting 
a high-risk HPV positive state (detailed data not shown).
Specific HPV genotypes 
In 43 of the 59 women positive for mucosal HPV (72.9%), a single HPV genotype was 
found. Sixteen women (27.1%) were found to have multiple genotypes. Table 4 shows 
the type-specific prevalence of all HPV genotypes identified. High-risk genotypes 
HPV 16 (n = 9, 4.1%), 51 (n = 9, 4.1%), and 66 (n = 7, 3.1%) showed the highest 
prevalence rates. In 13 samples (6%) the exact genotype could not be specified and 
was labelled genotype X. In one woman who reported to never having had sexual 
contact with another person, lrHPV genotype X was found. 
Anogenital screening and follow-up
A total number of 67 of the 71 HPV positive patients (mucosal or cutaneous type) 
underwent anogenital screening. Table 5 summarises the screening results. Five patients 
were newly diagnosed with a high-grade squamous intraepithelial lesion (HSIL) and 
two patients were diagnosed with usual vulvar intraepithelial neoplasia (uVIN). Prior 
anogenital screening was not performed in these seven patients. Condylomata 
acuminata (caused by lrHPV) was diagnosed in two patients. Follow-up data of 
HPV-positive patients are shown in table 5. Mean follow-up was 20 months (SD 5), 
with a minimum of one year. Nine patients who were positive for hrHPV developed 
relevant cervical pathology during follow-up. One patient with uVIN developed severe 
anal intraepithelial neoplasia and one patient positive for lrHPV was diagnosed with 
anal carcinoma in situ during follow-up. 25 Of the 67 initially screened HPV-positive 
patients (37%) had no follow-up screening cytology. Initial screening results of these 
25 patients were within normal limits.
Table 4   Human papillomavirus type-specific prevalence 
Prevalence
N % 95% C.I.
Total hrHPV # 38 17.4 12.9 – 23.1
hrHPV genotype *
16 9 4.1 2.1 – 7.8
18 2 0.9 0.0 – 3.5
31 4 1.8 0.6 – 4.8
35 2 0.9 0.0 – 3.5
39 2 0.9 0.0 – 3.5
51 9 4.1 2.1 – 7.8
52 5 2.3 0.8 – 5.4
53 5 2.3 0.8 – 5.4
56 2 0.9 0.0 – 3.5
58 1 0.5 0.0 – 2.8
59 3 1.4 0.3 – 4.2
66 7 3.2 1.4 – 6.6
68 2 0.9 0.0 – 3.5
69 1 0.5 0.0 – 2.8
Total lrHPV # 21 9.6 6.3 – 14.3
lrHPV genotype *
6 2 0.9 0.0 – 3.5
11 1 0.5 0.0 – 2.8
34 2 0.9 0.0 – 3.5
40 1 0.5 0.0 – 2.8
42 3 1.4 0.3 – 4.2
44 1 0.5 0.0 – 2.8
54 3 1.4 0.3 – 4.2
74 3 1.4 0.3 – 4.2
89 1 0.5 0.0 – 2.8
90 1 0.5 0.0 – 2.8
X 13 6.0 3.4 – 10.0
# = Total number of patients positive for HPV
* = Total number of different HPV genotypes detected. Percentages are calculated over total study 
population (n = 218). Multiple genotypes per patient do occur. 
C.I. = Confidence interval; hrHPV = High-risk HPV; lrHPV = Low-risk HPV; N = Number
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Our cohort of female RTRs showed an elevated overall HPV prevalence of 27.1% 
which is even higher than the prevalence rate of about 25% that was found with the 
same detection method in women of the general population aged 18-29 years.22,23 
Our findings differ from the results of two relatively small studies (n = 24 and n = 60, 
respectively) showing similar frequencies of HPV positivity in female RTRs compared 
to controls. 7,8 Notably, the prevalence in the control groups of these studies was 
rather high when compared to European data of the general population. 
 The increased HPV prevalence in our study cohort may be related to acquiring 
more new infections, delayed clearance of infections, or an increased reactivation of 
latent HPV infections. Our cohort of patients had a limited mean number of recent 
sexual partners and sexual abstinence during the last six months in about 50% of the 
participants. Therefore, the most plausible explanation for the high HPV prevalence is 
Discussion
Our study describes the genotype-specific HPV prevalence in the largest cohort of 
female RTRs until now (n = 218). The overall prevalence of mucosal HPV infections 
was 27.1% and 17.4% for hrHPV in particular. The studied cohort showed a broad 
range of HPV genotypes and multiple HPV genotypes were found in 27.1% of 
HPV-positive patients. Based on the HPV testing and subsequent diagnostic 
follow-up, seven participants with occult premalignant anogenital lesions were 
identified. During a mean follow-up of 20 months even more relevant lesions were 
detected. 
 The HPV prevalence in the West-European general female population aged 
45-55 years (corresponding to the average age of our participants) is 9-10%.21,22 
Table 5   Screening results of Human papillomavirus positive patients   
Screening results                       History                                               Follow up
N Cytology* Other N Cytology*                    Other
Cutaneous types  
(n=12)
12 WNL verruca plana (n=2) 10
2
WNL
No follow up data
Low risk mucosal types  
(n=21)
1 Lost 1 Lost
18 WNL morbus Bowen (n=1)
moderate/severe cervical dysplasia (n=1)
8
10
WNL
No follow up data
anal carcinoma in situ (n=1)
2 ASC-US 2 ASC-US
High risk mucosal types 
(n=38)
3 Lost 3 Lost
20 WNL LSIL / HSIL (n=5) 6
1
13
WNL
ASC-US
No follow up data
5 ASC-US condylomata (n=1)
usual VIN (n=1)
1
1
1
2
WNL
ASC-US
LSIL
HSIL
moderate cervical dysplasia (n=1)
severe cervical dysplasia (n=1)
4 LSIL usual VIN (n=1) mild/moderate cervical dysplasia (n=1)
mild cervical dysplasia (n=1)
2
2
LSIL
HSIL
mild cervical dysplasia (n=1)
severe cervical dysplasia (n=1)
severe anal intraepithelial dysplasia (n=1)
6 HSIL condylomata (n=1) mild - severe cervical dysplasia (n=1) 1
2
3
ASC-US
LSIL
HSIL
moderate cervical dysplasia (n=1)
severe cervical dysplasia (n=4)
* = Bethesda 2001 classification; N = Number; Lost = Lost to follow up; WNL = Within normal limits; 
ASC-US = Atypical squamous cells with unknown significance; LSIL = Low-grade squamous intraepithelial 
lesion; HSIL = High-grade squamous intraepithelial lesion (HSIL)
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transplant patients on immunosuppressive therapy.32 Pre-transplantation vaccination 
may be more beneficial and further studies are going on in this area.
 Overall, the women included in our study had limited knowledge about their 
elevated risk on HPV and HPV-related lesions. Besides, intensified cervical screening 
was not performed on a regular basis in a considerable number of participants. This 
might explain the finding of seven occult cervical/vulval lesions by anogenital 
screening of HPV positive study participants. Although patients were extensively 
verbally advised to have yearly follow-up after initial screening, a large part of patients 
was lost to follow-up. This was particularly true in patients with known positivity for 
high-risk HPV genotypes, where 13/35 patients were lost to follow-up. Notably, most 
of the high-risk HPV positive patients had abnormal cytology at follow-up visit and 
some patients showed progression of disease, underscoring the specific value of 
screening in this population. Based on these findings, we see a strong need for 
improvement of gynaecological follow-up in the transplant patients. Therefore, we are 
currently preparing a qualitative study assessing the barriers and facilitators for 
anogenital screening in both female RTRs and professional health care givers. We 
aim to find reasons for non-attendance and, subsequently, will develop a strategy to 
improve the attendance at annual anogenital screening. Possibly, education of 
immunocom promised patients and involved professionals about the obviously 
elevated risk for HPV-related anogenital malignancies and the consequent need for 
cervical screening is important. In women who are reluctant to undergo cervical screening 
by a physician or nurse, self-sampling for hrHPV testing may be a valuable alternative. 
Moreover, attention for other preventive strategies like vaccination and appreciation of 
pre-transplant HPV-related lesions is warranted. 
 Some limitations of this study need to be acknowledged. Due to the cross- 
sectional design, we have no data on the dynamics of HPV infections and the concurrent 
prevalence of genotypes over time, which might have provided more insight into the 
relationship with the intensity and type of immunosuppression. Furthermore, since 
only 40% of the invited female RTRs consented to participate, we cannot exclude 
some form of response bias. Possibly, either patients with regular anogenital 
screening or patients with known anogenital pathology opted to withdraw from this 
study. Finally, the possible use of immunosuppressive drugs before transplantation 
was not known, which made the data of total duration of immunosuppression slightly 
less accurate. 
 To investigate the epidemiology of HPV-infections in this cohort of immuno-
compromised female patients, the highly sensitive SPF10-LiPA PCR was used. It may 
be argued that, due to its low threshold values, this test cannot discriminate between 
active and latent infections, and has therefore a lower specificity for clinically relevant 
infections. However, in contrast to the recently shown lower pooled sensitivity of 
HPV-testing on self-collected samples for detecting CIN2 or worse compared to 
delayed clearance and reactivation of latent infections due to the immunosuppressed 
state.24,25 
 Somewhat surprising, the duration of immunosuppressive treatment and the 
occurrence of an acute rejection with subsequent intensifying of immunosuppressive 
therapy, were in this cohort not related to the risk of HPV positivity. This suggests that 
the current intensity of immunosuppression may be more important than the 
cumulative exposure. 
 A higher number of lifetime sexual partners was independently associated with 
HPV positivity. This is in concordance with previous epidemiological data showing 
that total number of sexual partners is one of the most dominant risk factors for HPV 
positivity.23 We have no clear explanation for the difference in HPV prevalence rates 
between the two participating centres. 
 Of the studied cohort, 7.3% showed infection with multiple HPV genotypes (27.1% 
of all mucosal HPV positive RTRs). These percentages are comparable with percentages 
of the general Dutch population aged 18-29 years.23 Former studies described 
having multiple HPV infections as a risk factor for hrHPV persistence.26,27 Multiple 
infections may increase the overall viral load which may overcome immune control. 
It can be speculated that this risk is even stronger in immunocompromised patients.
 Worldwide, the five most prevalent HPV genotypes in women with normal 
cytology are 16 (2.3-3.2%), 18 (0.8-1.4%), 31 (0.8%), 52 (0.6-0.9%), and 58 (0.7%).21,22 
We found a very broad spectrum of 24 individual HPV genotypes among our cohort 
of female RTRs enclosing seventeen patients with abnormal cytology. The five most 
common genotypes were somewhat different compared to the general population: 
16 (4.1%), 51(4.1%), 66 (3.2%), 52 (2.3%), and 53 (2.3%) prevailed. The genotypes 18, 
31, and 58 were less prevalent in our cohort. Besides, genotype 16 did not predominate 
over other HPV genotypes to the same extent as seen in the general population. 
A similar shift towards other HPV genotypes has been observed in HIV-infected 
patients. 28 It was previously shown that the association between CD4-cell counts 
and risk of infection is weaker for HPV16 than for other genotypes.28 This suggests 
that the prevalence of HPV16 is relatively independent of the immune status.
 Mucosal HPV-DNA, including high-risk HPV genotypes, has been repeatedly 
detected in a proportion of extra-genital NMSC. However, whether HPV plays a 
causal role in the oncogenesis of NMSC is still a matter of debate.29-31 Having NMSC 
on extra-genital skin was not registered in our current study. However, from previous 
work we know that the development of NMSC and gynaecological (pre)malignancies 
are not related to each other.4
 Prophylactic vaccines against hrHPV genotype 16 and 18 are highly effective for 
the prevention of persistent infections and anogenital cancer. It is attractive to 
speculate on the beneficial effect of this vaccine in transplant recipients. However, 
recent data showed suboptimal immunogenicity of the quadrivalent HPV vaccine in 
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testing on a clinician based sample, SPF10-LiPA PCR based hrHPV detection on 
self-collected samples approaches the sensitivity and specificity of clinician-taken 
samples.9,33,34 Therefore, using the SPF10-LiPA PCR seems a valuable strategy in 
HPV-based screening on self-collected specimens.
 In conclusion, the results of this observational, epidemiological study among a 
relatively large cohort of female RTRs show a high prevalence of HPV positivity with 
a shift in the distribution of genotypes as compared with the general population. Use 
of a self-sampling method for HPV positivity can help in early detection of (pre)
malignant anogenital lesions which are more frequent in this population. Where this 
study focused on the point-prevalence of HPV infections after transplantation, we are 
currently performing a prospective follow-up study to provide knowledge about 
the course of HPV infections before and after transplantation. This may contribute 
to strategies for the prevention of anogenital (pre)malignancies in the vulnerable 
population of RTRs. 
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CHAPTER 9 GENERAL DISCUSSION
In the present thesis, several clinical studies on genital psoriasis and genital (pre)
malignancies in female renal transplant recipients (RTRs) have been described. This 
thesis hereby provides more insight into these highly relevant, but frequently hidden, 
problems in the genital region. 
 The current chapter provides a general discussion of the themes that are presented 
in this thesis and describes the main conclusions in accordance with the aims as 
defined in chapter 1. Subsequently, implications for daily clinical practice will be 
highlighted. Finally, future suggestions for a multidisciplinary approach of the genital 
diseases as described in this thesis will be given. 
Discussion of study data
In psoriatic patients, genital involvement is frequently occurring in both males and 
females of all ages. Percentages of psoriatic patients who have significant genital 
problems during the course of their disease vary from at least 16.5% up to 46% 
(chapter 2 of the present thesis).1-5 
 Genital psoriasis has been erroneously classified as flexural psoriasis, both in 
the literature as in daily dermatological practice. This thesis (chapter 2) shows that 
38% of patients with genital psoriasis have no flexural psoriasis. Therefore, genital 
lesions are frequently missed when flexural skin (i.e. inguinal skin) is not affected with 
psoriasis and genital skin is neglected during physical examination. 
 As outlined in chapter 3, the quality of life and sexual health are diminished in a 
considerable number of male and female patients with psoriasis. Especially women 
experience high levels of sexual dysfunction (48.7%) and, in the presence of genital 
lesions, also high levels of sexual distress (50.8%). Therefore, health care professionals 
cannot ignore the major impact of genital psoriasis on (sexual) quality of life and need 
to pay attention to the consequences of involvement of the genital skin. The major 
impact on sexual health of other genital skin diseases, such as lichen sclerosus, is 
also well known and paid attention to.6,7 
 The quality of life indices that are frequently used for patients with psoriasis and 
other dermatoses, only sparsely cover the domain sexual function. The generic 
questionnaires SF-36 and EQ-5D do not mention sexual health at all, and in the 
disease specific DLQI the domain is restricted to one short question. The Skindex- 
questionnaire only questions about sexual health in the long version of the 
questionnaire; the frequently used short 16-item Skindex only mentions the term 
‘close relations’. Therefore, these commonly used questionnaires will probably not 
provide an adequate estimation of the actual impact of (genital) psoriasis and other 
skin diseases on sexual health. 
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that this policy of intensified screening will lead to decreased morbidity and 
mortality.19-21 Chapters 6 – 8 show that the uptake of intensified (ano)genital screening 
among the female renal transplant population is low and that many female RTRs have 
suboptimal cervical screening after their transplantation. This finding is in accordance 
with previous studies among female RTRs.22,23 Probably, both patients and 
healthcare professionals focus on the preservation of renal function. However, 
implementation of intensified anogenital screening and monitoring for potential lethal, 
though preventable, malignancies of the genital tract may have great benefits. 
 High-risk HPV has a major role in the development of genital (pre)malignancies. 
By using a self-sampling method, we show in chapter 8 of this thesis that female 
RTRs have an obviously elevated HPV point-prevalence compared to the general 
population (27%, vs. 9-10% in the general population). Moreover, there appears to be 
a shift in the distribution of HPV genotypes in female RTRs as compared to the 
general population. Both chapter 7 and 8 of this thesis describe that female RTRs 
may be infected with a broad pallet of HPV genotypes, including less common hrHPV 
genotypes (e.g. genotype 51 and 66). Interesting, chapter 7 shows that in case of 
multifocal lesions, frequently different HPV genotypes are present at different 
locations. These findings illustrate that immunocompromised RTRs are target for 
repeated and independent infections with various types of HPV.
 Screening through self-sampling of 67 HPV-positive RTRs at our outpatient clinic 
revealed about 10% of female RTRs with occult premalignant genital lesions that in 
the long term would have progressed towards invasive lesions (chapter 8). This 
indicates that HPV self-sampling may be very helpful in early detection of (pre)
malignant anogenital lesions in the vulnerable renal transplant population. 
Major conclusions
PART A: Genital psoriasis
1. The genital area is involved in up to 46% of patients with psoriasis. Flexural and 
genital psoriasis should be regarded as distinct manifestations. 
2. Quality of life and sexual health are considerably diminished in patients with 
psoriasis. Particularly women with genital psoriasis have high levels of sexual 
distress. Current scoring systems for quality of life in psoriasis do not sufficiently 
comprise the impact of (genital) psoriasis on sexual health.
3. Although numerous patients report a significant burden of disease, the 
consultation rate for genital psoriasis is low and examination of genital skin is 
frequently lacking. 
4. Adequate management of genital psoriasis leads to significant improvement of 
disease severity and (sexual) quality of life within limited time investment.
 When reconciling the frequency of genital psoriasis from the literature, it is of 
eminent importance that professionals actively ask for the existence of genital lesions 
and inspect the genital area in patients with psoriasis. Although, as presented in 
chapter 4 of this thesis, the vast majority of patients with genital psoriasis experiences 
significant discomfort such as itch, pain or a burning sensation, it turns out that about 
half of the patients does not discuss their complaints with their physician. Moreover, 
over two thirds of patients never receive treatment for genital psoriasis. Among this 
last group of patients, 20-40% is classified as having ‘severe symptoms’. The fact that 
physical examinations during standard dermatological consultations are practically 
always restricted to extra-genital skin and patients mostly keep wearing their 
underwear may explain this impressive unmet medical need. Chapter 5 shows that 
adequate diagnosis and treatment of genital lesions with attention for the possible 
impact on (sexual) quality of life has a significant impact on disease severity and 
quality of life within limited time exposure. Therefore, an active approach for possible 
genital psoriasis including inspection of the genital skin without any restraint is 
warranted. 
As a result of chronic use of immunosuppressive medication, RTRs have a significantly 
raised risk for the development of HPV-related (ano)genital (pre)malignancies 
compared with the general population.8-13 Chapter 6 of the current thesis confirmed 
this elevated risk, which appears to be twofold to sixfold for CIN, threefold to sixfold 
for cervical carcinoma, 45-50-fold for vulvar carcinoma and about 10-fold for anal 
cancer in RTRs. Recent data illustrate an elevated risk of solid organ recipients for 
vaginal (11-fold), vulvar (20-fold) and anal intraepithelial neoplasia (12-fold) as well.14 
Remarkably, cervical cancer showed no elevated incidence in that publication, which 
was attributed to effective cytological screening of the studied population.14
 It is known that the risk of progression of low-grade lesions toward high-grade 
lesions among immunocompromised patients may be considerable higher and the 
development may be exceedingly rapid in comparison with immunocompetent 
individuals.15,16 So, besides their elevated risk for HPV related anogenital lesions, 
female RTRs may be at higher risk for higher grade disease compared to immuno-
competent individuals.17 
 Parallel to vulvar (pre)malignancies, there is evidence for an HPV-mediated and 
a non-HPV-mediated pathway in penile intraepithelial neoplasia (PIN) and penile 
cancer.18 The risk for HPV-related PIN and penile cancer is also known to be evidently 
elevated in male organ transplant recipients (SIRs 4-19).8,14 To date, unfortunately, 
little is known about HPV infections in male transplant recipients and more detailed 
knowledge on this theme is needed. 
 Based on the elevated risk for anogenital (pre)malignancies in female RTRs, 
yearly anogenital screening is broadly advised although there is no strict evidence 
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treatment paradigm is advised for genital psoriasis: start with weak corticosteroids 
and, in case of resistance to treatment, increase the potency of the corticosteroid 
preparation. Treatment with potent corticosteroids should be limited to a few weeks 
in view of their atrophic effects, particularly on genital skin. The addition of topical 
vitamin D analogues or coal tar preparations has been suggested to be effective. 
These can reduce the side-effects of corticosteroids, although irritation may restrict 
their application. Evidence for the use of calcineurin inhibitors on genital skin is 
scarce. These should be regarded as final treatment options. At our research 
outpatient clinic for genital psoriasis the above mentioned treatment approach 
proved to be effective. 
Unmet medical need with respect to screening of genital (pre)
malignancies in female RTRs
As the elevated risk to develop genital (pre)malignancies is established for female 
RTRs, attention for the recommended intensified screening is necessary. Wong et al. 
showed that the recommended policy of annual screening for cervical malignancies 
using conventional cytology in transplanted women seems to be cost-effective.25 
However, they compared annual screening with no screening at all. The Netherlands 
have, as many other countries, an organised cervical cancer screening programme 
since the early 1970s. In the Dutch programme, women aged between 30 and 60 
years are invited for conventional cervical smears every 5 years. It would be interesting 
to compare the advised intensified annual screening with the standard organised 
Dutch screening programme for cost-effectiveness, but such a study will be hardly 
feasible. In addition to this, it has to be realised that in the near future screening 
strategies in the Netherlands will be changed towards primary hrHPV testing and 
additional triage for hrHPV-positive screening results. Besides, the impact of regular 
screening of female RTRs on reduction of vulvar (pre)malignancies still has to be 
demonstrated. 
 It is known that people with HIV/AIDS have an increased incidence of an extensive 
range of, particularly infection-related, cancers as well. The pattern of this increased 
cancer risk showed a striking similarity between people with HIV/AIDS and immuno-
suppressed transplant recipients in a meta-analysis by Grulich and colleagues.26 So, 
although the mechanisms are different, immune deficiency leads to increased cancer 
risk in both patient groups. 
 Recently, van der Zande and Ankum showed in a short literature review equal 
risks of cervical premalignancies among HIV-positive and HIV-negative women in 
case of repetitive negative cytology results or persistent negative hrHPV test results.27 
Therefore, they advocated extending the current yearly screening interval for 
HIV-positive women in these particular groups. It is attractive to speculate about a 
parallel with female RTRs, which pleads for further research. 
Part B:  HPV-related genital (pre)malignancies in female renal 
transplant patients
1. Cervical screening of female RTRs is not performed in accordance with the 
advised yearly intervals.
2. The risk for female RTRs to develop genital (pre)malignancies is obviously 
increased compared to women in the general population.
3. HPV plays a crucial role in the development of (ano)genital (pre)malignancies in 
female RTRs. Multifocal lesions within female RTRs frequently contain different 
hrHPV genotypes in both lesions. 
4. The prevalence of mucosal HPV infections in female RTRs is high, with a broad 
range of HPV genotypes. HPV-based screening on self-collected specimens is 
an adequate method to detect female RTRs with genital (pre)malignant lesions.
Implications for daily clinical practice
The current thesis underlines the need for more attention for the wide range of benign 
and (pre)malignant genital skin conditions that are highly prevalent but frequently 
missed in daily clinical practice. The prevalence, unmet medical need and 
psychosocial impact of these lesions are likely to be underestimated. 
Unmet medical need with respect to diagnosis and care for patients 
with genital psoriasis
The genital skin is involved in 16-46% of psoriatic patients and a considerable number 
of patients experience diminished (sexual) quality of life. Therefore, more attention for 
genital psoriasis and its implications has to be developed by healthcare professionals. 
 As an adequate diagnosis is the first step in the care for patients with genital 
psoriasis, inspection of the genital area should be performed in each new patient and 
in patients with genital complaints. A specialised clinic for genital diseases with 
attention for adequate diagnosis, treatment and impact on (sexual) quality of life 
proves worthwhile in chapter 5 of this thesis. In particular, the first two consultations, 
with an interval of approximately six weeks, prove to be crucial to reach a significant 
improvement of the genital skin disease and its impact. Thereafter, a plateau is 
reached. This illustrates that it is worthwhile to invest time by a healthcare professional 
with knowledge and skills to support patients with genital psoriasis during the first 
consultations. 
 Literature on therapy with respect to genital psoriasis has its limitations as the 
discrimination between flexural and genital psoriasis is often not made and 
randomised controlled trials on the efficacy and safety of investigated treatments for 
genital skin are sparsely available. Based on the available literature24, the following 
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care. As described in chapter 6 of this thesis, we suggest that yearly screening may 
be postponed to approximately 3 years after RT under the condition that patients are 
screened for anogenital pathology and HPV-status before their RT. However, it is 
unknown from which moment on screening should be performed after RT. More 
awareness of the elevated risk for (ano)genital lesions among both immunocompro-
mised patients as well as health care professionals is warranted. Bringing in the 
expertise of general physicians or nurse practitioners to counsel patients about their 
elevated risks may improve the screening rate of female RTRs.34,35 
Future perspectives
Education of professionals
Adequate knowledge about genital skin disease is essential for good clinical practice. 
However, so far, only little attention for genital skin has been given in medical school 
and subsequent training to become a medical specialist. It is known that the majority 
of vulvovaginal experts are self-taught and have learned their expertise from courses 
and mentorship experiences rather than through a standardised curriculum.36 In 
theory, all involved professionals should become more aware of the possibility of 
genital manifestations of general dermatological disorders like psoriasis or eczema. 
Moreover, knowledge about more specific genital dermatoses like lichen sclerosus 
or VIN is warranted. Recent initiatives to enlarge knowledge, like digital trainings with 
respect to genital skin disease, are promising and deserve a place in the training of 
young colleagues.
 Education and subsequent increased knowledge about genital skin pathology 
among general physicians will probably yield into a more suitable treatment and, 
when indicated, referral of patients towards the appropriate medical specialists.
Instructions for self-management and the value of nurse practitioners
Instructions for self-management are indispensable for patients as described in this 
thesis; they may help to stimulate patients in personal decision making and improve 
clinical outcomes.37 Therefore, we developed a brochure about genital psoriasis in 
association with the Dutch Psoriasis Society. In this way, information about genital 
psoriasis and its treatment is made easily accessible for patients. Even more, the 
possible emotional impact of genital psoriasis is acknowledged and possibilities for 
supportive care are mentioned. Chapter 5 of this thesis illustrates that invested time 
for instructions is indeed worthwhile. 
 It is attractive to speculate about the value of a specialised nurse practitioner in 
this particular field. Care provided by nurse practitioners may be preferable over care 
provided by medical specialists from a health economic perspective.38 Nurse 
 To improve the attendance to cervical screening of women with an increased risk 
for cervical cancer, it has previously been shown that a personal invitation for cervical 
screening by a woman’s own general practitioner achieves a higher screening rate 
compared to an invitation by a national call system through the local health authority.28 
Thus, to improve the cervical cancer screening of female RTRs in daily clinical 
practice, it seems reasonable to optimise the involvement of general practitioners in 
this screening. In the light of patient-centred care, a qualitative study involving both 
female RTRs and their physicians (both the nephrologists and general practitioners) 
may be suitable to explore ways to further improve anogenital screening of the 
high-risk transplant population. 
Multidisciplinary approach and awareness 
Because patients with genital lesions may consult different specialties, the question 
arises which professional will take the ultimate responsibility for those patients. In 
addition, when treating RTRs with genital (pre)malignant lesions, management 
decisions are complex because of the localisation of the donor kidney in the lower 
pelvis. Frequently, there is reluctance to reduce the immunosuppression to prevent 
progression of (pre)malignancies because of fear for graft loss. This illustrates the 
importance of a structured, multidisciplinary approach for genital skin lesions, 
combining the expertise of several medical specialists.
 A dedicated, multidisciplinary approach for vulvar skin pathology is indeed 
invaluable: it improves the understanding of vulvar disease, the making of correct 
diagnoses and the prescription of optimal treatment. Besides, attending a multidisci-
plinary vulvar clinic is associated with a significant improvement in quality of life of 
patients.29-32 Moreover, it may reduce the number of hospital visits for the patients, 
although further studies are needed to substantiate this statement. As a result, several 
multidisciplinary vulvar clinics arose worldwide. The Dutch Society for Vulvar 
Pathology is currently developing quality criteria for vulvar clinics, to preserve quality 
and high specialisation of these multidisciplinary clinics in the Netherlands.
 Awareness of the major impact on (sexual) quality of life is absolutely needed 
when treating patients with both benign and (pre)malignant genital lesions. With a 
pro-active and patient centred approach, professionals may remove barriers and 
create a safe environment in which such a sensitive topic can be discussed. A short 
questionnaire that patients complete at home or in the waiting chambers may give a 
quick overview of pressing psychosexual issues.33 In case of any impairment of 
(sexual) quality of life, a two-track policy seems the most appropriate way to tackle 
these problems. Medical treatment may diminish symptoms and, in addition, 
psychosexual therapy by a (dermato)psychologist or a (gynaeco)sexologist may 
ameliorate the coping behaviour with respect to genital skin disease. 
 The gynaecologist should ideally be involved in both pre- and post-transplantation 
9174 175
CHAPTER 9 GENERAL DISCUSSION
 Up until now, it remains uncertain which triage strategy is the most optimal after 
the detection of hrHPV positive cases. It is critical that the follow-up and further 
management are acceptable to participants and therefore, triage strategies directly 
applied on self-collected material are ideal. DNA methylation marker analysis as a 
triage test directly applied on self-collected cervicovaginal material seems promising.41 
DNA methylation is an epigenetic process involving the addition of a methylgroup 
(CH3) to DNA nucleotides. As a result, the DNA structure changes and the expression of 
genes is altered. Abnormal DNA methylation patterns are associated with malignant 
transformation. Currently, research is performed towards the development of specific 
DNA methylation markers which may be used as triage test for detecting ≥CIN3 in 
hrHPV positive cases. 
 Despite the promising future in the field of self-sampling and hrHPV based triage 
for secondary prevention of cervical cancer, it remains uncertain whether these tests 
also predict the presence of vulvar (pre)malignancies. It figures that vulvar lesions will 
infrequently be present in case of HPV negative cervicovaginal samples, although 
this is not confirmed by the present literature. For the time being, regular inspection 
of the genital skin for the detection of relevant cutaneous lesions remains important 
for the high-risk populations. However, the impact of this policy on reduction of vulvar 
(pre-)malignancies in RTRs remains to be demonstrated. 
Vaccination
The quadrivalent (genotypes 6, 11, 16 and 18) and bivalent (genotypes 16 and 18) 
HPV vaccines have proven to be very safe with long-term durability of protection 
against primary infection with vaccine types and a moderate degree of cross-protec-
tion against some none-vaccine types in the general population.45 Unfortunately, 
although the vaccine was safe and well tolerated, adult transplant recipients recently 
showed suboptimal immunogenicity of the quadrivalent HPV vaccine.46 On the other 
hand, in a small study among adolescent transplant recipients, the immunogenicity 
to the quadrivalent HPV vaccine showed to be robust with seroconversion to all four 
HPV genotypes.47 More clinical trials on the immunogenicity of the HPV vaccination 
and its potential to protect for HPV-related (pre)malignancies in immunocompro-
mised transplant recipients are needed. 
 Currently, the efficacy of a broad spectrum vaccine, against nine HPV subtypes 
is being studied in Phase III studies. This vaccine includes the four HPV genotypes of 
the quadrivalent vaccine and five additional oncogenic HPV genotypes (31, 33, 45, 
52, 58).48 It would be interesting to know the effects of this nine-valent vaccine in 
transplant recipients, especially because they carry a broad range of HPV genotypes 
as we showed in chapter 8 of this thesis. 
 In the light of the possible benefit of vaccination for female RTRs, it is important 
to know whether and when RTRs become HPV positive after renal transplantation to 
practitioners are pre-eminently trained to enlarge self-management of patients. They 
may provide counselling about diagnosis, treatment, elevated risks, importance of 
regular screening and self-inspection of the genital area. In addition, they may provide 
consultations on sexual problems with a lower threshold compared to medical 
specialists.39 
Guidelines and ’Treatment Goals’ regarding genital psoriasis
The most recent Dutch guideline ‘Psoriasis’ dates from 2011 and does not discriminate 
between genital and flexural psoriasis. The treatment advises for genital lesions are 
completely integrated in the advice for the treatment of flexural psoriasis. Besides, 
there is no attention for the impact on sexual health and the value of a sexologist in 
the care for patients with (genital) psoriasis. Therefore, there may be room for 
implementation of the previously described treatment paradigm and attention for 
sexual health in the next Dutch guideline. 
 The significant impact of psoriasis on health related quality of life and the frequent 
undertreatment of patients with moderate-to-severe psoriasis have led to a European 
group to develop consensus on psoriasis treatment goals, aiming to achieve the 
most optimal treatment results.40 It is clearly indicated that special clinical situations 
that may lead to a significantly impaired quality of life, may change mild psoriasis to 
moderate-to-severe disease that warrants more intense (systemic) treatment 
modalities. Involvement of genital skin is indicated as one of these situations by the 
European expert panel. So, based on the recently developed treatment goals, there 
may be room for systemic treatment in case of genital involvement although ‘overall’ 
psoriasis severity scores indicate only mild disease.40 Unfortunately, the evidence for 
efficacy of these systemic treatments in genital psoriasis is very limited and further 
research in this respect is needed.
HPV self-sampling and triage of hrHPV positive cases
Participation in screening is the most important factor determining the success of 
screening. Various studies have shown that self-sampling increases the participation 
of non-responders in current cervical cancer screening programs.41 As the ideal of 
yearly conventional cervical screening combined with anogenital inspection in female 
RTRs seems to be hardly feasible, it may be worthwhile to implement self-sampling 
as the primary screening tool for RTRs in the short term. Self-sampling is suitable for 
HPV-testing, has a high level of concordance with physician-collected samples and 
is highly accepted by women.42-44 Moreover, self-sampling may reduce the 
doctor-density for female RTRs, as only subsequent triage for women who tested 
hrHPV positive is necessary. When HPV self-sampling indicates the female RTRs 
who are at risk for genital (pre)malignancies, it may stimulate the concerning high-risk 
patients to have subsequent cervical screening.
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investigation towards HPV-infections before and after renal transplantation is currently 
conducted at our centre. Besides, further studies are advised to determine the 
optimal HPV vaccine genotypes, vaccination schedule and moment of vaccination 
(pre- or post-transplant) for prevention of genital neoplasia in organ transplant 
recipients. As vaccination against HPV will not provide 100% protection against 
genital (pre)malignancies, screening of the high-risk organ transplant population will 
remain important. 
Conclusion
This thesis focuses on both benign and (pre)malignant genital skin lesions and 
shows that a multidisciplinary approach with attention for prevention, adequate 
diagnosis and treatment and for the impact of these lesions on (sexual) quality of life 
is of great importance. Genital psoriasis should be regarded as a separate 
manifestation of psoriasis with its own treatment paradigm and implications on 
(sexual) quality of life. Improvement of screening and prevention of HPV-related 
genital (pre)malignancies in female RTRs remains necessary and deserves further 
attention in the near future. 
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Summary
This thesis includes clinical studies on genital psoriasis and HPV-related (pre)
malignancies in female renal transplant recipients (RTRs).
 The two main themes of this thesis are introduced in Chapter 1. Based on an 
overview of the literature, current knowledge about epidemiology, clinical presentation, 
diagnosis and therapy of genital psoriasis is described in this chapter. Furthermore, 
it gives an introduction on renal transplantation, immunosuppressive therapy and 
post-transplant genital (pre)malignancies. At the end of Chapter 1 therapeutic 
concessions that are frequently needed in female RTRs with genital (pre)malignancies 
and possible ways of prevention of these lesions in this immunocompromised 
population are reviewed. 
Part A: Genital psoriasis
The prevalence and other epidemiological characteristics of genital psoriasis in the 
Netherlands are described in Chapter 2. Data collected by using self-administered 
questionnaires show that up to 46% of patients with psoriasis suffer from genital 
involvement during the course of their disease. Genital skin can become affected 
with psoriasis at any age. Furthermore, Chapter 2 illustrates that 38% of patients with 
genital psoriasis do not have the flexural skin affected. From this study it is concluded 
that at least one third of patients with psoriasis suffer from genital lesions which are 
not associated with flexural psoriasis. Therefore, it is reasonable to assume that 
flexural and genital psoriasis are most probably distinct manifestations of psoriasis. 
More attention to the genital region of both male and female patients with psoriasis at 
any age is required. 
In order to increase knowledge about quality of life and (attention for) sexual health in 
patients with genital psoriasis, these issues are studied among a large group of 
patients with genital psoriasis. The results are described in Chapter 3. This chapter 
illustrates that patients with genital lesions have significantly worse quality of life 
compared to patients without genital lesions. Sexual health is diminished in a 
considerable number of patients with psoriasis and particularly women with genital 
lesions have high levels of sexual distress. This chapter underscores the need for 
physicians to pay attention to the impact of (genital) psoriasis on psychosocial and 
sexual health. 
Chapter 4 focuses on the experiences of patients regarding the role of the physician 
in the treatment of genital psoriasis and the symptom intensity of these lesions. It 
shows that the vast majority of patients with genital psoriasis experiences significant 
discomfort whereas about half of them does not discuss their complaints with their 
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As immunosuppressive treatment is clearly associated with an increase in the 
occurrence of HPV-related genital (pre)malignancies, Chapter 8 addresses the gen-
otype-specific prevalence of HPV infections in a large cohort of female RTRs. By 
analysing self-collected cervicovaginal samples, this chapter reflects an overall 
prevalence of mucosal HPV infections of 27.1% and 17.4% for high-risk HPV genotypes 
in particular. This is high compared to the age-matched West-European population. 
Besides, Chapter 8 shows a shift in the distribution of HPV genotypes as compared 
with the general population. By offering anogenital screening to all HPV positive 
participants, this study identifies a substantial number of female RTRs with occult 
genital premalignancies. We believe that the introduction of self-sampling for 
HPV-positivity can help in early detection of (pre)malignant anogenital lesions in 
RTRs.
physician. In addition, Chapter 4 illustrates that over two-thirds of patients never apply 
treatment for genital psoriasis lesions. All together, this chapter demonstrates that the 
consultation rate for genital lesions is low, while numerous patients report a significant 
burden of disease. An active and patient-centred approach to identify and treat 
patients with genital psoriasis is recommended.
It was aimed to assess the value of specialised care for patients with genital psoriasis 
in Chapter 5. Therefore, patients with genital psoriasis were invited for treatment and 
support for at least one year at our specialised outpatient clinic with extensive 
attention for genital lesions and (psychosexual) quality of life. Both genital psoriasis 
severity and quality of life parameters improved significantly within the first follow-up 
period of approximately six weeks. In female patients, also the sexual health 
significantly improved. Based on the results described in Chapter 5, it is concluded 
that genital psoriasis can relatively easily be treated within limited time exposure, also 
resulting in significant improvement of quality of life. Routine attention for possible 
genital psoriasis and accompanying impact on (psychosexual) quality of life is 
advised.
 
Part B:  HPV-related genital (pre)malignancies in female renal 
transplant recipients
Immunosuppressive therapy in RTRs is associated with an increased risk for the 
development of (pre)malignancies involving the female lower genital tract. Therefore, 
intensified genital screening is advised, although there is a lack of evidence for this 
policy. In Chapter 6 it is presented that cervical screening is not performed yearly in 
a cohort of 224 female RTRs. Besides, the increased risk for female RTRs in this 
cohort to develop gynaecological (pre)malignancies is described: 2-6 fold for cervical 
intraepithelial neoplasia, 3-fold for cervical carcinoma and 50-fold for vulvar 
carcinoma. This chapter emphasises the need for more attention to both anogenital 
and cervical surveillance of female RTRs.
In Chapter 7, an overview of female anogenital post-transplantation (pre)malignancies 
over a period of 40 years renal transplantation is given. Besides, the genotype-spe-
cific prevalence of HPV in these (pre)malignancies is studied. Chapter 7 illustrates a 
high number of anogenital malignancies in female RTRs, nearly all caused by HPV. 
Interestingly, in case of multifocal lesions within one patient, frequently different 
high-risk HPV genotypes are identified at different locations. This demonstrates that 
immunocompromised RTRs are target for repeated and independent infections with 
various types of HPV. Chapter 7 underlines the importance of anogenital screening 
and monitoring before and periodically after renal transplantation. 
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Samenvatting
In dit proefschrift zijn klinische studies over genitale psoriasis en over HPV-gerela-
teerde (pre)maligniteiten bij vrouwelijke niertransplantatiepatiënten beschreven.
De twee hoofdthema’s van dit proefschrift worden geïntroduceerd in Hoofdstuk 1. Er 
wordt in dit hoofdstuk een overzicht gegeven van de huidige kennis over epidemiologie, 
klinische presentatie, diagnose en behandeling van genitale psoriasis. Daarnaast 
geeft Hoofdstuk 1 een introductie op de onderwerpen niertransplantatie, immuun-
suppressieve therapie en genitale (pre)maligniteiten die ontstaan na transplantatie. 
Hoofdstuk 1 eindigt met een beschrijving van therapeutische concessies die vaak 
gedaan moeten worden bij vrouwelijke niertransplantatiepatiënten met genitale (pre)
maligniteiten en mogelijkheden tot preventie. 
Deel A: Genitale psoriasis
In Hoofdstuk 2 worden de prevalentie en andere epidemiologische kenmerken van 
genitale psoriasis in Nederland beschreven. Door middel van vragenlijstonderzoek is 
vastgesteld dat tot 46% van de psoriasispatiënten genitale psoriasislaesies heeft 
gedurende het beloop van hun huidziekte. Genitale psoriasis kan zich op elke leeftijd 
manifesteren. Hoofdstuk 2 toont tevens aan dat 38% van de patiënten met genitale 
psoriasis geen betrokkenheid van de huidplooien heeft. Hieruit wordt geconcludeerd 
dat minimaal een derde van de psoriasispatiënten ook genitale laesies heeft die niet 
geassocieerd zijn met flexurale psoriasis. Er wordt gesteld dat flexurale en genitale 
psoriasis zeer waarschijnlijk aparte manifestaties van psoriasis zijn en ook apart 
aandacht behoeven. Hoofdstuk 2 pleit voor meer aandacht voor de genitale regio 
van zowel mannen als vrouwen met psoriasis, ongeacht hun leeftijd. 
De kwaliteit van leven en (aandacht voor) seksuele gezondheid van patiënten met 
genitale psoriasis worden bestudeerd in Hoofdstuk 3. Dit hoofdstuk illustreert dat 
patiënten met genitale psoriasis een significant slechtere kwaliteit van leven hebben 
dan psoriasispatiënten zonder genitale laesies. Ook de seksuele gezondheid is 
verminderd bij een aanzienlijk aantal psoriasispatiënten, met name bij vrouwen met 
genitale psoriasis. Dit hoofdstuk onderstreept het belang van aandacht voor de 
impact van (genitale) psoriasis op psychosociale en seksuele gezondheid. 
De rol van artsen bij de zorg voor patiënten met genitale psoriasis wordt onderzocht 
in Hoofdstuk 4. Tevens worden de symptomen van genitale psoriasis, zoals deze 
door patiënten worden ervaren, bestudeerd. Uit deze studie blijkt dat de overgrote 
meerderheid van patiënten met genitale psoriasis matige tot ernstige klachten 
ervaart, waarbij de helft van deze patiënten dit niet bespreekt met hun behandelaar. 
Tevens laat Hoofdstuk 4 zien dat meer dan tweederde van de patiënten met genitale 
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voorkomen en dat deze vrijwel allemaal HPV-gerelateerd zijn. Het is opmerkelijk dat 
in geval van multifocale laesies bij een patiënt regelmatig verschillende hoog-risico 
HPV-genotypen aanwezig zijn op de verschillende locaties. Dit duidt erop dat im-
muungecompromitteerde niertransplantatiepatiënten vatbaar zijn voor herhaaldelijke 
en onafhankelijke infecties met verschillende HPV-genotypen. In Hoofdstuk 7 wordt 
de nadruk gelegd op het belang van anogenitale screening en controle voorafgaand 
aan en periodiek na niertransplantatie. 
Wetende dat immuunsuppressieve therapie geassocieerd is met een toename van 
HPV-gerelateerde anogenitale (pre)maligniteiten, wordt in Hoofdstuk 8 de genotype-
specifieke prevalentie van HPV-infecties in een groot cohort vrouwelijke niertrans-
plantatiepatiënten getoetst. Uit analyse van cervicovaginale samples die verkregen 
zijn middels een zelftest blijkt dat de punt-prevalentie van mucosaal HPV bij vrouwelijke 
niertransplantatiepatiënten 27.1% in het algemeen en 17.4% voor hoog-risico HPV in 
het bijzonder is. Dit is evident hoger dan in de algemene populatie. Hoofdstuk 8 laat 
tevens zien dat bij vrouwelijke niertransplantatiepatiënten de HPV-genotypes verschuiven 
in vergelijking met de algemene populatie. Middels anogenitale screening van alle 
HPV-positieve patiënten identificeert deze studie een belangrijk aantal vrouwelijke 
niertransplantatiepatiënten met verborgen genitale premaligniteiten. Het introduceren 
van zelftests op HPV-infecties kan behulpzaam zijn bij het tijdig ontdekken van (pre)
maligne anogenitale laesies bij niertransplantatiepatiënten.
psoriasis nooit behandeld wordt voor hun genitale laesies. Concluderend beschrijft 
dit hoofdstuk dat de consultatiegraad voor genitale psoriasislaesies laag is, terwijl 
veel patiënten een aanzienlijke ziektelast ervaren. Om patiënten met genitale psoriasis 
adequaat te identificeren en te behandelen, wordt een actieve benadering, waarbij 
de patiënt centraal staat, aanbevolen. 
De waarde van gespecialiseerde zorg voor patiënten met genitale psoriasis wordt 
bekeken in Hoofdstuk 5. Patiënten met genitale psoriasis werden hiertoe uitgenodigd 
gedurende minimaal een jaar behandeld en ondersteund te worden op een 
 gespecialiseerde polikliniek. Hier werd uitgebreide aandacht aan genitale psoriasis 
en de impact op (psychoseksuele) kwaliteit van leven gegeven. Zowel de ernst van 
genitale psoriasis als de kwaliteit van leven van patiënten vertoonde significante 
verbetering binnen de eerste follow-up periode van ongeveer 6 weken. Bij vrouwen 
verbeterde ook de seksuele gezondheid significant. Op basis van de bevindingen in 
dit hoofdstuk wordt geconcludeerd dat genitale psoriasis relatief eenvoudig 
behandeld kan worden binnen een beperkte tijdsspanne waarbij ook de kwaliteit van 
leven van patiënten significant verbetert. Routinematige aandacht voor mogelijk 
aanwezige genitale psoriasis en de daarbij behorende impact op (psychoseksuele) 
kwaliteit van leven wordt aanbevolen. 
Deel B:  HPV-gerelateerde genitale (pre)maligniteiten bij vrouwelijke 
niertransplantatiepatiënten
Het is bekend dat immuunsuppressieve therapie bij niertransplantatiepatiënten 
geassocieerd is met een verhoogd risico op het ontwikkelen van genitale (pre)
maligniteiten. Derhalve wordt bij vrouwelijke niertransplantatiepatiënten frequentere 
genitale screening geadviseerd, hoewel er geen bewijs is dat dit daadwerkelijk de 
morbiditeit en mortaliteit als gevolg van genitale (pre)maligniteiten verlaagt. In 
Hoofdstuk 6 wordt beschreven dat in een cohort van 224 vrouwelijke niertransplan-
tatiepatiënten geen jaarlijkse cervixscreening plaatsvindt. Tevens is het verhoogde 
risico van de vrouwelijke niertransplantatiepatiënten in dit cohort op de ontwikkeling 
van genitale (pre)maligniteiten bepaald: 2 tot 6-voudig voor cervicale intraepitheliale 
neoplasie, 3-voudig voor cervixcarcinoom en 50-voudig voor vulvacarcinoom. Dit 
hoofdstuk benadrukt het belang van voldoende aandacht voor cervixscreening en 
inspectie van de anogenitale huid bij vrouwelijke niertransplantatiepatiënten. 
Hoofdstuk 7 geeft een overzicht van alle na transplantatie optredende anogenitale 
(pre)maligniteiten die zich bij vrouwelijke niertransplantatiepatiënten gedurende 40 
jaar niertransplantatie in ons centrum ontwikkelden. Tevens wordt de genotype- 
specifieke prevalentie van HPV in deze (pre)maligniteiten geanalyseerd. Hoofdstuk 7 
toont dat anogenitale maligniteiten bij vrouwelijke niertransplantatiepatiënten vaak 
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Zomer 2014, Wyler
Terwijl ik dit schrijf besef ik me: dit is de laatste zomer waarin ik buiten op het terras 
aan mijn proefschrift heb gewerkt. Het is namelijk klaar. Er zijn ontzettend veel mensen 
die op wat voor wijze dan ook hebben bijgedragen aan dit werk. Dank! Ik heb het 
enorm gewaardeerd. 
Dr. J.A. de Hullu en Dr. M.M. van Rossum, Joanne en Michelle, jullie namen werden 
door mij de afgelopen jaren bijna dagelijks uitgesproken als een continuüm. Ik heb 
het ontzettend getroffen met jullie om me heen. Jullie onvoorwaardelijke begeleiding 
en coaching heeft niet alleen dit proefschrift, maar ook zeker mij als persoon doen 
groeien. Jullie vulden elkaar altijd perfect aan in commentaar en advies, ieder met 
zijn eigen en zeergewaardeerde persoonlijkheid. 
 Michelle, jouw vermogen om te luisteren en te helpen zaken te relativeren is 
ongekend. Je ziet dingen vaak al voordat ze worden uitgesproken en je maakt op elk 
moment van de dag tijd wanneer ik bij je aanklop. Je kritische en altijd zeer opbouwende 
commentaren hielpen mij om mijn stukken te verbeteren. De hoeveelheid ‘goed 
bedoelde rode tekst’ heb ik geen moment als vervelend ervaren. Dank je wel voor 
alles wat je de afgelopen jaren voor me hebt gedaan. Het is fijn dat je me nu op 
klinisch vlak mag scholen. 
 Joanne, ik ken weinig mensen die zo kort en krachtig kunnen zijn als jij, zonder 
daarop in te leveren aan duidelijkheid of interesse. Van jouw nuchterheid, pragmatisme 
en efficiëntie heb ik erg veel kunnen leren. Hoe je het voor elkaar krijgt weet ik niet, 
maar je hebt de gave tussen je drukke werkzaamheden door alles te horen wat er 
tegen je gezegd wordt en ad hoc mee te denken over oplossingen. Desnoods ’s 
avonds via Whatsapp of op woensdagmiddag bij je thuis in de tuin. Hierdoor kon ik 
altijd weer verder. Veel dank ook voor alle kansen die je me hebt gegeven om me ook 
buiten het onderzoekswerk te ontwikkelen. We blijven gelukkig samenwerken op het 
gebied van de vulvapathologie, daar kijk ik naar uit.
Professor P.C.M. van de Kerkhof, Peter, oneindig veel dank voor je begeleiding tijdens 
mijn promotietraject. Je nieuwe ideeën en altijd oplossingsgerichte, praktische adviezen 
maakten dat ik na onze onderzoeksbesprekingen altijd goedgestemd verder kon 
werken aan de projecten. Je hartelijkheid en onvoorwaardelijke support zijn goud 
waard. Je hebt het tempo er tot op het eind ingehouden, zodat de grootste slag 
geslagen was voordat ik de kliniek in ging. Het is een voorrecht om als dermatoloog 
in opleiding te mogen blijven werken op je afdeling. 
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Marison Kooijmans – Otero, je faciliteert veel klinisch onderzoek en hierbij heb je
altijd oog voor je ‘pupillen’. We hebben erg prettig samengewerkt. Heel veel succes 
met je eigen projecten. 
Onderzoekers Gynaecologie, wat hebben we een mooie tijd gehad in de tuin. Nadat 
ik eenmaal mijn draai gevonden had, was ik er erg vaak. De fijne werksfeer maakten 
we met zijn allen. Publicatie-taart, verjaardagen, onderzoekersweekendjes, sparren 
over onderzoek met een kop koffie in het keukentje: dank jullie wel voor deze mooie 
herinneringen aan mijn werkplek ‘op de Gyn’.
Remko Bosgraaf, je gaf me veel praktische adviezen die van pas kwamen tijdens 
mijn (onderzoeks)spreekuren. Nooit was het teveel moeite mij dingen uit te leggen. 
Samen konden we onze onderzoeken tegen het daglicht houden en onder het genot 
van een kop koffie of goede maaltijd bediscussiëren. We moeten de Derma-Gyn 
synergie maar niet uit het oog verliezen. 
Floor Hinten, het stokje van de niertransplantatiepatiënten werd via de bekende ‘dak-
panconstructie’ aan je overgedragen. Inmiddels zijn onze eerste gezamenlijke 
publicaties een feit en heb je zelf waardevolle onderzoekslijnen lopen. Mooi dat we 
nog steeds samen kunnen brainstormen. Heel veel succes met alles wat gaat komen. 
Hanneke, Iris, Emilie en Anke, jullie hebben tijdens stages alle vier veel werk verzet 
wat heeft bijgedragen aan verschillende publicaties. Ik heb jullie graag begeleid. Het is 
goed om te zien dat jullie allemaal jullie weg binnen de dermatologie hebben gevonden.
Brigitte Slangen en Maarten Christiaans, een multi-center studie is geen sinecure. 
Ontzettend bedankt voor jullie inspanningen om dit project tot een geslaagd einde te 
brengen. 
Andrea Evers en Marianne Vergeer, jullie leerden me veel over ziektegerelateerde 
kwaliteit van leven en seksuele gezondheid. Bedankt voor de goede samenwerking, 
zowel bij mijn onderzoeksprojecten als binnen de patiëntenzorg. 
Hedwig van de Nieuwenhof, inmiddels ben je zelf al weer een hele tijd weg uit de tuin. 
Ik vergeet echter nooit dat je me hielp toen ik met mijn twee linkerhanden steriele 
paraffine coupes nodig had. Ook werkten we plezierig samen aan de kwaliteit van 
leven studies die leidden tot twee mooie publicaties. 
Patrick Zeeuwen, je vlotte en keurige grafische ondersteuning heeft me menig maal 
uit de brand geholpen.
Professor L.F.A.G. Massuger, Leon, ook al was ik misschien een vreemde eend in de
tuin, je bent altijd betrokken geweest bij de projecten. Je hield overzicht en bewaakte 
de rode draad in dit proefschrift. Je kritische feedback, inspirerende ideeën en open 
discussies hebben me veel geleerd. Je wees me er vooral het laatste jaar regelmatig 
op dat ik naar huis moest gaan na een lange werkdag. Nu de afstand weer wat groter 
is, zal ik hier voortaan zelf aan proberen te denken. 
Professor A. J. Hoitsma en Professor L.B. Hilbrands, Andries en Luuk, jullie leerden 
me de relevante zaken van de niertransplantatiegeneeskunde kennen. De input voor 
onze artikelen kwam altijd snel en volledig mijn kant op, waarbij extra inhoudelijke 
uitleg nooit teveel gevraagd was. Jullie leverden keer op keer, met behulp van de 
goedgevulde lokale niertransplantatiedatabase, in vlotte tijd veel relevante data aan. 
Geen complexe syntax was hierbij te veel gevraagd. Het was erg plezierig om met 
jullie te mogen samenwerken. 
Dr. W.J.G. Melchers, Willem, door de jaren heen heb je me de wereld van het Humaan 
papillomavirus laten zien. Je gaf me begrijpelijke uitleg over laboratoriumtechnieken 
en schreef kritisch mee aan de stukken, waarbij je uit je hoofd altijd nog relevante 
literatuur wist toe te voegen. Je opgeruimde mailbox is altijd een voorbeeld voor me 
geweest. Je vlotte en kritische feedback gaf steeds weer energie om het stuk nóg 
beter te krijgen. We hebben samen een aantal mooie projecten afgerond. Gelukkig 
zit er nog wat in het vat waar we na vandaag mee verder kunnen. 
Joanna in ‘t Hout, je mag trots zijn op jouw gave om mij met een glimlach statistische 
hobbels te laten nemen. We hebben samen menig middag in je kamer doorgebracht 
waarbij we uitdagingen in SPSS aangingen. De smaakjesthee en cup-a-soup onder - 
steunden ons hierbij. Ik ben je ontzettend dankbaar voor al je statistische ondersteuning 
waarbij je altijd oog had voor mijn klinische achtergrond. Veel succes met je eigen 
proefschrift. 
Haike, Rieke en Michelle, mijn onderzoekscollega’s van het eerste uur. Jullie maakten 
me wegwijs in onderzoeksland toen ik als stagiaire begon in ‘de bieb’. Wat was het 
een mooie tijd. We deelden de afgelopen jaren intens geluk maar helaas ook intens 
verdriet. De band die we hebben reikt verder dan de werkvloer en dat is geweldig. 
Fijn dat ik jullie weer dagelijks als ‘buddy’ om me heen heb. Samen op naar alle 
volgende mijlpalen!
Onderzoekers Dermatologie, de club is door de jaren enorm uitgebreid. Al was ik 
vooral de laatste jaren niet meer dagelijks aanwezig in de bieb, het was daar altijd 
thuiskomen. Jullie zijn een gezellige club onderzoekers en het is mooi dat we elkaar 
weer in de kliniek (gaan) treffen. 
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‘Mannen van de HTS’, een groot deel van mijn studentenleven en de eerste onder-
zoeksjaren speelden zich af in Tilburg. Jullie zorgden voor de nodige ontspanning 
met spontane uitspattingen en gezellige stapavonden waar ik af en toe bij aansloot. 
Ondanks dat mijn onderzoek een ver-van-jullie-bed-show was, toonden jullie altijd 
veel interesse. Fijn dat we elkaar nog altijd in den lande treffen, ik waardeer jullie 
gezelschap ontzettend.
Sjaak en José, we zijn blij dat we jullie hebben leren kennen. We zijn graag bij jullie en 
het is heel prettig om te weten dat jullie Daya en Lewa mee uit nemen wanneer wij weer 
eens drukke dagen hebben. Als ik weet dat de dames comfortabel zijn, is het stukken 
rustiger werken voor me. 
Loes, vanaf het moment dat je in ‘de tuin’ kwam werken was er een klik. We hebben 
de afgelopen jaren ontzettend fijn samengewerkt. Er was regelmatig ruimte voor een 
goed gesprek, waarbij we ons steeds vaker niet beperkten tot alleen maar sparren 
over het werk. Van collega werd je een vriendin die me erg goed kent en me blijft 
verbazen met rake opmerkingen. Tijdens en naast het werk hebben we veel beleefd, 
wat leidde tot onuitwisbare herinneringen. Sinds we alle twee weer actief in de kliniek 
werken, zien we elkaar minder dan ooit tevoren. Het is dan ook geweldig dat je 
vandaag de hele dag naast me staat als paranimf.
Anke en Robbert-Jan, ongedwongen lekker eten en goede gesprekken typeren onze 
vriendschap. Jullie steunen ons wanneer nodig en we kunnen altijd aankloppen. De 
afgelopen jaren hadden we genoeg gespreksstof en ik twijfel er niet over dat dit zo 
zal blijven. Mooi dat Eva voortaan gezellig mee kletst. Jullie zijn tijdens mijn hele 
 promotietraject erg betrokken geweest en konden elk vanuit jullie eigen professionele 
achtergrond meedenken. Super dat jullie er vandaag bij zijn. 
Heidi, van oud-klasgenootje van Sjoerd werd jij een fantastische vriendin van mij. Ik 
houd van de avonden die we met Toine en jou doorbrengen. Dat Janne hier sinds 
kort bij is, maakt me blij. Het feit dat ik regelmatig mijn sloffen meeneem, zegt wel wat 
over hoe thuis ik me bij jullie voel. Jullie interesse, steun en vriendschap zijn me erg 
dierbaar. Je taak als paranimf trok je enthousiast naar je toe en je nam me veel werk 
uit handen. Het betekent ontzettend veel voor me dat je vandaag naast me staat.
Familie Meeuwis & familie van de Ven, het was vaak moeilijk uit te leggen wat ik nu 
precies voor werk deed in het ziekenhuis. Waarschijnlijk maakt dit boekje het wat 
duidelijker. Jullie oprechte interesse, gezelligheid en goede zorgen maken dat ik me 
altijd thuis voel bij jullie. 
Administratie Pathologie, in het bijzonder Els Schut, Danielle van Duuren- van Cleff en 
later Kim van der Gouw, jullie hebben me oneindig vaak geholpen met het opzoeken 
van coupes en pathologieverslagen. Altijd snel en goedgehumeurd. Zonder jullie 
ondersteuning was veel van het werk uit dit proefschrift niet mogelijk geweest. Er komt 
snel weer wat lekkers voor bij de koffie.
 
Muriël van Bergen – Verkuyten en Monique Mullens, jullie hebben me ongelofelijk 
ondersteund bij het grote HPV-zelftest project. We regelden samen de logistiek, waarna 
alles soepel verliep. Dank voor alle administratieve ondersteuning, analyses en vlotte 
dataverwerking.
Geen goedlopende (onderzoeks)poli zonder adequate ondersteuning. Administratief 
medewerkers en verpleegkundigen van de afdelingen Gynaecologie en Dermatologie, 
bedankt voor de prettige samenwerking. 
Jan Boezeman, ondanks dat het niet je primaire taak was, kon ik in de beginjaren van 
mijn onderzoek altijd bij je binnenlopen voor ondersteuning bij analyses in Excel. 
Menig trucje dat je me leerde komt nu nog altijd van pas. 
Sectie Gynaecologische Oncologie, de Oncologie Onderzoeksavonden brachten 
vaak mooie discussies en voor mij een verbreding van mijn kennis. Ik heb het als voorrecht 
gezien dat ik bij jullie mocht werken. 
Lenno Dukel en Carine van der Vleuten, ontzettend bedankt voor de fijne samen- 
werking op de vulvapoli. Mede door jullie betrokkenheid en laagdrempelige supervisie 
heeft deze poli een waardevolle basis gelegd voor mijn toekomst. 
Dokter Tiemes, Demia, toen wij in 2008 alle twee begonnen op C10 had ik niet kunnen 
bedenken hoe alles daarna zou lopen. Mijn eerste stappen als senior coassistent bij 
de Dermatologie werden door jou omlijst. Je begeleidde me naar een zelfstandig 
werkend jonge assistent en hielp me bij mijn sollicitatie. Ik ben je hier nog altijd 
dankbaar voor. Door de jaren heen hebben we goed contact gehouden. De cirkel is 
rond nu je mij als dermatoloog mag opleiden. 
AIOS Gynaecologie, dank voor de gezellige samenwerking op de vulvapoli. Ik heb 
ontzettend veel van jullie geleerd. AIOS Dermatologie, jullie zijn een aangename club 
collega’s. Ik kijk ernaar uit om de komende jaren met jullie te blijven samenwerken. 
Loes Hilhorst, ontzettend veel dank voor je kaftontwerp. Je enthousiasme en profes-
sionaliteit gaven me vanaf het eerste moment alle vertrouwen. 
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Familie Neijenhuis, bedankt voor jullie interesse in mijn werk en de uitjes die zorgden 
voor de nodige ontspanning. Door de jaren heen boden jullie geregeld een helpende 
hand op vele fronten, waarvoor dank. 
Omaatje van de Ven, ik ben blij dat u deze belangrijke dag kunt meemaken. U heeft 
me altijd gesteund bij de keuzes die ik maakte en vanaf de stille zijlijn alles gevolgd. 
Ik weet zeker dat mama morgen alles komt vertellen, ik ben er zelf ook weer snel. 
Lieve Nicky, we deelden totdat we alle twee het huis uitgingen de zolderkamer. Ook al 
zien we elkaar tegenwoordig minder vaak, we voelen haarfijn aan als het weer de hoogste 
tijd is voor een kop koffie op zaterdag. Ik waardeer die fijne zussenmomenten enorm 
en hoop dat we dat blijven doen, ook al is de afstand sinds kort een stuk groter. 
Lieve Bibi, al blijf je voor mij altijd Bianca. Je blijft me verbazen, maar gelukkig is dat 
een kracht van je geworden in plaats van een zwakte. Ik ben trots op je en houd van je, 
altijd. Vergeet dat nooit. Het geluk dat je gevonden hebt bij je mannen is je zo gegund. 
Lieve Iris, kleine grote zus. ‘Great minds think alike’. Dat we daar steeds vaker achter- 
komen is mooi om te beseffen. Ik heb je zien ontwikkelen tot een jonge krachtige 
vrouw die weet waar ze staat en waar ik altijd op terug kan vallen. Daar heb je zelf 
keihard voor gewerkt en mag je trots op zijn. Ik koester de momenten dat je bij ons 
in Wyler bent, en dat dit altijd zo heerlijk ‘thuis’ voelt. 
Lieve Papa en Mama, dit boekje is voor jullie. Het is bijna niet mogelijk om op papier 
te zetten hoe dankbaar ik jullie voor alles ben. Jullie maakten alles mogelijk en boden 
ons een liefdevol thuis waar iedereen gestimuleerd werd het beste uit zichzelf te 
halen. Jullie motto ‘kan-niet ligt op het kerkhof’ heeft mij gemaakt tot wie ik ben. Ik 
heb hier de afgelopen periode vaak aan teruggedacht. De laatste maanden ben ik 
minder thuis geweest dan ooit tevoren, maar na vandaag komen er écht weer andere 
prioriteiten. Jullie niet-aflatende steun is een voorrecht wat al jullie kinderen kennen. 
Dank dat jullie er altijd voor ons zijn. 
Sjoerd, met jouw lijfspreuk ‘een genie beheerst de chaos’, geef jij ons leven elke dag 
weer kleur. Ik waardeer je ontwapenende lach en altijddurende positivisme enorm. 
De manier waarop jij dingen kan relativeren heeft me tot op het einde geholpen bij het 
schrijven van dit proefschrift. Al was het niet altijd eenvoudig, ik weet dat wij bijzonder 
zijn en dat jij alles waard bent. Zonder jou was alles vast veel minder mooi.
Dank!  
Kim
11
200 201
CHAPTER 11 BIBLIOGRAPHY
Bibliography
van de Nieuwenhof HP, Meeuwis KA, Nieboer TE, Vergeer CM, Massuger LF, de 
Hullu JA. The effect of vulvar lichen sclerosus on quality of life and sexual functioning. 
J Psychosom Obstet Gynaecol 2010; 31: 279-284.
Meeuwis KA, de Hullu JA, de Jager ME, Massuger LF, van de Kerkhof PC, van 
Rossum MM. Genital psoriasis: a questionnaire-based survey on a concealed skin 
disease in the Netherlands. J Eur Acad Dermatol Venereol 2010; 24: 1425-1430.
de Jager ME, de Jong EM, Meeuwis KA, van de Kerkhof PC, Seyger MM. No evidence 
found that childhood onset of psoriasis influences disease severity, future body mass 
index or type of treatments used. J Eur Acad Dermatol Venereol 2010; 24: 1333-1339.
Meeuwis KA, van Rossum MM, van de Kerkhof PC, Hoitsma AJ, Massuger LF, de 
Hullu JA. Skin cancer and (pre)malignancies of the female genital tract in renal 
transplant recipients. Transpl Int 2010; 23: 191-199.
Meeuwis KA, van Rossum MM, van de Kerkhof PC, Hoitsma AJ, Massuger LF, de 
Hullu JA. Huidkanker en gynaecologische (pre)maligniteiten bij vrouwelijke nier-
recipiënten. Ned Tijdsch Derm Ven 2010; 20: 25-26.
Meeuwis KA, van Rossum MM, Hoitsma AJ, de Hullu JA. (Pre)malignancies of the 
female anogenital tract in renal transplant recipients. Transplantation 2011; 91: 8-10.
Meeuwis KA, de Hullu JA, van de Nieuwenhof HP, Evers AW, Massuger LF, van de 
Kerkhof PC, van Rossum MM. Quality of life and sexual health in patients with genital 
psoriasis. Br J Dermatol 2011; 164: 1247-1255.
Meeuwis KA, de Hullu JA, Massuger LF, van de Kerkhof PC, van Rossum MM. Genital 
psoriasis: A systematic literature review on this hidden skin disease. Acta Derm 
Venereol 2011; 91: 5-11.
Meeuwis KA, van de Kerkhof PC, Massuger LF, de Hullu JA, van Rossum MM. 
Patients’ experience of psoriasis in the genital area. Dermatology 2012; 224: 271-276.
Meeuwis KA, Hinten F, van Rossum MM, de Hullu JA. HPV-related (pre)malignancies 
of the female anogenital tract in renal transplant recipients. Crit Rev Oncol Hematol 
2012; 84: 161-180.
11
202 203
CHAPTER 11 BIBLIOGRAPHY
Meeuwis KA, Melchers WJ, Bouten H, van de Kerkhof PC, Hinten F, Quint WG, 
Massuger LF, Hoitsma AJ, van Rossum MM. Anogenital malignancies in women after 
renal transplantation over 40 years in a single center. Transplantation 2012; 93: 
914-922.
Meeuwis KA, de Hullu JA, Inthout J, Hendriks IM, Sparreboom EE, Massuger LF, van 
de Kerkhof PC, van Rossum MM. Genital Psoriasis Awareness Program: Physical 
and Psychological Care for Patients with Genital Psoriasis. Acta Derm Venereol 2014, 
Epub ahead of print. 
Meeuwis KA, Hilbrands LB, InthHout J, Slangen BF, Hendriks IM, Hinten F, Christiaans 
MH, Quint WG, van de Kerkhof PC, Massuger LF, Hoitsma AJ, van Rossum MM, 
Melchters WJ, de Hullu JA. Cervicovaginal HPV-infection in female renal transplant 
recipients: An observational, self-sampling based, cohort study. Provisionally accepted, 
American Journal of Transplantation, 2014.
11
204 205
CHAPTER 11 CURRICULUM VITAE
Curriculum Vitae
Kim Meeuwis werd op 17 april 1983 geboren in Berkel-Enschot. Daar groeide ze op 
en ging er naar de basisschool. Tijdens haar schooljaren was Kim actief in de 
paardensport en speelde zij in een blokfluitkwartet. In 2001 behaalde zij haar 
vwo-diploma aan het Theresialyceum in Tilburg. Nadat zij aanvankelijk was uitgeloot 
voor de studie Geneeskunde, behaalde zij in 2002 haar propedeuse Medische 
Biologie aan de Radboud Universiteit Nijmegen. In datzelfde jaar mocht zij starten 
met de studie Geneeskunde aan deze faculteit. Kim ontwikkelde al tijdens haar 
studie een grote interesse in de specialismen Dermatologie en Gynaecologie. 
Daarom koos zij ervoor om een seniorcoschap Dermatologie en een keuzecoschap 
Verloskunde & Gynaecologie te volgen. Haar wetenschappelijke stage verrichtte zij 
op de afdelingen Dermatologie en Verloskunde & Gynaecologie van het UMC St 
Radboud onder leiding van dr. M.M. van Rossum en dr. J.A. de Hullu. Tijdens deze 
stage hield zij zich bezig met HPV-gerelateerde anogenitale problematiek bij nier-
transplantatiepatiënten. Nadat ze haar doctoraalexamen in november 2008 behaalde, 
werd Kim aangesteld als promovendus om deze onderzoekslijn voort te zetten. 
Daarnaast zette zij een onderzoekslijn naar genitale psoriasis op. Ze werd hierbij 
begeleid door prof. dr. P.C.M. van de Kerkhof, prof. dr. L.F.A.G. Massuger, dr. M.M. 
van Rossum en dr. J.A. de Hullu. Tijdens de najaarsronde van 2010 werd een AGIKO-
stipendium intern gehonoreerd, waardoor de onderzoeksprojecten die hebben 
geleid tot dit proefschrift konden worden voortgezet en uitgebreid. In 2012 startte Kim 
naast haar onderzoek als arts op de vulvapoli van het UMC St Radboud, waar zij met 
veel enthousiasme de zorg voor patiënten met vulvaire klachten had. Daarnaast is zij 
sinds 2012 bestuurslid van de Nederlandse Vereniging voor Vulvapathologie. Kim is 
sinds juli 2013 in opleiding tot dermatoloog aan het Radboudumc te Nijmegen. 
Ze woont samen met Sjoerd Neijenhuis en hun twee Afrikaanse jachthonden Hedaya 
en Dalewa in het Duitse Wyler.
